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ABSTRACT 
 
 
 
 
Bacteriophages are the most abundant biological entities on earth, yet relatively 
few have been characterized. In this project, a novel bacteriophage was isolated from the 
environment, characterized, and compared with others in the databases. Mycobacterium 
smegmatis, a harmless soil bacterium, served as the host and facilitated the enrichment 
and recovery of mycobacteriophages. A single phage type was purified to homogeneity 
and named TiroTheta9 (TT9). Electron microscopy revealed that the phage particles have 
icosahedral heads 58 ± 2 nm in diameter and tails 174 ± 5 nm in length. The TT9 genomic 
DNA was purified and sequenced using 454 pyrosequencing technology. The 51,367 bp 
genome contains 87 genes that were identified using the gene prediction programs 
Glimmer and GeneMark. However, only 31 genes could be assigned functions based on 
BLAST analysis. Genome wide comparisons using the Phamerator program and BLAST 
revealed that TT9 is most closely related to members of the A4 subcluster of 
mycobacteriophages. Although the A4 subcluster phages have been isolated from 
geographically distinct locations, their genomic sequences are highly conserved. 
Comparative analysis of the subcluster reveals evidence of evolution through both 
vertical sequence divergence and horizontal gene transfer, as evidenced by the existence 
of three unique groups of integrases. These results have contributed to the rapidly 
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expanding database of mycobacteriophage genomes; mining this rich source of genetic 
information should provide new insights into phage diversity and evolution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Bacteriophage, Mycobacteriophage, Mycobacterium smegmatis, Phage 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
Mere nanometers in length, they are among nature’s tiniest biological entities, and 
yet the scientific mysteries they have already helped us unlock are unimaginably 
immense. Inhabiting almost every conceivable environment, altogether more than 10
31
 
individual particles populate the planet, a number so large that despite the miniscule size 
of a single entity they could form a line stretching 200 million light years [1], and yet 
only an infinitesimal sliver of that line has been even superficially studied. The study of 
bacteriophage (phage), viruses that attack bacteria, is full of such ironies. As researchers 
delve deeper into the mysteries of phage, it becomes ever clearer that although they have 
already taught us much, we have barely begun to truly understand their astounding 
complexity.     
Ever since their discovery in the early 1900s, bacteriophage have been at the 
center of numerous applied and basic research initiatives. Throughout the mid-1900s, 
they starred in landmark experiments that identified DNA as the genetic material in living 
organisms, uncovered the existence of messenger RNA, and revealed the triplet nature of 
the genetic code, among numerous other contributions to bacterial genetics, molecular 
biology, and virology [2]. In fact, phages were so essential to the development of 
molecular biology that a dedicated Phage Course was taught each year from 1945 to 1970 
2 
 
at Cold Spring Harbor Laboratory to train researchers on the cutting edge of the nascent 
field [3].  
Despite their utility in the laboratory, our knowledge of phage has been largely 
limited to a few well-studied model species, Lambda, T4, and M13 being among the best 
known. With the advent of next-generation sequencing methods, however, there has been 
renewed interest in expanding our knowledge of phages through the isolation and 
sequencing of a variety of novel phage genomes. Given the ecological importance of 
phages as well as their current and potential applications in basic research, medicine, and 
industry, such efforts promise to catalyze a wealth of new discoveries across a diverse 
range of fields.  
This work describes a new contribution to the effort to expand our knowledge of 
bacteriophage in the form of the isolation and sequencing of the novel 
mycobacteriophage TiroTheta9. In order to place this research in the proper context, the 
first part of this work attempts to capture the current scope of knowledge regarding 
bacteriophage, as well as highlight their importance in nature, in the laboratory, and in 
day-to-day life, by describing their biology, ecology, history, and applications. 
Mycobacteriophages are introduced in the second half of this work, which details the 
discovery, characterization, and sequencing of TiroTheta9. Finally, TiroTheta9 is 
compared with a group of related mycobacteriophages across several dimensions, 
including geography, genomic sequence, and other genomic parameters, in order to draw 
conclusions related to bacteriophage genetics and evolution.  
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PART I 
 
 
INTRODUCTION TO BACTERIOPHAGE – 
BIOLOGY, HISTORY, AND APPLICATIONS 
 
 
Be it in nature or in the lab, bacteriophage possess undeniable power. Although 
structurally very simple, bacteriophage are ubiquitous and play key roles in the biosphere.  
Ever since their discovery in the early 20
th
 century, their power has also been harnessed 
in the lab, resulting in a variety of useful applications across several diverse fields. These 
applications, as well as the biology, ecological significance, and research history of 
bacteriophage, are detailed in the following chapters.   
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CHAPTER 2 
 
 
BIOLOGICAL CHARACTERISTICS OF BACTERIOPHAGE 
 
 
A. BACTERIOPHAGE STRUCTURE 
 
Bacteriophage are viruses that infect bacteria. Like all viruses, they consist of a 
very simple structure: each phage particle consists of two main components, structural 
protein and genetic material; a few phage types also incorporate lipids. Although 
morphology varies greatly (see Chapter 2C and Figure 3), all phage have a protein head 
or capsid that functions to protect and transport the genetic material that it surrounds. 
Packaged inside the capsid, the genetic material can be single-stranded DNA, double-
stranded DNA, single-stranded RNA, or double-stranded RNA. In addition to these 
universal components, many phage also have protein-based components such as a tail 
sheath, a baseplate, and tail fibers that serve to facilitate host infection (Figure 1).   
 
 
 
 
 
 
 
Figure 1: Structure of a Bacteriophage Particle. The figure depicts a typical myoviridae phage particle 
with an icosahedral head, DNA, full-length contractile tail, and tail fibers. All phage have protein-based 
heads, or capsids, and either DNA or RNA as their genetic material, but capsid and tail morphologies vary. 
Tails and related components may be absent. Source: https://biology10thgrade.wikispaces.com/ 
Cell+structure+and+function%3B+review. 
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Phage bind to receptors on the host cell surface. Because different receptors are 
expressed by different species of bacteria, each type of bacteriophage is limited to a 
specific range of host bacterial species depending on which receptor it utilizes for 
infection. Adsorption is the first step in the infection process; after adsorption to the 
bacterial cell surface, many phage inject their genetic material into the host. Unlike many 
eukaryotic viruses, the protein components of bacteriophage do not enter the cell along 
with the genetic material, but rather remain attached to the host cell surface. 
 
B. BACTERIOPHAGE LIFECYCLES    
 
After infecting its host, many bacteriophages undergo one of two distinct 
lifecycles. The first is the lytic cycle. After the genome of a lytic phage enters its host, it 
circularizes and immediately begins replicating. Normal functioning of the bacterium is 
brought to a halt as the phage hijacks the cellular machinery, utilizing the cell’s resources 
to synthesize new capsids and tails, if applicable, as well as to produce copies of the 
phage’s genetic material. Newly synthesized genetic material is packaged into the capsids, 
any additional components such as tail sheaths and tail fibers are appended onto the 
capsid, and as little as 20 minutes after initial infection, fully-formed progeny phage burst 
from the host in a process called lysis. The progeny phage are then free to disperse, each 
with the potential to infect a healthy cell and carry on the replication process.  
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Figure 2: Bacteriophage Lifecycles. After infecting its host, a bacteriophage can undergo one of two 
lifecycles depending on environmental cues. The lytic cycle (1) involves immediate replication of phage 
particles and ultimately results in the death of the host bacterium, which is lysed at the end of the process to 
release progeny phage. The lysogenic cycle (2) involves incorporation of the phage genome with the host 
chromosome, where it remains dormant and is replicated along with the bacterial chromosome. An 
integrated phage can be induced by factors such as DNA damage to excise itself and enter the lytic cycle. 
Not all phage are capable of forming lysogens; those than can are known as temperate phage. Source: 
http://www.bio.miami.edu/dana/pix/bacteriophage_life_cycle.jpg. 
When environmental conditions are not optimal for sustaining lytic growth – for 
example, when host density is low or nutrients are scarce – some phage are capable of 
undergoing an alternate lifecycle known as the lysogenic lifecycle. Unlike a phage 
undergoing the lytic cycle, a phage undergoing the lysogenic cycle does not immediately 
begin replication after injecting its genetic material into the host. Instead, the genetic 
material is integrated into the host’s genome as double stranded DNA, becoming a 
prophage and transforming its host into a lysogenic cell, or lysogen. The prophage uses a 
DNA binding repressor protein to prevent expression of its own replication and lytic 
genes, instead replicating along with the host genome whenever the host divides. 
However, environmental factors such as DNA damage can induce the prophage to excise 
7 
 
itself from the host chromosome and begin the lytic cycle. While some phages are 
exclusively lytic, phages that are capable of undergoing the lysogenic cycle are known as 
temperate phage. 
Although most known phages adhere to these two lifecycles, a select group of 
phage known as filamentous phage exhibits yet another mechanism of replication. Like 
lytic phage, filamentous phage genomes generally circularize and begin replication 
immediately after entering a host cell. However, rather than killing and lysing their hosts 
as they replicate, filamentous phage release their progeny through channels in the cell 
membrane without killing the host bacterium, although bacterial growth is slowed in 
many cases [4]. Parallel to the typical lytic and lysogenic cycles described above, some 
filamentous phage exhibit strictly episomal replication, while others are “temperate,” 
alternating between periods of integration into the host chromosome and periods of 
episomal replication.  
 
C. BACTERIOPHAGE CLASSIFICATION 
 
Given that viruses are generally considered nonliving, the rigorous binomial 
nomenclature system in place for classifying living organisms cannot be applied. Instead, 
scientists typically classify bacteriophage based on lifecycle, type of genetic material, 
morphology, and/or host range. As discussed previously, bacteriophage can be classified 
as either lytic or temperate based on the lifecycle they follow. Alternatively, they can be 
grouped into four distinct categories based on the type of genetic material they contain: 
single stranded (ss) RNA, double stranded (ds) RNA, ssDNA, and dsDNA. Taking 
differences in morphology into account, these four types can be further divided into 14 
subtypes as depicted in Figure 3. The figure also showcases the wide diversity of 
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bacteriophage morphologies, ranging from the archetypal tailed phages with icosahedral 
capsids to tailless phages consisting of only a capsid to the long, fiber-like filamentous 
phages. Selected characteristics of each subtype are summarized in Table 1.  
Of the bacteriophages that have been isolated so far, the vast majority belong to 
the double stranded DNA subtype siphoviridae [5], which have long, noncontractile tails 
attached to icosahedral or elongated capsids. However, it should be noted that this may 
reflect a bias inherent in the laboratory techniques used to isolate environmental phages 
rather than a naturally greater abundance of this type of phage. In addition to these 
classification systems, bacteriophage can also be grouped based on their host range; for 
example, phages that infect bacteria of the genus Mycobacterium are collectively known 
as mycobacteriophage. 
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Figure 3: Bacteriophage Subtypes. Bacteriophage can be classified into fourteen different subtypes based 
on genetic material and morphotype. Source: http://www.snow.edu/kevins/Biol_2200_files/ 
Prescott17_Viruses.pdf. 
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Table 1: Selected Characteristics of Phage Subtypes. Source: Ackermann, HW. Bacteriophage 
classification, p 69-90. In  Kutter E, Sulakvelidze A (ed), Bacteriophage: Biology and Applications, 1st ed. 
CRC Press, Boca-Raton, FL. 
Nucleic 
Acid 
Type Capsid Tail 
Adsorption 
Site 
Release 
Host-Virus 
Relationship 
Example 
dsDNA Myoviridae 
Icosahedral 
or prolate 
Contractile 
Cell wall, 
capsule, 
pili, flagella 
Lysis 
Lytic or 
Temperate 
T4 
 
Siphoviridae 
Icosahedral 
or prolate 
Long, non-
contractile 
Cell wall, 
capsule, 
pili, flagella 
Lysis 
Lytic or 
Temperate 
Λ 
  Podoviridae 
Icosahedral 
or prolate 
Short, 
non-
contractile 
Cell wall, 
capsule, 
pili, flagella 
Lysis 
Lytic or 
Temperate 
T7 
 
Lipothrix-
viridae 
Filamentous, 
external lipid-
containing 
envelope 
None Pili Lysis Temperate TTV1 
  
Cortico-
viridae 
Internal 
phospho-
lipoprotein 
vesicle 
None Cell wall Lysis Lytic PM2 
 
Tectiviridae 
Internal 
lipoprotein 
vesicle, 
apicle spikes 
Pseudotail 
formed by 
lipoprotein 
vesicle  
Pili, cell 
wall 
Lysis Lytic PRD1 
  Rudiviridae 
Filamentous -            
stiff rods 
None Cell wall Unknown Carrier state SIRV-1 
 
Fusello-
viridae 
Lemon-
shaped, 
external lipid-
containing 
envelope 
None Unknown Extrusion 
Temperate or 
carrier state 
SSV1 
  
Plasma-
viridae 
Lipid-
containing 
envelope only 
None 
Plasma 
membrane 
Budding Temperate L2 
  
Guttaviridae 
(SNDV-like) 
Droplet-
shaped 
None Unknown Unknown Carrier state SNDV 
ssDNA Microviridae Icosahedral None Cell wall Lysis Lytic φ, X174 
 
Inoviridae 
(Plectrovirus) 
Filamentous - 
long 
filaments 
None 
Plasma 
membrane 
Extrusion Carrier state Fd 
  
Inoviridae 
(Inovirus) 
Filamentous - 
short rods 
None Pili Extrusion 
Carrier state 
or temperate 
MV-L51 
dsRNA Cystoviridae Icosahedral None 
Pili, cell 
wall 
Lysis Lytic φ6 
ssRNA Leviviridae Icosahedral None Pili Lysis Lytic MS2 
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D. BACTERIOPHAGE ECOLOGY 
 
To appreciate the enormous roles bacteriophage play in nature, their abundance in 
the environment must first be quantified. Given that phage require bacterial hosts to 
replicate, they tend to be found wherever their hosts are abundant. As bacteria have been 
identified in almost all environments on Earth, it follows that bacteriophage are equally 
ubiquitous. But just how numerous are bacteriophage? Measures of virus particles in 
estuarine water estimate 10
7
 particles/ml, corresponding to about a 10:1 virus-to-
bacterium ratio [6]. Similar numbers apply to marine waters, with an estimated total of 
10
30
 phage populating the ocean. High phage titers have also been reported in marine 
sediment (10
9
 particles/g), terrestrial soil (10
7
 particles/g), the feces of ruminant animals 
(10
7
 particles/g), food products such as whey (10
9
 particles/ml), and even the air (10
5 
particles/m
3
) [7]. 
What are the consequences of such ubiquity and high abundance of phage 
particles? In short, it means that phage play a large and essential role in their 
environments. The environmental role of phage can be considered from four hierarchal 
levels of influence: organismal, population, community, and ecosystem [8]. Phage 
organismal ecology involves factors that affect a phage’s ability to survive in the 
environment, infect a host, and produce viable progeny. A number of environmental 
factors influence free phage in their search for a host bacterium. For example, terrestrial 
soils are often only partially hydrated, hampering diffusion of phage particles. Phage can 
become trapped in biofilms, sticky networks of bacteria and sometimes other 
microorganisms that frequently grow on surfaces, and often experience reversible non-
specific adsorption to particles in the environment or adsorb to nonviable bacterial 
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fragments. In addition, high pH and UV radiation can degrade free phage particles [9] 
[10]. Adaptations in surface chemistry, virion size, and pH resistance can improve a 
phage’s ability to survive and find a suitable host for replication [11].  
Phage population ecology includes phage growth patterns and competition among 
multiple phages for hosts.  A primary factor at this level is the balance between the lytic 
and lysogenic lifecycles. In general, the lytic lifecycle is associated with rapid phage 
population increase and is best suited to environments where nutrients are plentiful and 
bacteria are actively dividing so that there are enough healthy hosts available to support 
the burgeoning phage population. The lysogenic lifecycle, on the other hand, is useful for 
sustaining phage populations at carrying capacity in environments where the bacterial 
population is stable or declining because most phage in these conditions exist as dormant 
prophage rather than actively replicating. Due to the binding kinetics of the DNA 
repressor proteins that prophages use to remain integrated in the host chromosome, a 
basal level of spontaneous induction effects the replication and release of small quantities 
of phage particles, but their small numbers coupled with the immunity afforded to 
lysogens carrying homoimmune prophage ensure that the limited host population is not 
rapidly depleted. The filamentous phage lifecycle can similarly maintain phage and host 
populations when viable hosts are limited.  
Phage also have a significant impact on the ecology of their bacterial hosts; these 
phage-host interactions are encompassed by phage community ecology. On the level of 
individual bacteria, phage infection can induce abnormal patterns of gene expression that 
often alter the bacterial phenotype. These shifted gene expression patterns can be related 
to the host stress response invoked by infection or to certain phage-encoded factors. It is 
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also possible for temperate phages to encode genes that are expressed when the phage 
integrates into the host chromosome. In fact, many bacterial virulence genes, including 
the toxin produced by Vibrio cholera that is responsible for the diarrheal disease cholera, 
are encoded by temperate phage that convert their nonpathogenic hosts into pathogens 
upon infection.  
Phage-host interactions are also extremely important from an evolutionary 
standpoint. The constant selective pressure that phage apply to their hosts drives bacterial 
diversification as the bacteria evolve new defense systems to evade their viral attackers 
[12]. Accordingly, as non-resistant bacteria are decimated during lytic phage growth, 
bacterial populations are shifted towards phage-resistant varieties, which may differ in 
additional ways from their non-resistant predecessors.  
Phage also facilitate horizontal gene transfer between themselves and their hosts; 
in fact, up to 20% of the genome of some bacteria is comprised of phage DNA [13]. As 
detailed previously, some phage are capable of integrating into the chromosome of their 
bacterial hosts, where they can confer new biological properties, such as virulence, on 
their hosts. This process is called lysogenic conversion. In addition, over time, integrated 
prophage may lose the ability to excise themselves through mutation, deletion, or genetic 
rearrangement; their genes thus become permanent fixtures in the genomes of their hosts. 
Such phages are referred to as defective or cryptic. Examples of this phenomenon are 
abundant in the well-characterized E. coli K-12 strain, which contains nine cryptic 
prophages that constitute 3.6% of its genome [14]. Both active and cryptic prophages 
contribute to bacterial evolution and have been shown to increase the fitness of their 
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bacterial hosts in some cases, boosting resistance to certain antibiotics and environmental 
stresses, increasing growth, and facilitating biofilm formation among other benefits [14].  
In a phenomenon known as transduction, transducing phage can also ferry 
bacterial DNA between hosts. During lytic replication, an empty phage capsid can 
occasionally be packaged with bacterial DNA, which is then transferred to a new host 
upon infection by the faulty phage in a process known as generalized transduction. 
Specialized transduction occurs when a prophage excises itself imprecisely from the host 
genome, taking adjacent bacterial genes along with it. These genes are packaged into the 
capsids of the progeny phage, which can transfer them to new hosts upon lysogenization. 
Depending on the host range of the phage in question, genes can be transferred between 
different strains or even different species of bacteria.  
It is important to note that the sheer abundance of phage in the environment 
makes their role in bacterial evolution even greater. Because their numbers are so 
immense, even relatively rare phage-mediated events occur with striking overall 
frequency. For example, transduction is observed in only one out of every 10
8
 infections 
under optimal laboratory conditions [7]. However, when the 10
30 
estimated marine phage 
and the 10
23
 estimated infections they initiate every second [15] are taken into account, 
transduction events occur about 20 million billion times per second in the ocean alone 
[16]. This represents an enormous amount of potential horizontal gene flow among 
marine bacterial species and is likely to play a significant role in their evolutionary 
histories.  
Despite their tiny size, phage can exert an enormous influence on the level of 
entire ecosystems, an area examined by phage ecosystem ecology. As mentioned 
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previously, phages exert selective pressure on bacterial populations that can favor the 
dominance of phage resistant strains in the presence of phage. Often, however, this 
resistance comes at a metabolic cost to the bacteria. This in turn can reduce metabolic 
activities such as nitrogen fixation that are beneficial to plant growth, thereby affecting 
entire ecosystems. For example, observations recorded in a 1935 study by Demolon and 
Dunez demonstrated large-scale obstruction of plant growth in an agricultural setting 
after phage infection. Researchers have hypothesized that selection for a bacterial 
phenotype that was phage-resistant but less efficient at fixing nitrogen was the root cause 
[17]. Alternatively, phage can destroy bacteria that benefit animal or plant members of an 
ecosystem.  
Phage can also play a largely positive role in the ecosystems to which they belong. 
They can prevent bacterial population explosions that might drive other microorganisms 
to extinction or cause disease in higher organisms. Additionally, as they are responsible 
for the death of 80% of prokaryotes in deep sea sediments [18] at a rate of about 15% of 
the total bacterioplankton population per day [7], phage are major players in the shifting 
of nutrients from living organisms back into the environment. Consequently, they play 
major roles in global biogeochemical cycles, including the carbon, nitrogen, and 
phosphorus cycles vital to the maintenance of essentially every ecosystem on the planet. 
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CHAPTER 3 
 
 
HISTORY OF BACTERIOPHAGE RESEARCH 
 
 
A. THE DISCOVERY OF BACTERIOPHAGE 
 
As early as 1896, British bacteriologist Ernest Hankin noted an unknown 
antibacterial agent at work in the waters of the Ganges River while studying cholera in 
India. Several years later in 1915, another British bacteriologist Frederick Twort was 
studying staphylococcal contamination of smallpox vaccines when he noticed small, clear 
spots emerging on his plates of Staphylococcus bacteria. Although he knew these spots 
were indicative of areas where the bacteria had been killed by some sort of antibacterial 
substance, Twort did not state conclusively that the substance was a virus; rather, he 
speculated that it may be an enzyme secreted by the bacteria themselves among other 
possibilities. Although Twort published his observations in the British journal The Lancet 
[19], the significance of his discovery was not immediately recognized.  
Around the same time, French-Canadian microbiologist Felix d’Herelle noticed 
similar clear spots on his own plates while investigating a severe outbreak of bacterial 
dysentery among a group of French troops stationed outside of Paris. Having observed 
the same phenomenon five years earlier while researching infectious insect diseases in 
Mexico, d’Herelle decided to investigate further and published his findings in a French 
journal in 1917 [20]. He proposed that the mysterious substance was a type of virus and 
coined the name “bacteriophage” – meaning “eater of bacteria” [21]. However, it was not 
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until German scientist Helmut Ruska utilized the newly-invented electron microscope to 
take the first pictures of bacteriophage in 1940 [22] that the rest of the scientific world 
was convinced that d’Herelle’s bacteriophage were indeed viruses. 
 
B. BACTERIOPHAGE RESEARCH FROM THE 1920S TO THE 1940S 
Bacteriophage research from the 1920s to the 1940s was primarily concerned with 
the medical applications of bacteriophage. The concept of bacteriophage therapy, in 
which bacteriophage are employed to treat bacterial infections, especially in humans, was 
proposed and developed during this period. Phage therapy’s earliest proponent was Felix 
d’Herelle, who used the viruses he had helped discover to develop treatments for avian 
typhosis in chickens and shigella infections in rabbits [23]. After achieving success, he 
initiated similar experimental treatments in humans in 1919, successfully treating 
bacterial dysentery in several patients at a hospital in Paris [21].  
Over the next few years, researchers used lytic bacteriophage to treat an 
increasingly wide variety of bacterial infections. In 1921, French researchers Richard 
Bruynoghe and Joseph Maisin published the first article related to phage therapy of 
human disease, reporting the successful treatment of Staphylococcus infections on the 
skin [24]. After completing his work on dysentery in France, d’Herelle traveled to India 
to work on phage therapy strategies for cholera; under his direction, one of India’s 
research institutes began researching phage therapy and achieved great success in treating 
cholera during the 1920s and 30s [25]. In 1932, American doctor Robert Schless 
published results reporting the successful use of phage to treat bacterial meningitis caused 
by Staphylococcus aureus [26]. During the late 1930s and early 1940s, phage therapy 
research was especially productive in the former Soviet Union. Soviet researchers 
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reported great successes in using phage to treat bacterial infections in fields as diverse as 
dermatology, ophthalmology, urology, stomatology, pediatrics, and otolaryngology [27] 
as well as to prevent and cure infections in surgical incisions and open wounds [28]. 
During this time, there were also reports of Soviet and German soldiers utilizing phage 
therapeutics to treat wounds and prevent bacterial infections [25].   
The earliest commercial phage products also appeared during this time period 
[21]. The French company L’Oreal marketed at least five different phage products for 
human use, all developed by d’Herelle in his commercial laboratory in Paris. In the 1940s, 
the American company Eli Lilly developed and marketed seven therapeutic phage 
preparations effective against such maladies as Staphylococcus, Streptococcus, and 
Escherichia coli among other pathogens. These products were primarily used in the 
treatment of abscesses, suppurative wounds, vaginitis, upper respiratory tract infections, 
and mastoid infections. In addition, significant research efforts into phage therapeutics 
were carried out at the George Eliava Institute of Bacteriophage, Microbiology, and 
Virology in Tbilisi, Georgia, which was founded in 1923 by d’Herelle and Georgian 
bacteriologist Giorgi Eliava. At its height, the Institute was capable of producing twelve 
different phage products targeted against Staphylococcus, Pseudomonas, Proteus, and 
several enteric pathogens, often in large amounts for use throughout Eastern Europe and 
the Soviet Union, and also provided many of the phage used in experiments by Soviet 
researchers.  
 
C. BACTERIOPHAGE RESEARCH SINCE 1950 
 
From the 1950s onward, bacteriophage research in Eastern European countries, 
including most prominently the Soviet Union and Poland, continued to be centered 
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around phage therapy. In 1968, a team of Georgian researchers led by E.G. Babalova, 
K.T. Katsitadze, and L.A. Sakvarelidze conducted a particularly influential large-scale 
study in Tbilisi, Georgia, to provide further evidence for the efficacy of phage therapy 
[29]. The study involved 30,769 children between the ages of six months and seven years 
divided into two groups. The first group consisted of 17,044 children who were given a 
dose of Shigella bacteriophage orally once per week. The second group, consisting of 
13,745 children, served as a control and was not given phage. After 109 days of treatment, 
the researchers discovered that the incidence of diarrheal disease in the control group was 
3.8 times higher than that of the group treated with phage based on clinical diagnosis and 
2.6 times higher based on cases confirmed through laboratory culture. Despite the fact 
that the phage administered to the experimental group had been specific to Shigella 
bacteria, the incidence of diarrheal disease of unknown cause was also 2.3 times higher in 
the control group. The results of this experiment provided strong evidence for the 
effectiveness of phage therapeutics in preventing diarrheal disease in children.    
In the 1970s, Polish and Soviet researchers successfully used phage therapy to 
treat peritonitis, osteomyelitis, abscesses, post-operative infections, antibiotic-associated 
dysbacteriosis, and suppurative surgical infections caused by antibiotic resistant 
Staphylococcus aureus, Streptococcus, and Proteus species. Many similar studies and 
experiments continued throughout the 1980s and 90s, providing researchers with 
additional evidence for the efficacy of phage therapy in treating bacterial infections [21]. 
Although the majority of phage therapy research during this time period was 
conducted by scientists in Eastern Europe, several notable projects were completed in 
other countries, as well. In the late 1960s, the World Health Organization conducted 
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research directed towards using phage therapy against cholera in Pakistan, although they 
ultimately concluded that phage therapy as used in the study was inferior to standard 
antibiotic treatments [30], citing problems such as differential susceptibility to the 
therpeutic phages among vibrio serotypes and rapid passage of orally administered phage 
through the GI tract. In the 1980s, a group of British researchers headed by H. Williams 
Smith and M.B. Huggins successfully used phage therapy to treat E. coli infections in 
animals [31] [32]. In addition, several countries, including France, Poland, 
Czechoslovakia, England, and a few North American countries, launched mostly 
successful clinical trials of phage-based therapies throughout the 1960s, 70s, and 80s [25]. 
In contrast to the focus on phage therapy by Eastern European researchers, 
starting in the 1950s, most phage research in the West was focused on basic molecular 
biology. One of the main factors that deterred Western researchers from pursuing phage 
therapy with the same fervor as their Eastern European counterparts was the advent of 
antibiotics in the 1940s. Easy to manufacture and highly effective against a wide range of 
infectious diseases, antibiotics quickly took center stage in the clinic as Western 
enthusiasm for phage therapy was all but extinguished. However, despite minimal 
contributions to the field of phage therapy during this time, Western researchers instead 
utilized model phages such as T4 and Lambda to make revolutionary discoveries in 
molecular biology and genetics. One such groundbreaking experiment was that of Alfred 
Hershey and Martha Chase, who in 1952 used the E. coli phage T2 to prove that DNA 
and not protein served as the genetic material in living organisms [33] (Figure 4). Model 
phage catalyzed many other important discoveries, including messenger RNA, DNA 
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recombination, the triplet nature of the genetic code, DNA ligase, gene regulation, and 
epigenetic gene regulation (see Reference [2] for list of relevant citations).  
 
Figure 4: The Hershey-Chase Experiment. In 1952, A. Hershey and M. Chase used radioactively-labeled 
bacteriophage to show that it was the phage’s DNA, and not its protein coat, that entered the host cell and 
provided instructions for the synthesis of new phage. This, combined with similar conclusions from O. 
Avery, C. MacLeod, and M. McCarty’s transformation studies with Streptococcus pneumoniae bacteria, 
served as conclusive evidence that DNA, and not protein, serves as the genetic material in living organisms. 
Source: https://www.msu.edu/course/lbs/333/ fall/hersheychaseexpt.html. 
 
In recent years, bacteriophage research has expanded into many different fields 
and yielded a variety of innovative applications. Some of the most significant of these 
applications will be discussed in the next chapter. 
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CHAPTER 4 
 
 
CURRENT APPLICATIONS OF BACTERIOPHAGE 
 
 
A. BASIC RESEARCH APPLICATIONS 
 
As touched upon previously, bacteriophage have been utilized in basic research 
since the mid-1900s. Today, they continue to be important tools in molecular biology 
laboratories. Temperate phage such as P1 can be engineered and used as vectors to insert 
genes of interest into bacterial genomes [34]. Phage can also be programmed to express 
foreign proteins on the surface of their protein coats. For example, in 1994 a team of 
American scientists led by Maruyama succeeded in expressing E. coli and plant proteins 
on the protein coat of Lambda phage [35].  
A derivative of this concept is phage display technology, in which scientists 
express a protein of interest on the protein coat of a phage in order to explore its 
interactions with DNA, peptides, and other proteins. Generally, a DNA, peptide, or 
protein target is attached to the surface of a microtiter plate well. A library of phages, 
each displaying a different protein, is added to the well; those expressing interaction 
partners of the target will bind, while the other phage will be washed away. The attached 
phage are then eluted and amplified in bacterial hosts, resulting in an enhanced library 
containing much fewer non-binding phages. The process can be repeated several times 
with the new library to further refine the population, and then the genomes of the 
interacting phages can be sequenced to identify the protein interaction partners of the 
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target. Recently, phage display has been of great interest in screening libraries of 
antibodies for those with the desired affinity for a particular antigen [36] and has also 
been utilized in drug discovery [37].  
Certain phage gene products are also being utilized in basic research. One such 
product is integrase, the enzyme responsible for mediating site-specific recombination 
between the genome of an integrating temperate phage and that of the host bacterium. 
Life Technologies (Invitrogen Corporation, Carlsbad, CA) manufactures a commercial in 
vitro cloning method called GATEWAY
TM
 that utilizes integrase from phage Lambda to 
clone a variety of bacterial, mammalian, and plant inserts more efficiently than is 
possible with traditional restriction enzyme methods [38]. In addition, certain phage 
integrases have been shown to facilitate site-specific recombination in mammalian cells, 
opening up promising new avenues for integrase-mediated cell line manipulation, 
transgenic organism creation, and gene therapy. In fact, several gene therapy successes 
have already been achieved with the φC31 integrase in the lab. For example, Olivares et 
al. have reported stable, long-term, and therapeutically significant expression of human 
α1-antitrypsin and human factor IX in the livers of mice [39], while other studies have 
reported the use of φC31-mediated gene therapy to restore function of laminin B3 in 
human skin cells and human Type VII collagen in human skin cells and fibroblasts [38].  
Another novel application for phage integrases is in developing rewritable digital 
data storage modules to store digital information, such as cell division or differentiation 
events, within a chromosome in live cells. Such modules are potentially applicable to the 
study and engineering of a variety of biological systems related to aging, cancer, 
development, and other diseases and processes [40]. 
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Phage studies also continue to contribute to our understanding of gene regulation. 
The processes that regulate gene expression in the temperate E. coli phage Lambda, 
including the “switch” that allows the phage to shift between the lytic and lysogenic 
lifecycles, are well-characterized [41]. However, phage encompass a vast range of 
genetic diversity that still holds many secrets, particularly in terms of how different phage 
regulate their gene expression. For example, in 1993, Oberto et al. identified a novel type 
of antitermination in the E. coli phage HK022, a relative of Lambda [42]. In Lambda and 
many of its relatives, early phage genes are located downstream of a set of transcription 
termination sites, or terminators, that cause RNA polymerase to halt transcription. To 
achieve full gene expression, these phages express a protein called N, which, in 
conjunction with several E. coli-encoded genes, modifies RNA polymerase so that it can 
read through these terminators and continue to transcribe downstream genes. Thus, N is 
called a transcription antiterminator. As a Lambda relative, HK022 contains a similar 
genetic organization, with early phage genes located downstream of terminators. 
However, unlike for Lambda, no protein outside of RNA polymerase is required to 
achieve antitermination [43]. Instead, the phage genome contains two cis-acting sites 
called putL and putR whose transcripts form putative stem-and-loop structures that 
directly modify RNA polymerase to promote “factor-independent” antitermination [44].  
Characterization of these new RNA structures has been limited by a lack of 
knowledge of similar structures in other phages, but the increasingly availability of new 
phage sequences has facilitated the identification of similar sites in other phage through 
comparative sequence analysis. Notably, in 2011 King et al. reported the discovery of 
put-like elements in two other E. coli phages as well as in the Erwinia tasmaniensis 
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phage Et88 [44]. Interestingly, such elements were also identified in the genomes of 
three bacterial species, and similar but likely mechanistically distinct cis-acting RNA 
elements have been described in Bacillales bacteria [45]. As these Bacillales elements 
have been implicated in antitermination of operons that control biofilm and capsular 
polysaccharide formation, a thorough understanding of such novel RNA molecules could 
be useful in unraveling these processes, which are often related to pathogenesis, and 
perhaps open new therapeutic avenues.  
 
B. INDUSTRIAL APPLICATIONS 
 
Bacteriophage have traditionally been considered a nuisance in industries that 
utilize bacteria to make products, including the food, chemical, pharmaceutical, feed, and 
pesticide industries [46]. One industry in which these problems have been extensively 
documented is the dairy industry. The production of milk-based products such as yogurt 
and cheese requires inoculation of starter cultures of lactic acid bacteria, which are added 
to pasteurized milk to begin the production process. If even a single active phage capable 
of infecting the starter culture strains is present in the milk or any of the other ingredients, 
it can multiply rapidly, killing sensitive starter culture bacteria and reducing the quality of 
the final product. In severe cases, the inoculated milk has to be thrown out entirely. Since 
the first report of phage contamination in dairy starter cultures in 1935, several advances 
have been made towards alleviating the problem, including adapted factory design, 
improved sanitation, production process alterations, strain rotation, and use of phage-
resistant strains. At the same time, research into these solutions has catalyzed the 
biological characterization of dairy phages. Efforts to understand phage diversity and 
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phage-host interactions continue as new phage variants emerge and the search for novel 
control strategies continues [47]. 
Despite their notoriety in the dairy industry, phage have many promising 
beneficial applications in other fields. Just as phage contamination can be detrimental in 
the dairy industry, bacterial contamination is a major problem in many other industries, 
including biofuel production and food safety. In these industries, phage are a potential 
ally rather than a foe. In the food industry, contamination by pathogenic bacteria can 
sicken consumers, trigger costly product recalls, and damage a company’s reputation 
permanently. Chemical or antibiotic treatments, while they may be effective at killing 
bacterial contaminants, are undesirable as they may be harmful to humans who later 
purchase and consume the product. Thus, phage represent an ideal solution for combating 
pathogenic bacteria on food products. Recognizing their potential, the biotechnology 
company Intralytix (Baltimore, MD) has developed whole-phage preparations effective 
against Listeria monocytogenes, E. coli, and certain Salmonella serotypes. ListShield
TM
, 
EcoShield
TM
, and SalmoShield
TM
 each contain a mixture of several lytic phage strains 
and have been demonstrated to significantly reduce levels of their target pathogens on 
food [48].  
Another phage-based approach to reducing bacterial contamination has shown 
promise in the biofuel industry. Like the use of integrase in basic research, this approach 
utilizes a phage gene product rather than whole phage – phage lysis enzymes called 
endolysins, or simply lysins, are isolated and used to destroy bacterial contaminants 
through the degradation of peptidoglycan, the major structural component of bacterial 
cell walls. Ironically, some of the most detrimental of these contaminants are the same 
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lactic acid bacteria that are essential to the dairy industry. To eliminate them in biofuel 
production settings, where they can reduce ethanol production by up to 27%, Roach et al. 
have purified several phage lysins and demonstrated their utility in reducing 
contamination by gram positive bacteria in a biofuel production context [49]. 
In addition to the many applications of natural phage and phage gene products, 
genetic engineering can further expand the utility of bacteriophage in industry to almost 
limitless possibilities. In one particularly innovative initiative, a team of material 
scientists at MIT has created functional nanobatteries from engineered filamentous M13 
phage. The engineered phage, dubbed E4, express a compound called tetra glutamate on 
their outer protein coats; this compound allows them to organize into nanowires when 
exposed to aqueous Co3O4, a paramagnetic compound that is the main component of the 
anodes found in lithium-ion batteries [50]. The virus nanowires then self-assemble on 
polymer films to form anodes. The same E4 phage were used as the starting point for the 
cathode-forming phage; in the cathode, the tetra glutamate reacts with FePO4 to form 
nanowires. To improve the conductivity of the cathode, essential to ensure the speed of 
the completed battery, the researchers modified a minor protein coat protein so that it 
would bind to conductive carbon nanotubes. These phage-nanotube complexes self-
assemble to create a highly conductive material for the cathode [51]. When combined, the 
phage-based anode and cathode produce an economical and environmentally friendly 
alternative to traditional lithium-ion batteries. The nature of these self-assembling viral 
arrays is such that they could be formed into extremely light-weight batteries of virtually 
any shape, from traditional button-cell disks to pliable, unobtrusive films that could be 
utilized in products such as high-tech clothing and electric blankets [52].  
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Another phage engineering project that demonstrates the wide applicability of 
engineered phage is one led by Timothy Lu, who created phage capable of dispersing 
bacterial biofilms [53]. Biofilms are communities of bacteria that frequently grow on 
surfaces in a variety of environments, including dental plaque, water pipes, medical 
devices, and industrial equipment. Bacteria in biofilms are surrounded by an extracellular 
matrix of polysaccharides, proteins, nucleic acids, and lipids that provides an 
impenetrable barrier to antibiotics and other chemical treatments, meaning that biofilms 
are difficult to remove and thus can constitute a continuous source of contamination or 
infection. There has been some success in using natural lytic phage to destroy biofilms, 
but phage, too, are often hindered by the sticky extracellular matrix. To alleviate this 
problem, Lu engineered phage to produce a matrix-degrading enzyme during replication. 
Upon release at the conclusion of the lytic cycle, the enzyme degrades the extracellular 
matrix, allowing phage to penetrate into the innermost layers of the biofilm (Figure 5). Lu 
reported approximately 99.997% reduction in bacterial biofilm counts using the 
enzymatic phage, representing a 2 orders of magnitude improvement over nonenzymatic 
phage. This project, along with the phage-based batteries discussed earlier, demonstrates 
the vast array of possibilities that can be unlocked by customizing phage form and 
function through genetic engineering.  
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Figure 5: Engineered Phage Produce an Antibiofilm Enzyme. To combat biofilms, which are 
characterized by a thick extracellular matrix that constitutes a significant barrier to antibiotic treatment, T. 
Lu has engineered lytic bacteriophage to produce a matrix-degrading enzyme as they replicate. Upon lysis, 
the enzyme is released into the environment along with the progeny phage particles, where it degrades the 
extracellular matrix and renders inner-layer bacteria accessible to the phage. Source: http://www2. 
technologyreview.com/TR35/Profile.aspx?TRID=967. 
C. MEDICAL APPLICATIONS 
 
As touched upon in the last chapter, researchers have been interested in the 
medical applications of bacteriophage ever since their discovery. Because of the recent 
explosion of antibiotic resistant pathogens, research into these applications is of 
increasing importance. As mentioned previous sections, phage-based treatments can be 
applied to contaminated foods to kill pathogenic bacteria and prevent infection, and 
phage integrases have shown promising applications in gene therapy. However, phage 
can also be used to prevent and treat disease more directly. One application for which 
researchers are developing phage is the diagnosis of bacterial pathogens. Because of their 
specificity of infection, phage can distinguish between different species, and often 
different strains, of bacteria, which can aid in the rapid culture-based diagnosis of 
pathogens such as tuberculosis. Such research has been abundant recently in China. In 
2000, for instance, Lu Bin et al. developed recombinant phage capable of recognizing 
rifampicin-resistant tuberculosis [54]. Similarly, in 2004, Hu Zhong-Yi et al. described a 
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method for rapid diagnosis of tuberculosis using phage [55], and in 2007 Lin Zhao-Yuan 
et al. researched phage-based methods for early diagnosis of tuberculosis-related pleurisy 
[56].  
Phage have also been shown to be an effective means of vaccine delivery. Using 
phage display technology, immunogenic peptides can be expressed on the protein coat of 
filamentous phage. Once injected into a macroscopic host, these phage are capable of 
inciting both cellular and humoral immune responses, making them superior to vaccines 
containing just the peptide itself [57]. Additionally, in 2003, Westwater et al. genetically 
engineered a phage strain capable of delivering an antibacterial agent to pathogenic 
bacteria [58]. 
Facing the growing threat of antibiotic-resistant pathogens, many researchers have 
once again begun to consider phage therapy as a viable strategy to treat bacterial 
infections. Besides a number of anecdotal reports, phage therapies have recently been 
tested more rigorously in clinical trials. In 2006-2007, for example, phage were 
successfully used to treat chronic Pseudomonas aeruginosa ear infections in one of the 
first modern phase-two clinical trials involving phage therapy; within six weeks of 
treatment with a single 2.4-ng dose of a six-phage mixture, 92% of patients showed 
marked improvement, while the infections in 25% had resolved completely [59]. In 2009, 
a phase-one safety trial of phage active against Staphylococcus aureus, Pseudomonas 
aeruginosa, and E. coli reported no adverse effects in 39 patients with chronic venous leg 
ulcers after 12 weeks of treatment with targeted bacteriophage [60]. Also in 2009, a 
research team in Bangladesh began a clinical trial sponsored by multinational food and 
beverage giant Nestlé to assess the efficacy of bacteriophage-based therapeutics in 
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treating childhood diarrhea caused by E. coli [61]; the trial was completed in January 
2013, but results have yet to be published [62].  
The great potential that bacteriophage hold with regards to the treatment of 
bacterial infections is particularly important as ever more deadly antibiotic-resistant 
pathogens emerge. Phage therapy, including its advantages, its disadvantages, hurdles 
hindering its development, and some strategies for overcoming those hurdles, is treated in 
more detail in the next chapter. 
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CHAPTER 5 
 
 
PHAGE THERAPY 
 
 
Of all the applications of bacteriophage, phage therapy is perhaps the one whose 
potential benefits have been most underdeveloped. As described in previous chapters, 
phage therapy is a method of using lytic phage to treat bacterial infections, especially in 
humans, and was first utilized by Felix d’Herelle in 1919. Phage therapy was further 
developed primarily in Eastern Europe and the former Soviet Union. In the West, 
however, the widespread emergence of antibiotics in the 1940s caused most research into 
phage therapy to cease. At the time, phage therapy was plagued by low efficiency and 
toxicity (due to contamination of phage preparations with bacterial cell wall components) 
that stemmed primarily from an insufficient understanding of phage biology; to Western 
researchers, it seemed no match for the wide applicability, ease of production, and 
staggering efficacy of antibiotics. In addition, the stigma attached to anything associated 
with the Soviet Union provided further reason for some Western scientists to abandon the 
pursuit of phage as therapeutics. 
Despite the relative dearth of phage therapy research in the West, it has been 
continuously developing in Eastern Europe and the former Soviet Union since the 1940s. 
Although the majority of research results reported have been positive, the fact that it has 
mostly been published in non-English language journals and often has not adhered to the 
rigorous scientific standards required in most Western countries has caused the potential 
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value of phage therapy to be largely overlooked in other parts of the world. However, 
recently a formidable new threat has emerged: the rapid rise of antibiotic resistant 
bacterial infections. In the scramble for a solution, an increasing number of scientists, 
including those in the West, are looking to phage therapy.     
 
A. THE RISING THREAT OF ANTIBIOTIC RESISTANCE 
 
Antibiotic resistance itself is not a new phenomenon. Even before the first 
antibiotic was discovered by Swiss scientist Alexander Fleming in 1928, there existed 
many bacteria naturally immune to their effects. But since humans began utilizing 
antibiotics to treat bacterial infections on a global scale, antibiotic-resistant bacteria have 
been emerging at an accelerated rate, and many bacterial pathogens that were once easily 
conquered by common antibiotics have already developed resistance. 
The recent rapid increase in antibiotic resistant bacteria can be attributed 
primarily to human abuse and overuse of antibiotics. To understand how this sort of 
human activity can lead to antibiotic resistance, it is helpful to consider the development 
of resistance on a molecular scale. In general, a bacterium can become resistant to 
antibiotics through two different pathways. The first is random mutation (Figure 6a). As 
bacteria grow and divide, occasional mutations can occur randomly in their genomes. 
Sometimes, one or more mutations alters the bacteria in a way that makes them 
invulnerable to a particular antibiotic. For example, the mutant bacteria may produce an 
enzyme that modifies or degrades the antibiotic, rendering it inactive. The second is 
horizontal gene transfer (Figure 6b). Bacteria containing resistance genes can sometimes 
transfer these genes horizontally to non-resistant bacteria, making them resistant as well. 
When antibiotics are applied, non-resistant bacteria are killed, leaving behind a few 
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resistant bacteria that can multiply rapidly without competition. The abuse and overuse of 
antibiotics by humans only increases this selective pressure.  
 
Figure 6: Molecular Pathways Involved in the Development of Antibiotic Resistance. Panel a.) shows 
how drug resistance is generated through random mutation. Panel b.) illustrates how drug resistance 
spreads to non-resistant bacteria through horizontal gene transfer. In both cases, the use of antibiotics 
facilitates the propagation of drug resistant bacteria by removing non-resistant competitors. Source: 
National Institute of Allergy and Infectious Diseases, http://www.niaid.nih.gov/topics/antimicrobial 
Resistance/Understanding/Pages/causes.aspx. 
The Infectious Disease Society of America estimates that as much as half of 
antibiotic use is unnecessary or inappropriate [63]. As human abuse of antibiotics 
continues, antibiotic resistant infections have become an increasingly serious problem 
worldwide. Take Streptococcus pneumoniae, the infectious agent responsible for 
pneumonia, meningitis, sepsis, and acute sinusitis among other diseases, for example. In 
1980, only 5% of S. pneumoniae bacteria were resistant to the commonly used antibiotic 
Penicillin. Today, that number has risen to a staggering 40% [64].  
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Another startling phenomenon has been the emergence of methicillin-resistant 
Staphylococcus aureus (MRSA). Its rise has been marked by a similar trend – 2.4% of 
Staph infections in U.S. hospitals were methicillin resistant in 1987, a figure that had 
risen to 29% by 1991 and 59.5% in 2003, representing a growth rate of more than 12% 
per year on average [65]. In 2005, there were 100,000 cases of MRSA infection recorded 
in the United States. Of those, 20,000 died of their illness, exceeding the number of 
patients who died of AIDS that same year [66]. Multiple-resistant tuberculosis is another 
deadly disease that has been on the rise; each year, it infects 440,000 people and kills 
150,000 globally [67].  
In addition the loss of human life, there are also serious economic costs associated 
with antibiotic resistant infections. Patients afflicted with such infections spend an extra 
1-2 weeks in the hospital and require $20,000-$30,000 extra in treatment costs, equating 
to $35 billion in lost wages and a $20 billion burden on the health care system in the 
United States alone [68]. It is easy to see from these statistics that in order to ease these 
heavy economic burdens and prevent further loss of life, we need a solution to antibiotic 
resistant infections as quickly as possible. 
In accordance with the severity of the problem, a number of potential solutions 
are currently under development. Many researchers are focusing their efforts on the 
development of new antibiotics. However, not only is this expensive and time-consuming, 
but it is also unlikely to provide a lasting solution: in a few years, bacteria resistant to 
newly developed antibiotics will begin to emerge as well. In fact, some experts even 
maintain that existing antibiotics already represent the best we will ever have [69]. To 
combat antibiotic resistance, then, we need to look elsewhere for a solution. 
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Fortunately, many novel approaches are currently being considered by researchers 
and doctors across the globe. Potential alternatives to antibiotics include colloidal silver, 
antibacterial peptides, antibacterial vaccines, bacterial interference, and a number of 
natural antibacterial molecules found in foods such as cranberries, honey, garlic, and 
coconut oil. However, one of the most promising of these “new” approaches is not new at 
all. Phage therapy already has almost 100 years of documented success in treating 
bacterial infections to back it up, and several clear advantages help it stand out further as 
a promising alternative to our rapidly dwindling antibiotic lineup. 
 
B. PHAGE THERAPY CASE STUDIES 
 
Although phage therapy is not a new idea, it is still a relatively novel concept to 
most people, especially Westerners. However, in a number of isolated cases, primarily in 
Eastern Europe and the former Soviet Union but also occasionally in the West, many 
patients have already reaped its benefits. One such patient is Roy Brillion, a Texas retiree 
who struggled with an antibiotic-resistant bacterial infection in a palm-sized open wound 
on his thigh for months until his doctor, Randy Wolcott, took a chance on phage therapy. 
Wolcott, having exhausted his hospital’s arsenal of antibiotics to no effect, had heard of a 
clinic in the Republic of Georgia that offered over-the-counter phage preparations. Out of 
conventional options and with his patient’s infection only worsening, he decided to give 
phage therapy a shot and headed to Georgia. Incredibly, just a few drops of the phage 
solution Wolcott brought back were sufficient to completely heal the wound within three 
weeks [60]. 
Brillon’s case is by no means the only success story. The George Eliava Institute 
in Tbilisi, Georgia, from which Wolcott obtained his phage preparations, has successfully 
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treated countless patients using phage therapy since its founding in 1923. Records of 
phage therapy successes are also present in more recent literature. Of these, a series of 
studies undertaken by Polish microbiologist and immunologist Stefan Slopek at the 
Hirszfeld Institute in Poland have been particularly influential. From 1981 to 1986, 
Slopek used phage therapy to treat 550 patients with various bacterial illnesses, including 
Staphylococcus aureus, Pseudomonas, E. coli, Salmonella, and Klebsiella pneumoniae 
infections [70]. Of the 550 patients, who ranged in age from one week to 86 years, a full 
92.4% regained health following their treatment; 6.9% showed transient improvement, 
and phage therapy had no effect in only 0.7% of cases.  
A similar, more recent study was conducted by Beata Weber-Dabrowska et al. at 
the Polish Academy of Sciences Institute of Immunology and Experimental Therapy 
from 1987 to 1999 [71]. Of the 1307 patients who received phage therapy as part of the 
study, 85.9% completely recovered, while another 10.9% showed transient improvement 
and just 3.8% did not improve at all. Notably, most of the cases involved in these two 
studies were chronic infections where antibiotics had already failed; in fact, in the Slopek 
study, 94.2% of cases were antibiotic-resistant, meaning that phage therapy provided 
these patients with perhaps their only means of recovery. A number of other successful 
phage therapy studies conducted over the second half of the 20
th
 century are summarized 
in Table 2.  
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Table 2: Major Phage Therapy Successes in Poland and the Former Soviet Union. Source: 
Sulakvelidze A, Alavidze Z, Morris JG Jr. 2001. Bacteriophage therapy. Antimicrob. Agents Chemother. 
45(3):649-59. 
Pub. 
Year 
Authors 
Targeted 
Infection(s) 
Targeted 
Pathogen(s) 
Study Details 
1968 
Babalova     
et al. 
Bacterial 
dysentery 
Shigella Successful prophylaxis using phage 
1974 
Sakandelidze 
and 
Meipariani 
Peritonitis, 
osteomyelitis, 
lung abscesses, 
post-surgical 
wound infections 
Staphylococcus, 
Streptococcus, 
Proteus 
Antibiotic-resistant infections in 236 
patients treated with phage; infection 
eliminated in 92% 
1978 
Litvinova     
et al. 
Intestinal 
dysbacteriosis 
E. coli, Proteus 
Combination of phage and bifidobacteria 
successful in treating antibiotic-resistant 
dysbacteriosis in 500 low birth weight 
infants 
1978 
Zhukov-
Verezhnikov 
et al. 
Suppurative 
post-surgical 
infections 
Staphylococcus, 
Streptococcus, E. 
coli, Proteus 
Adapted phages selected against bacterial 
strains isolated from individual patients 
reported to be to superior to commercial 
phage preparations in the treatment of 60 
patients 
1980 
Ioseliani et 
al. 
Lung and pleural 
infections 
Staphylococcus, 
Streptococcus, E. 
coli, Proteus 
Combination of phage and antibiotics 
successful in treating 45 patients 
1981 
Tolkacheva     
et al. 
Bacterial 
dysentery 
E. coli, Proteus 
Combination of phage and bifidobacteria 
superior to antibiotics in treatment of 59 
immunosuppressed leukemia patients 
1982 
Meladze         
et al. 
Lung and pleural 
infections 
Staphylococcus 
Full recovery observed in 82% of 223 
patients treated with phage versus 64% of 
117 treated with antibiotics 
1987 Cislo et al. 
Suppurative skin 
infections 
Pseudomonas, 
Staphylococcus, 
Klebsiella, E. coli, 
Proteus  
Chronically infected skin ulcers in 31 
patients treated with phage; 74% success 
rate 
1987 
Kucharewicz-
Krukowska 
and Slopek 
Various 
infections 
Pseudomonas, 
Staphylococcus, 
Klebsiella, E. coli, 
Proteus  
Immunogenicity of therapeutic phages not 
observed to impact therapy in 57 patients 
1987 
Weber-
Dabrowska  
et al. 
Suppurative 
infections 
Staphylococcus, 
various gram-
negative bacteria  
Successful treatment of 56 patients; orally 
administered phage observed to reach blood 
and urine 
1989 
Kochetkova 
et al. 
Post-surgical 
wound infections 
Staphylococcus, 
Pseudomonas 
Successful treatment in 82% of 65 cancer 
patients treated with phage versus 61% of 
66 treated with antibiotics 
1991 
Bogovazova 
et al. 
Skin and nasal 
mucosa 
infections 
Klebsiella ozaenae, 
K. rhinoscleromatis, 
K. pneumoniae 
Successful treatment of 109 patients using 
adapted phage 
1991 Sakandelidze 
Rhinitis, 
pharyngitis, 
dermatitis, 
conjunctivitis 
Staphylococcus, 
Streptococcus, E. 
coli, Proteus, 
Enterococcus, P. 
aeruginosa 
Clinical improvement observed in 86% of 
360 patients treated with phage, 48% of 404 
treated with antibiotics, and 83% of 576 
treated with both phage and antibiotics 
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1993 
Miliutina and 
Vorotyntseva 
Bacterial 
dysentery, 
salmonellosis 
Shigella, Salmonella 
Combination of phage and antibiotics 
successful in cases where antibiotics 
ineffective 
1994 
Kwarcinski  
et al. 
Recurrent 
subphrenic 
abscesses 
E. coli 
Antibiotic-resistant strain successfully 
treated with phage 
1995 
Perepanova 
et al. 
Inflammatory 
urologic diseases 
Staphylococcus, E. 
coli, Proteus 
Clinical improvement observed in 92% and 
bacterial clearance observed in 84% of 46 
patients treated with adapted phage 
1999 Stroj et al. 
Cerebrospinal 
meningitis 
K. pneumoniae 
Successful treatment by orally administered 
phage after failure of antibiotics in a 
newborn  
 
 
C. ADVANTAGES OF PHAGE THERAPY 
 
As these reports illustrate, phage therapy has the potential to become a highly-
effective replacement for our failing antibiotics. In particular, phage therapy possesses 
several major advantages over antibiotics and many other potential alternatives; five such 
advantages are detailed below. 
1. Ability to Self-Replicate: Unlike antibiotics, bacteriophage when used in the treatment 
of disease are a self-replicating therapeutic; that is, as they exert their anti-bacterial 
effects, they also replicate to create more therapeutic agents – more phage. In the last step 
of the lytic cycle, the bacterial host cell is lysed, releasing these new therapeutics into the 
environment to infect and kill more bacteria. This way, the number of therapeutic agents 
available is uniquely tied to the number of host bacteria – the phage multiply more 
rapidly when hosts are plentiful and disappear once their hosts have been depleted, 
ensuring they are present in large numbers when necessary to fight pathogens and recede 
once their job is done. Another advantage lies in the fact that unlike antibiotics, which are 
dispersed throughout the body after administration, phage are concentrated at the site 
where their hosts are located, potentially affording them very high efficiency in fighting 
infection.  
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       The relatively large number of progeny phage released per cycle, known as burst 
size, in conjunction with the short amount of time required make the self-replicative 
ability of phage an even greater advantage. In general, a single DNA phage can generate 
several hundred progeny in a span of 30 to 60 minutes, while an RNA phage can produce 
5,000 to 10,000 [72]. To fully appreciate the powerful multiplicative effect this produces, 
consider the well-characterized E. coli phage T4 as a typical example. A double-stranded 
DNA phage, T4 has a burst size of around 200 and requires about 30 minutes per 
replication cycle [73]; under ideal conditions and with an unlimited host population, a 
single T4 phage particle is capable of producing 10
23
 progeny in just five hours. Thus, a 
relatively low initial dose of therapeutic phage could theoretically be sufficient to tackle a 
bacterial infection of any magnitude, and massive stocks of phage can be produced easily 
and cost-effectively for distribution to patients. 
2. Cost Effectiveness: A second advantage of phage therapy is cost effectiveness. The low 
cost of phage therapy is due to two main factors. The first is the self-replicative ability of 
phage. Because phage are self-replicating, only a suitable host species and an appropriate 
culture medium are required to manufacture almost unlimited amounts in vitro for use in 
therapeutic preparations. The self-replicative ability of phage also means that the dosage 
size and frequency of reapplication can potentially be very low, minimizing treatment 
costs for patients.  
The second factor that contributes to the cost-effectiveness of phage therapy is 
that novel phage types can be isolated from the environment with relative ease. In 
contrast, most new antibiotics must be synthesized in the lab, generally a very costly 
process in terms of both time and capital. In fact, a new phage strain can be isolated and 
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purified in a matter of weeks with a few hundred dollars, but a new chemical antibiotic 
takes on average eight to ten years and $800 million to $1.7 billion to bring to the market 
[74].  
Because of these two factors, phage preparations are generally much less 
expensive than antibiotics. For example, phage preparations such as the ones Randy 
Wolcott obtained in his search for an alternative to antibiotics can be purchased from the 
George Eliava Institute for just $2 per vial [75]. In stark contrast, a typical regimen of 
common antibiotics such as Ciprofloxacin, Ofloxacin, and Azithromycin can cost 
upwards of $100, with newer and more powerful antibiotics costing even more [65].    
3. Specificity: As covered in Chapter 1, each type of phage is capable of infecting only a 
limited range of bacterial hosts based on the receptors to which it adsorbs. This 
specificity represents a unique advantage to phage-based therapeutics, as it means that a 
properly chosen phage strain will destroy pathogenic bacteria while leaving the beneficial 
bacteria normally present in the body intact. In contrast, most antibiotics exert a much 
more generalized effect, killing both pathogenic and beneficial bacteria. This leads to a 
variety of side effects, including diarrhea, vomiting, stomachaches, headaches, 
opportunistic infections by other microbes or parasites, and liver damage. These are 
unpleasant at the very least and can even be fatal in patients already weakened by disease. 
Because of the strong specificity of phage, phage therapy eliminates almost all of these 
adverse side effects.       
4. Ability to Evolve: The dynamic evolutionary nature of phage is another of phage 
therapy’s main advantages. Just as bacteria can develop resistance to antibiotics, they are 
also capable of becoming resistant to phage. However, unlike static antibiotics, phage can 
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counteract the resistance mounted against them and evolve right alongside their hosts to 
regain their infectivity. Thus, a constant evolutionary arms race naturally rages between 
bacteria and the phage that infect them. This phenomenon has been documented 
experimentally; in 2002, English scientists Angus Buckling and Paul Rainey performed a 
series of experiments involving multiple generations of bacteria and phage [76]. Starting 
from a single isogenic culture of Pseudomonas fluorescens SBW25, they inoculated 
bacterial cells with the naturally associated bacteriophage SBW25Φ2. Every two days, 
the researchers isolated bacterial colonies and phage particles from the culture before 
transferring a portion of the culture to a new culture vessel, completing a total of 50 
transfers (representing approximately 400 bacterial generations). After every two 
transfers (~15 bacterial generations), they evaluated the resistance of the bacteria to the 
phage from the same culture as well as to phage from previous and subsequent cultures.  
While the phage from previous cultures encountered a high rate of bacterial resistance 
due to the evolution of bacterial mechanisms against them, those from subsequent 
cultures were able to infect bacterial hosts at a higher rate than those from the same 
culture, showing that they had evolved through the generations to renew their infective 
abilities. 
Contributing to phage evolutionary dynamics is the acquisition of new traits 
possible through horizontal gene transfer between different phages and even between 
phages and their bacterial hosts. Horizontal gene transfer between different phages, 
illustrated in Figure 7a, can occur when two or more lytic phages co-infect a single host 
bacterium. As they replicate, their genomes can recombine with each other, producing 
unique progeny with genes from multiple parent phages. As an extreme example of this 
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recombination, there have even been reports of phage genomes containing the entire 
genome of another phage [77]. This suggests that some phage genomes may be able to 
shuttle between the genomes of other phage and create viral chimeras that could lead to 
the rapid evolution of new phage types.  
Temperate phage can also undergo recombination with their bacterial hosts as 
depicted in Figure 7b. When an integrated prophage excises itself from the host 
chromosome, on occasion it can erroneously excise a portion of the host genome as well. 
As the excised phage subsequently undergoes lytic replication, its progeny will all 
contain a copy of the mistakenly-excised bacterial genes. These two avenues for 
horizontal gene transfer coupled with the quick replication cycles of bacteriophage serve 
to greatly facilitate phage evolution as they fight to maintain infectivity against their 
hosts.  
5. Natural Abundance: Besides their evolutionary prowess, the natural abundance of 
phage types in the environment provides another avenue for combating phage resistance: 
even if a population of bacteria develops resistance to one phage type, there naturally 
exist many more distinct phages to which these resistant bacteria may still be vulnerable. 
In fact, for each of the approximately 10 million bacterial species on the planet it is 
estimated that there exist 10 distinct bacteriophage genomes that can infect it [78]. 
Moreover, if the case of the soil bacterium Mycobacterium smegmatis is any indication, 
these numbers may be severe underestimates – more than 4000 distinct phage types 
specific to M. smegmatis have already been isolated, over 600 of which have been fully 
sequenced (The Mycobacteriophage Database [phagesdb.org]). Furthermore, phage can 
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be easily manipulated in the lab to produce “artificial” phage with certain desired 
properties; examples of such engineered phage were discussed in Chapter 3. 
 
 
Figure 7: Mechanisms of Horizontal Gene Transfer. Panel a.) depicts horizontal gene transfer between 
two different parent phages. In clonal infection (low multiplicity of infection), a single parent phage infects 
a host bacterium, and the resulting progeny phage are clones of the parent. In co-infection (high 
multiplicity of infection), two or more different phages simultaneously co-infect the same host bacterium. 
As they replicate, their DNA recombines, producing a diverse set of progeny with genes from some or all 
of the parent phages. Source: Dennehy JJ. 2009. Bacteriophages as model organisms for virus emergence 
research. Trends Microbiol. 17(10):450-7. Panel b.) shows a mechanism of horizontal gene transfer 
between a temperate phage and its bacterial host. The integrated prophage excises itself imprecisely from 
the bacterial chromosome, and the extra bacterial DNA is incorporated into the phage progeny when the 
parent phage replicates. Source: http://www.personal.psu.edu/czc5161/blogs/testing/transduction.html. 
 
D. CHALLENGES FACING PHAGE THERAPY 
 
Given the clear advantages of phage therapy over antibiotics and even other 
antibiotic alternatives, why are researchers everywhere not scrambling to isolate new 
phages effective against increasingly common antibiotic resistant infections such as 
MRSA? Why are Western doctors not already routinely prescribing phage capsules 
instead of antibiotic pills? Unfortunately, there have been, and are still, many obstacles 
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blocking the road to making widespread phage therapy a reality. Some are inherent in the 
biology of phage themselves, an area that remains poorly understood, while others are 
man-made. Several challenges from both realms are outlined in this section.  
Biological Challenges 
1. Kinetics: As the title of an article published in 2000 suggests, phage are subject to 
“peculiar kinetics” [79] in vivo that have complicated efforts to apply them 
therapeutically. In particular, their status as self-replicating therapeutics means that 
dosage is inherently impossible to control with any sort of rigor – no matter how many 
phage are initially administered, the numbers to which they multiply after reaching their 
hosts cannot be controlled or even accurately predicted. This means that it is difficult to 
determine how to dose phage therapeutics, as well as how often to re-administer them, in 
order to treat a particular infection. Even assuming the dosage could be determined 
accurately, reaching the target bacteria is no easy matter, especially for internal infections 
such as in the lungs. Although phage cannot harm human cells directly, they are still a 
foreign entity and are recognized as such by the immune system, which is very efficient 
at clearing them from the body entirely before they ever reach their intended bacterial 
targets [80].  
Another kinetics issue lies in the fact that the behavior of phage observed in vitro 
is often very different from their behavior in vivo. This is often because conditions in the 
body affect the way phage interact with their hosts. For example, the efficiency of phage 
infection is tied to host density, and there is often a threshold density below which phage 
replication is not observed at all – studies have reported threshold values of 102 cells/mL 
for cyanophage and 10
4
 cells/mL for T4 phage [7]. Host bacteria may therefore be 
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present in high enough concentrations to cause disease, but not high enough to achieve 
robust phage replication. In addition, phage are generally only able to infect actively 
dividing hosts – if bacterial populations within the body enter a latent state, as is the case 
for the agent of tuberculosis Mycobacterium tuberculosis, phage may be unable to 
remove them or even physically reach them in the first place. 
2. Toxicity: As described previously, phage themselves do not harm human cells. 
However, they may incite harmful effects while interacting with their host bacteria. In the 
last step of the lytic cycle, for example, lysis of the host can release endotoxins located on 
the bacterial cell surface into the body (Figure 8a). These endotoxins can subsequently 
induce detrimental reactions such as septic shock.  
Some temperate phage also carry toxin genes within their genomes; when these 
phage integrate into the host chromosome, they transfer these genes to their host, which 
can then begin to produce the toxin and become pathogenic. Pathogenic strains of Vibrio 
cholera, E. coli, Clostridium botulinum, Corynebacterium diphtheria, and Streptococcus 
pyogenes all obtain their respective toxin genes from bacteriophage as summarized in 
Table 3.   
Table 3: Bacterial Virulence Factors Carried on Phage. Source: http://www.sci.sdsu.edu/~smaloy/ 
MicrobialGenetics/topics/phage/phage-virulence.html. 
 
Bacterium Phage Disease 
Vibrio cholerae CTX phage Cholera 
Escherichia coli Lambda phage Hemorrhagic diarrhea 
Clostridium botulinum Clostridial phages Botulism 
Corynebacterium diphtheriae Corynephage beta Diphtheria 
Streptococcus pyogenes T12 Scarlet fever 
 
3. Specificity: The host specificity of bacteriophage is a double-edged sword: on one hand, 
it can be considered an advantage in that it precludes the destruction of beneficial bacteria 
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in the body, thus preventing many of the adverse side-effects associated with antibiotics. 
On the other hand, specificity can also be considered a disadvantage to phage-based 
therapies. As detailed previously, most antibiotics are effective against a relatively wide 
range of bacterial species, while each type of bacteriophage is limited to a very narrow 
host range, sometimes even restricted to specific strains within a species. This means that 
it is essential that the pathogen be identified to a high degree of accuracy before an 
effective therapeutic can be prescribed. This can sometimes be a relatively time-
consuming process, and for some patients in critical condition identification results may 
come too late. Furthermore, if the pathogen is misidentified, a patient’s condition may 
worsen as they waste time taking a phage therapeutic that is ineffective against the true 
cause of their infection.  
This challenge in particular played a large role in the widespread abandonment of 
phage therapy research with the advent of antibiotics in the mid-1900s. Because the 
specificity of phage was not well understood at the time, many researchers interpreted 
disappointing experimental results as a failure of the entire concept of phage therapy 
when in reality many of these failed trials were likely due to the administration of the 
incorrect phage types. In contrast, antibiotics often showed dramatic effects against broad 
classes of bacterial pathogens, and thus were adopted as the preferred method of treating 
bacterial infections in the West.       
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Figure 8: Toxicity and Specificity Issues Pose Problems in Phage Therapy. Panel a.) illustrates the 
toxicity problems sometimes associated with phage therapies that involve lytic phage. When the phage lyse 
their hosts, bacterial endotoxins can be released, leading to adverse inflammatory responses in the body. 
Panel b.) depicts the downside of phage specificity: each type of phage can only infect a select range of 
bacterial species, meaning an accurate diagnosis is a mandatory prerequisite to ensure a phage therapy 
regimen has any effect. Source: Lu TK, Koeris MS. 2011. The next generation of bacteriophage therapy. 
Curr. Opin. Microbiol. 14(5):524-31.  
Additional Challenges 
1. Regulatory Restrictions: In many areas of the world, regulatory restrictions pose a 
large obstacle to the establishment of phage therapy as a viable treatment strategy for 
bacterial infections. This problem is especially evident in the United States due to the 
relative unfamiliarity of the U.S. Food and Drug Administration (FDA) with 
bacteriophage. According to general FDA regulations for therapeutics, the safety of every 
distinct type of bacteriophage would have to be established separately before it could be 
approved for use in humans. For cocktails containing multiple phage types, a common 
strategy to alleviate difficulties with specificity and the development of resistance, the 
safety of each combination of phages would also have to be confirmed in addition to the 
safety of each individual phage in the mixture [81]. This represents an expensive and 
time-consuming process that could deter U.S. drug companies from investing in the 
development of phage therapies.  
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2. Intellectual Property Issues: Issues of intellectual property are another barrier 
hindering widespread development of phage therapies. Almost a century old, the concept 
of phage therapy itself cannot be patented. Although patents can be issued for specific 
phage types, the immense diversity and ubiquity of phages means that a competitor could 
easily isolate another distinct but still efficacious phage and develop a competing 
pharmaceutical for a particular disease [80]. As an illustration, a company may spend 
several years and considerable capital developing a phage-based pharmaceutical for E. 
coli infections. To protect their investment, the company could obtain a patent for the 
particular phage type their product employs, but another company looking to develop a 
similar product would only have to go through the relatively simple process of isolating a 
different E. coli phage to develop its own competing product. Because making a profit is 
what ultimately motivates pharmaceutical companies to mass-produce and distribute 
products, such an easily-copied product as a phage therapeutic is much less likely to be 
the subject of enthusiastic development than, for example, a newly-synthesized and 
patentable chemical antibiotic.    
3. Lack of Awareness: A general unfamiliarity with phages is perhaps one of the greatest 
non-biological obstacles that stand in the way of phage therapy’s further development. 
Because the development of phage therapy has historically taken place in Eastern Europe 
and the former Soviet Union, most early phage therapy research was published in 
Russian- and Polish-language journals, where it largely escaped the notice of Western 
scientists. Another consequence was that many of these studies, lacking important 
experimental components such as control groups and sufficiently large study populations, 
did not adhere to the relatively rigorous standards of Western science. As a result, most 
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scientists in the West were unable to keep up with new developments in the field, much 
less realize its potential, and this general ignorance of the concept of phage therapy 
remains in effect today. 
Currently, one of the only clinics actively pursuing phage therapy is the George 
Eliava Institute. Located in the Republic of Georgia, the Institute and its phage-based 
therapeutics remain far from the minds of scientists, doctors, and patients in the West. 
Complicating matters further is the fact the general public possesses little to no 
understanding of bacteriophages. Even if a patient was offered a phage-based treatment 
for his or her illness, he or she might remain extremely skeptical, and perhaps even be 
afraid to try the therapy. The patient may wonder: how can a virus cure another disease? 
Don’t viruses cause diseases themselves? Without a basic understanding of phage 
biology, these questions and fears might be enough to deter the patient from selecting a 
phage therapy regimen. If this general ignorance of phage therapy among patients, 
doctors, and scientists continues, it will be difficult, if not impossible, for phage therapy 
to develop on a large scale. Fortunately, the various obstacles described in this chapter, 
including lack of awareness, can be overcome. The next chapter explores several 
potential strategies for conquering each of these challenges. 
 
E. POTENTIAL STRATEGIES FOR ADVANCING PHAGE THERAPY 
 
Solutions to Biological Challenges 
Several strategies exist for combating the challenges associated with phage 
kinetics. The first is the continued study of phage characteristics and behavior, especially 
in vivo. Through such study, researchers will gain a better understanding of the 
conditions required to eliminate pathogens in vivo. This will help them to better predict 
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phage behavior, thus allowing them to decide which phages in what doses are most 
appropriate for therapeutic use. A team of British scientists led by Robert J.H. Payne at 
Oxford University have already made significant headway in this type of research. In 
2000, they published a series of equations that describe key events in phage in vivo 
kinetics [79]; such mathematical descriptions of phage behavior will be useful in making 
phage therapy maximally effective. Furthermore, although different equations would 
likely be required for distinct phage groups, kinetic behaviors observed in one phage 
could potentially be extrapolated to phages of similar genetic makeup to further simplify 
the complications associated with currently unpredictable kinetic patterns.   
Another strategy for overcoming the kinetic challenges posed by phage 
therapeutics is the utilization of artificial selection and genetic engineering to generate 
maximally effective therapeutic phage strains (Figure 9a-b). Take the problem of 
clearance by the immune system for example. In order to obtain phages capable of 
resisting clearance for a longer period of time, researchers can follow the example of Carl 
Merril et al., who developed a unique artificial selection method called serial passaging 
[82]. After injecting phage into the bloodstream of mice, the researchers re-isolated those 
phages that were able to survive in the bloodstream the longest, repeating the experiment 
until they had succeeded in directing the evolution of long-circulating phages that also 
had greater antibacterial capabilities than the parent strains. Researchers can also utilize 
genetic engineering to create phage with desired kinetic characteristics. For example, 
phage can be engineered to express certain proteins on their capsids that can prevent 
antibodies from recognizing and subsequently clearing the phage [83].  
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Circumventing the challenges associated with the self-replicating nature of phage 
therapeutics altogether, some researchers have proposed using lysis enzymes isolated 
from phage to treat bacterial infections [84] [85] [86], a strategy parallel to the use of 
lysins in the biofuel industry described in Chapter 3B. Working toward developing such 
strategies to combat Mycobacterium tuberculosis infections, several groups have 
analyzed various properties of lysinB proteins isolated from mycobacteriophages [87]. 
Although this strategy eliminates many of the kinetic issues associated with whole-phage 
preparations, it also reduces some of the advantages of phage therapy that arise from the 
self-replicative and evolutionary abilities of the phage and does not address the issue of 
potential toxicity from release of bacterial endotoxins upon lysis of the host cell.   
Other researchers have considered using engineered phage incapable of lysing 
their hosts to prevent possible toxic effects from the release of bacterial endotoxins [88]. 
However, similar to the use of phage lysins, therapeutics derived from these phage would 
lack the benefits associated with the self-replicative and evolutionary properties of 
normal lytic phage. To address the issue of toxicity induced by phage-mediated transfer 
of toxin genes to bacteria, continuing large-scale research efforts into the genetic 
characteristics of bacteriophage should provide immense benefits. The analysis of a large 
number of phage genomes will allow researchers not only to catalog toxicity genes, but 
also to identify which phages contain these genes. Such information will aid researchers 
in selecting phages without the potential of transferring toxicity to their bacterial hosts for 
therapeutic use. 
For this strategy to be maximally effective, it necessarily involves the isolation 
and characterization of novel phage types. Fortunately, new phage sequences are by no 
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means elusive. In fact, it is estimated that the current volume of sequence-characterized 
phages represent less than 0.0002% of the total worldwide diversity of phage genomes 
[78]. Given the vast number of phage genomes that remain to be discovered, it is crucial 
that researchers engage in large-scale isolation and genomic analysis of novel phage 
types in order to identify a more complete set of toxicity genes and work towards a better 
understanding of phage genomics and phage biology in general.        
The isolation and characterization of novel phage types also promises benefits for 
solving the problems related to phage host specificity – with more phages to choose from, 
a more diverse range of bacterial infections can be treated through phage therapy. 
However, phage researchers in Eastern Europe have already arrived at another solution, 
the efficacy of which has been demonstrated many times throughout phage therapy’s long 
history. Their strategy is to use a cocktail of bacteriophages containing multiple types of 
phages in a single solution (Figure 9c). For example, a pharmaceutical may contain 30 
different phages targeting five different species of bacteria [81]. This way, even if the 
specific pathogen infecting a particular patient is undetermined, there is still a high 
likelihood of the medication having an effect.        
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Figure 9: Potential Solutions to Phage Therapy Challenges. To address the problem of clearance by the 
immune system, a.) artificial section for phages able to circulate in the body longer can be applied to obtain 
phages capable of evading the immune system, and b.) phages can be engineered to circulate longer in the 
body, for example by expressing proteins on their capsids that prevent antibodies from recognizing and 
clearing them. To address the problem of phage specificity, c.) cocktails containing several different types 
of bacteriophage targeting a variety of common bacterial pathogens can be used to increase the likelihood 
of a therapy being effective. Source: Lu TK, Koeris MS. 2011. The next generation of bacteriophage 
therapy. Curr. Opin. Microbiol. 14(5):524-31.     
In Eastern Europe, where medical regulations are comparatively relaxed, the 
production and distribution of these sorts of phage cocktails presents few problems. 
However, in Western countries such as the U.S. with much stricter rules governing the 
pharmaceutical industry, the safety of every phage type used in such cocktails would 
have to be established both individually and in combination, an issue detailed in the 
previous section. Therefore, in order to implement many of the strategies for overcoming 
the biological challenges facing phage therapy, including the use of phage cocktails, 
Western countries need first to address some of these regulatory roadblocks. 
Solutions to Additional Challenges 
Finding solutions to bureaucratic challenges will represent a critical step in the 
advancement of phage therapy, particularly in Western countries. Towards such solutions, 
the U.S. FDA, along with regulatory agencies in other countries, needs to modify policies 
for managing phage-based therapeutics based on their unique characteristics, many of 
which were described in the previous section. However, for this to occur, regulatory 
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agencies must first establish a better understanding of these characteristics. Strategies to 
achieve this could include special training courses or the establishment of a small 
department with express regulatory control over phage therapeutics. In fact, the U.S. 
FDA has already begun to encounter phage therapeutics. Recently, the FDA approved 
three whole-phage preparations developed by the biotechnology company Intralytix 
(Baltimore, MD) to kill common food-borne pathogens on human food [48]. Through 
these sorts of encounters, the FDA will continue to develop experience in working with 
phage, and the approval of phage therapies for direct use in human patients will move 
closer and closer to becoming a reality. 
Key to overcoming issues of intellectual property is the fact that, although a 
patent cannot be obtained for the concept of phage therapy itself, many aspects related to 
phage therapy are in fact patentable if companies would invest in research to develop 
superior phage. Carl Merril’s serial passage technique to isolate phages able to circulate 
in the body for a longer time, for example, has been patented; a company owning such a 
patent could expect to rise above competition due to the biological superiority of their 
phage product. Genetically engineered phage strains, such as phage expressing special 
proteins on their coats to evade the immune system, are also patentable. In short, the issue 
of intellectual property and patentability is no more severe for phage therapy than for any 
other product. It comes down to the willingness of companies to think outside the box in 
order to create their own unique phage product that edges out the competition by its own 
superiority. 
To address the challenges presented by general lack of awareness, the best 
strategy is to heighten the awareness of phage and their therapeutic potential among both 
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scientists and the general public. This way, more scientists will be willing to devote their 
efforts to researching phage therapy, and, once such therapies are realized, more patients 
will be willing to use them to treat their illnesses. Specific strategies for achieving this 
goal could include placing an introduction to bacteriophage in middle and high school 
science courses to ensure that almost all members of the general public have at least a 
basic understanding of phage. To target future scientists, more detailed information about 
phage and phage therapy could be integrated into college biology courses. In addition, 
including the premise of phage therapy in medical school coursework would ensure that 
doctors have an understanding of phage therapy, as well. If the majority of scientists, 
doctors, politicians, policy-makers, pharmaceutical company managers, and the general 
public are made knowledgeable about phage therapy through these mechanisms, the other 
challenges facing phage therapy will be easier to overcome. 
Some researchers have already realized the importance of alleviating this general 
lack of awareness and begun to work towards a solution. In 2008, University of 
Pittsburgh professor Graham Hatfull along with several colleagues at the Pittsburgh 
Bacteriophage Institute that he co-founded in 1993 teamed up with the Howard Hughes 
Medical Institute Science Education Alliance (HHMI SEA) to create a national 
bacteriophage research program [89]. To date, more than 4,800 students from 73 
institutions have participated in the HHMI SEA Phage Hunters Advancing Genomics and 
Evolutionary Science (SEA-PHAGES) course (formally known as the National 
Genomics Research Initiative) [90]. A similar mycobacterial genetics program has even 
been set up at the Kwazulu-Natal Research Institute for Tuberculosis and HIV in South 
Africa. A list of participating U.S. institutions ordered by the year they joined the 
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program as well as a summary of the educational impact the program has had can be 
found in Reference [90]. 
The general sequence of the two-semester course is outlined in Figure 10. In the 
first semester, each enrolled student isolates a novel bacteriophage from a self-collected 
environmental soil sample. Working on an individual basis, they characterize their 
phages using molecular and imaging techniques including electron microscopy, DNA 
extraction, and DNA restriction digests. During the students’ winter break, one phage 
from the class with a high-quality and high-quantity DNA preparation is sent to a 
sequencing center to undergo whole-genome sequencing. In the second semester, 
students form small groups and work together to explore, analyze, and complete the 
annotation of the raw sequence, which involves using a suite of bioinformatics tools to 
determine the location of genes within the genomic sequence and identify functions for 
some of those genes based on database matches to known sequences. Finally, the 
completed genome is published on GenBank, the open-access sequence database 
maintained by the U.S. National Center for Biotechnology Information (NCBI).  
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Figure 10: SEA-PHAGES Course Sequence. During the first semester of the course, students work 
independently to isolate and characterize novel mycobacteriophages from environmental soil samples. One 
phage from the class is selected to be sequenced over the winter break, and students work together during 
the second semester to complete the annotation of the genome, which is ultimately published on GenBank, 
where it is available to researchers worldwide. 
How does a program like this help raise awareness of bacteriophage and phage 
therapy? Through working with phage in a research setting over the course of a year, 
undergraduate students are able to forge a deeper understanding of phage biology. At 
some participating schools, these students are all biology majors. Thus, the future 
biologists, researchers, doctors, and professors among them all receive a thorough 
introduction to the world of phage and may even develop a lasting interest that will fuel 
future research pursuits. Other schools intentionally limit participation in the course to 
non-science majors. This arrangement also has major benefits for increasing general 
awareness of phage: these schools are introducing phage to future businesspeople, 
lawyers, politicians, and journalists. After these students enter the workforce in their 
respective fields, they can use their understanding of and interest in phage to start phage-
based pharmaceutical companies, advocate for policies to promote phage therapy, and 
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write compelling articles to share phage-related concepts with the general public. Outside 
of the future contributions students who participate in the course may make, they also 
naturally introduce bacteriophage to their friends and family as they share their work. In 
this way, even more people are able to learn about phage and phage therapy. 
It is worth noting that this program provides additional benefits beyond raising 
general awareness of phage – another important goal of the program is to increase the 
amount of phage-related data available to bacteriophage researchers. Each year, hundreds 
of novel phage types are isolated and characterized by students in the program. These 
phages and the completely annotated genomes the students publish are all added to the 
pool of information available for researchers across the globe to access and analyze. To 
make this data more readily available to researchers, the Pittsburgh Bacteriophage 
Institute maintains the Mycobacteriophage Database at phagesdb.org, where information 
regarding all currently known mycobacteriophages is stored in a highly accessible 
fashion. Archived samples of each phage isolated in the program are also stored and 
available to researchers upon request.  
These efforts to isolate and characterize novel mycobacteriophages have also 
inspired similar projects for other groups of phage, including Arthrobacter, Bacillus, and 
Streptomyces phages. In an effort to streamline information regarding these phages in a 
similar manner to the mycobacteriophage, the Pittsburgh Bacteriophage Institute has 
recently established databases for these phage groups as well (The Arthrobacter Phage 
Database [http://arthrobacter.phagesdb.org/], The Bacillus Phage Database [http://bacillus. 
phagesdb.org/], The Streptomyces Phage Database [http://streptomyces.phagesdb.org/]). 
Although currently very small in comparison to the mycobacteriophage database, these 
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databases can be expected to follow the example of their predecessor and continue to 
expand rapidly. Such a huge amount of new data stemming from a variety of geographic 
locations and encompassing a growing number of phage types greatly facilitates 
researchers as they work to solve the many biological challenges currently facing phage 
therapy.  
 
F. CONCLUSIONS AND OUTLOOK 
 
Phage therapy is a form of treatment for bacterial infections that was first 
developed in 1919, shortly after the initial discovery of bacteriophage. As described 
previously, it utilizes lytic bacteriophage as agents to kill pathogenic bacteria. Although it 
was largely overshadowed by the advent of antibiotics in the 1940s, phage therapy has 
several distinct advantages over antibiotics and has especially great potential for 
combating antibiotic-resistant infections. As detailed throughout this chapter, over the 
course of its more than 90-year history, researchers from all over the world have 
successfully used phage therapy to combat a wide range of bacterial infections, but 
because of a variety of biological and bureaucratic challenges, its true potential has yet to 
be realized. However, as noted in the last section, these challenges are by no means 
insurmountable, and many investigators are already engaged in research to solve some of 
these challenges. 
Overall, it can be said that the road to wide-spread implementation of phage 
therapy is still long. However, if more researchers, supported by policy-makers, 
politicians, doctors, journalists, and the general public, join the effort to make it a reality, 
phage therapy could very well become one of our most powerful weapons in the fight 
against the growing threat of antibiotic resistance.      
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PART II 
 
 
ISOLATION AND CHARACTERIZATION OF TIROTHETA9, 
A NOVEL MYCOBACTERIOPHAGE 
 
 
Bacteriophage play key ecological roles and have a wide range of potential 
applications. However, the development of many of these applications, including phage 
therapy, has been limited by a lack of understanding of phage biology. Thus, the full 
potential of such applications will only be realized if we work to increase our knowledge 
of phage and their biology.  
New applications for phage will also only come through improving our 
understanding of phage genetics and diversity. With so much of the phage metagenome 
yet to be discovered, phage represent an enormous pool of unknown genetic information 
that could harbor new gene products with compelling applications of similar significance 
to those of phage integrase and lysis enzymes. Through the characterization of novel 
phage genes, it may even become possible to develop “designer” phage composed of 
genes selected from a central database. Insights into bacterial evolution are also possible 
– with an increased knowledge of phage genetics, phage-derived genes, including both 
active and cryptic prophages, could be identified within a number of different bacterial 
species, yielding insights into the evolutionary history of these species. Such insights 
could be important in understanding the divergence and continuing evolution of clinically 
relevant bacteria such as Mycobacterium tuberculosis, recently discovered to be 
comprised of seven related but distinct strains, one of which appears to be particularly 
well-equipped to take advantage of the high levels of interconnectedness and population 
density that characterize modern society [91]. These novel phage genes and their 
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functions will only be uncovered through the isolation and sequencing of new phage 
types. 
The research presented in the following chapters describes just such an endeavor. 
The work was completed in part through the HHMI SEA-PHAGES program, a national 
bacteriophage research initiative described in Part I Chapter 4E. The phages isolated 
through this program all belong to a group of phages called mycobacteriophage, which 
infect bacteria of the genus Mycobacterium. The significance of mycobacteriophage, as 
well as an overview of their characteristics, diversity, evolution, and research history, is 
detailed in the following chapter, which consists of a review of relevant literature in the 
mycobacteriophage field. The remaining chapters present original research regarding 
TiroTheta9, a novel mycobacteriophage isolated from the soil, and its relationship to 
other mycobacteriophages.            
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CHAPTER 6 
 
 
REVIEW OF MYCOBACTERIOPHAGE DIVERSITY AND EVOLUTION 
 
 
The first mycobacteriophages were isolated more than 60 years ago using the 
harmless soil bacterium M. smegmatis as a host. The isolation of mycobacteriophages 
specific to the agent of tuberculosis, M. tuberculosis, followed a few years later [92]. 
While early mycobacteriophage research focused predominately on their utility in typing 
clinical isolates of mycobacteria [93], more recent efforts have centered on developing 
mycobacteriophage as i) tools for elucidating and manipulating the genetics of their 
mycobacterial hosts [93] [94], ii) as models for phage evolution and diversity [93] [95] 
[96], and iii) as an educational platform for introducing young scientists to authentic 
scientific research [97] [98].   
Although all three of these roles for mycobacteriophage have been researched 
rather extensively, the scope of this chapter focuses mainly on the insights into 
mycobacteriophage evolution and diversity gained through recent comparative analyses. 
Such studies have been fueled by the recent explosion of newly discovered 
mycobacteriophages and sequenced mycobacteriophage genomes, largely due to 
contributions from student participants in the Howard Hughes Medical Institute SEA-
PHAGES program, who isolate and characterize their own novel bacteriophages in a 
year-long course (see Chapter 5E). Just ten years ago, only four mycobacteriophage 
genomes had been sequenced [96]. By 2008, that number had risen to more than 50 [98] 
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and had reached upwards of 70 by 2010 [93]. As of May 2014, there were 4666 archived 
mycobacteriophages (and counting) and 671 finished sequences registered in the online 
Mycobacteriophage Database (phagesdb.org), with 348 of those sequences published in 
the National Center for Biotechnology Information’s open-access sequence database 
GenBank. This profusion of sequence data has greatly facilitated the elucidation of phage 
genetics and evolution. 
This chapter covers four main topics under the overarching theme of 
mycobacteriophage evolution and diversity. First, “General Characteristics and Diversity 
of Mycobacteriophages” provides a brief overview of the general morphologic and 
genomic properties of the mycobacteriophages that have been characterized and reported 
in the literature thus far. Although some general conclusions can be made, this section 
also highlights the remarkable diversity of these phages. The second section, “Taxonomy 
of Mycobacteriophages and Their Genes,” explains the clustering system that has been 
designed to classify mycobacteriophages based on nucleotide similarities, as well as the 
system of “phamilies” that has been developed to categorize mycobacteriophage genes. 
This establishes the basis for the next section, “Further Insights from Mycobacteriophage 
Comparative Analyses,” which recaps some of the major conclusions of comparative 
analysis studies involving mycobacteriophages. This category specifically incorporates 
discussion of the mosaic nature of the mycobacteriophage genomes, their geographic 
distribution and its relation to genome sequences and cluster classification, and immunity 
studies that investigate the superinfective abilities of related phages. Finally, “Generation 
of Mycobacteriophage Diversity” covers some major theories that exist to explain the 
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mechanism by which the wide degree of diversity evident among mycobacteriophages 
and bacteriophages in general has been generated throughout their evolutionary history. 
            
A. GENERAL CHARACTERISTICS AND DIVERSITY OF 
MYCOBACTERIOPHAGES 
 
Except for the first three mycobacteriophages to be sequenced, all of the 
mycobacteriophages with genomes currently available through GenBank were isolated 
using Mycobacterium smegmatis, which is a common, non-pathogenic soil bacterium 
[93]. All but one of these phages are known to infect the commonly-used laboratory 
strain M. smegmatis strain mc
2
155 [99]. Although the sequenced phages share a common 
host, they are still remarkably diverse both morphologically and at the nucleotide 
sequence level.   
As more and more mycobacteriophages have been isolated, several studies 
comparing these phages have been conducted in efforts to generalize basic 
mycobacteriophage characteristics and catalog their diversity. As one of the first such 
studies, a 2008 paper published by Hatfull et al. [98] comparing 32 phages revealed that 
all of the mycobacteriophages analyzed are tailed, double-stranded DNA phages with 
genomes ranging from 42 kilo base pairs (kbp) to 150 kbp in length and averaging about 
70 kbp. The GC content
1
 of the genomes, which can sometimes be a useful predictor of 
host range as phage are often assumed to have a similar GC content to their preferred host, 
averaged 63.7%. This is similar to that of M. smegmatis (63%), although the range of GC 
contents observed (59% to 69%) may reflect differences in the natural host ranges of the 
various phages. Despite these differences, all of the 32 phages analyzed and many of the 
                                                          
1
 The GC content of a genome is the percentage of nucleotide bases in the genome that are either guanine 
(G) or cytosine (C).  This value varies greatly among organisms.  
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other hundreds of mycobacteriophages that have since been reported in the literature were 
isolated using a single host, the relatively fast-growing and avirulent Mycobacterium 
smegmatis mc
2
155.  In addition, at least one phage has been isolated on M. avium, and 
approximately 10% are estimated to be capable of infecting M. tuberculosis as well.   
All of the mycobacteriophages analyzed in the paper fell into two of the three 
morphotype categories currently identified for dsDNA phages, although in very unequal 
proportions. Thirty, possessing long, flexible, non-contractile
2
 tails, were of the 
siphoviridae type, while two belonged to the myoviridae, characterized by shorter, 
contractile tails. Interestingly, no mycobacteriophages of the stubby-tailed podoviridae 
type were observed (see Part I Chapter 1C and Figure 3 for a review of phage 
morphotypes). Finally, the authors noted that the majority of the phages analyzed have 
isometric heads, but a few display a prolate, or elongated, head morphology. These 
morphologies are illustrated in Figure 11, which shows representative phages of each 
type (siphoviridae and myoviridae) as well as examples of each of the two observed head 
shapes, isometric and prolate. This article provided one of the first comprehensive 
analyses of the growing number of mycobacteriophages and serves as a definitive starting 
point for both the studies which came after as well as future investigations.  
                                                          
2
 In phages with contractile tails, the tail fiber is covered by a contractile sheath that contracts when the 
phage adsorbs to the outside of its host to reveal the inner tail fiber. The contraction facilitates passage of 
the phage’s genetic material into the host. Phages with non-contractile tails do not have a contractile sheath 
and utilize various other infection mechanisms. 
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Figure 11: Mycobacteriophage Morphotypes. Most characterized mycobacteriophages belong to the 
siphoviridae, exemplified by Gumball and Corndog, while the others are myoviridae like Cali.  Of the 
siphoviridae, most have isometric heads like Gumball, while a few display a prolate head morphology 
similar to Corndog. Source: Hatfull GF, Cresawn S, Hendrix R. 2008. Comparative genomics of the 
mycobacteriophages: insights into bacteriophage evolution. Res. Microbiol. 159(5):332-339. 
A second paper published by Hatfull et al. in 2010 expanded these observations to 
a much larger group of sixty phages, providing additional morphological details that 
further elucidated the general characteristics and diversity of mycobacteriophage [100]. 
Despite the addition of nearly 30 new mycobacteriophages to the analysis, the average 
genome length (72.6 kbp) as well as average GC content of the genomes (63.4%) 
remained remarkably close to the values reported in 2008. Although the averages 
remained constant, the limits of the ranges observed for each of these parameters were 
expanded slightly – genome size ranged from 41.9 kbp to 164.6 kbp and GC content 
ranged from 56.3% to 69.1%. An additional characteristic of the mycobacteriophage 
genomes analyzed was also reported: thirty-five of the genomes contained defined 
physical ends
3
 with small, single-stranded extensions on the 3’ end ranging from 4 to 14 
                                                          
3
 Defined physical ends are characteristic of phages whose genomes are cleaved at specific recognition 
sequences as they are packaged into the progeny phage heads (cos packaging). This method ensures that 
each progeny phage is packaged the same way and possesses a single copy of the genome. The single-
stranded 3’ overhang, known as the cos site, allows the phage genome to circularize upon injection into a 
host bacterial cell.   
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bp, while the remaining twenty-five genomes were observed to be circularly permutated
4
. 
The authors also noted that the average mycobacteriophage genome contains 114 protein-
coding genes, each of which was an average of 616 bp long (about two-thirds the average 
length of a mycobacterium gene).  
In terms of morphology, a higher proportion of the phages in this expanded study 
were identified as myoviridae (7/60, approximately 11%) compared to the 2008 study 
(2/32, approximately 6%), although the vast majority still belonged to the siphoviridae, 
and no podoviridae examples were reported. The tails varied greatly in length, ranging 
from 135 nm to 350 nm, a more than two-fold spread. All of the myoviridae phages had 
isometric heads approximately 85.9 nm in diameter, while fifty of the phages belonging 
to siphoviridae (94.3%) had smaller isometric heads ranging from 55 nm to 60 nm in 
diameter.  The remaining three siphoviridae phages (5.7%) contained prolate heads of 
varying length-to-width ratios. The authors noted that in general, head dimensions tended 
to correlate with genome size, although dimensions measured from electron micrographs, 
as these were, can sometimes misrepresent actual values in active phages. However, if 
this relationship is true, it would suggest that the DNA packaging densities are similar 
across the mycobacteriophages. This paper provided an even more comprehensive 
analysis of the general characteristics and diversity of the mycobacteriophages and 
additionally served to reinforce the general patterns reported in the 2008 paper described 
above.                 
                                                          
4
 In contrast to defined physical ends, circularly permuted genomes result when progeny phage heads are 
packaged with genetic material until the head is completely full (headfull packaging). Each progeny phage 
is packaged differently and contains more than a complete genome, generally displaying terminal 
redundancy. 
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Following the isolation and sequencing of increasing numbers of 
mycobacteriophage, other studies reporting similar results have been published [101] [96] 
[95], including a recent Journal of Virology paper that formally announced the genomic 
sequence of 138 novel mycobacteriophages [102]. From these studies, it is evident that 
the typical mycobacteriophage has a genome about 70 kbp in length with a GC content of 
about 63%, contains approximately 114 protein-coding genes, belongs to the siphoviridae 
(i.e. has a long, flexible, non-contractile tail), and has an isometric head between 55 nm 
and 60 nm in diameter. The prevalence of long-tailed siphoviridae and absence of stubby-
tailed podoviridae consistently observed among the mycobacteriophages may indicate the 
utility of the tail structure in maneuvering around the unusually thick cell wall that 
characterizes the Mycobacteria during infection [98].  
Of course, these measurements are only averages, and it is clear that despite their 
utilizing a common host species, remarkable diversity has been established among these 
phages, evident from the wide range in genome size and differences in head and tail 
morphologies described above. And this may represent just the tip of the iceberg when it 
comes to the full range of mycobacteriophage diversity – the fact that most currently 
known mycobacteriophages have been isolated using a common host has likely precluded 
the discovery of much of this diversity. The techniques used have also been exclusive to 
the isolation of dsDNA phages, leaving potential ssDNA, ssRNA, and dsRNA 
mycobacteriophages yet to be discovered. As more mycobacteriophages are isolated and 
characterized, this vast diversity as well as the mechanisms that shaped it are becoming 
increasingly apparent, and through the use of a wider variety of Mycobacterium hosts and 
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different sets of isolation techniques, we may find that the true extent of 
mycobacteriophage diversity is much greater than we ever imagined. 
 
B. TAXONOMY OF MYCOBACTERIOPHAGES AND THEIR GENES 
 
Bacteriophage genomes, including those of mycobacteriophage, are mosaic in 
nature, meaning they often contain genes originating from various phylogenetic 
backgrounds concatenated together into a sort of genetic mosaic [1]. This mosaicism 
makes the classification of bacteriophages inherently difficult, especially under the 
classical Linnaean paradigm, wherein new species are traditionally placed into the 
framework based on shared physical characteristics. With the development of the field of 
genetics and advent of wide-spread genome sequencing, it has become clear that this 
system has its faults, particularly when attempts are made to use it for the classification of 
microorganisms, particularly viruses like bacteriophage. Lawrence, Hatfull, and Hendrix 
described these flaws as they relate to viral taxonomy at length in a paper published in 
2002 [103]. Although there are plenty of phenotypic characteristics by which 
bacteriophages can be grouped, including host range and morphology, these oftentimes 
are not correlated with sequence similarities. For example, the phages T4 and Mu, as 
members of the myoviridae group of phages, both have contractile tails, but the genes 
encoding for their respective tails are completely unrelated. This would suggest that the 
phages represented in the myoviridae group are not, in fact, recently derived from a single 
common ancestor phage. Clearly, a fundamentally different paradigm is necessary to 
classify bacteriophages in a meaningful way. 
Two such paradigms have been developed for mycobacteriophage. One organizes 
the mycobacteriophages themselves into groups called clusters on the basis of nucleotide 
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similarity, while the other is a system for arranging mycobacteriophage genes into 
“phamilies” of related genes. The system of phamilies, or phams, was first introduced by 
Hatfull et al. in a 2006 paper [101] that explained how the 3,357 open reading frames 
encoded in 30 mycobacteriophage genomes were organized into groups of related genes 
dubbed phamilies. In order to be classified as a member of a particular pham, a candidate 
open reading frame must code for a protein that shares at least 25% amino acid identity 
with at least one other member of the phamily across its entire length. According to this 
criterion, the open reading frames were classified into 1,536 phams of various sizes, with 
the average pham containing 2.19 genes. Strikingly, 50.3% of the phamilies contained 
just a single member, and 1,306 (about 85%) contained genetic sequences that had never 
been identified before, hinting at the profusion of phage genes yet to be discovered. Three 
phams contained representatives in all 30 of the mycobacteriophages examined. Thus, 
these phams, which contain putative lysins and tail proteins, potentially correspond to 
hallmark genes that may be conserved among most mycobacteriophage genomes. The 
authors noted, however, that great sequence diversity still exists even among members of 
a single phamily, as a candidate only has to match a single existing member with 25% 
identity in order to be included.  
Comparison of phage genes leads, in turn, to the identification of similar groups 
of phages, called clusters. By grouping together phages that contain genes from the same 
phamilies, the authors classified twenty-one of the phage genomes into six clusters, 
designated A-F, with the remaining nine classified as singletons that did not share a close 
enough relationship with any other mycobacteriophages at the sequence level to be 
placed into a cluster. These clusters do not completely represent the evolutionary history 
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of their member phages as the members are mosaics and may still contain instances of 
genes common to phages of other clusters. However, later studies established that overall, 
there is very little DNA sequence similarity between different clusters [102]. The exact 
methods by which the clustering was accomplished were not made explicitly clear; 
nevertheless, this paper proposed a feasible paradigm by which mycobacteriophages and 
their genes, and perhaps all phages and phage genes, can be organized. 
The clustering and pham systems have since been adopted by many researchers 
investigating mycobacteriophages and have predictably been expanded as new 
mycobacteriophages and genes have been added. In their 2010 paper that describes the 
comparative analysis of sixty mycobacteriophages, Hatfull et al. added three new clusters 
to the six previously established and rigorously described four methods by which cluster 
membership was determined [100]. With new insights from these methods, they 
additionally proposed alterations to a few of the previous classifications. The number of 
singleton phage genomes was reduced from nine to five, and the number of phams 
containing single members (orphams) was also lowered to 46.1% from 50.3%. 
Interestingly, the increased sample size of 6,858 open reading frames resulted in 1,523 
phams, slightly fewer than the 1,536 initially identified. This is perhaps due to the 
bridging of former orphams by newly discovered genes. Taking the gene classification 
system a step further, the three phams containing more than 250 members were further 
subdivided into subphams, as were nine smaller phams, resulting in a total of 1723 
distinct phams and subphams.   
The authors took a more rigorous approach to the clustering process than 
previously described, utilizing four different methods in an attempt to more completely 
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address the three types of relationships they identified among the phage genomes. They 
recognized one class of relationships containing genomes that are very closely related and 
obviously belong to the same cluster, while another contained those having no observable 
relationship and clearly belonging to different clusters. The third, more complex case 
encompassed genomes where large but weakly similar genome segments, highly similar 
but short genome segments, or divergent nucleotide sequences corresponding to similar 
amino acid sequences are observed. Taking these relationships into account, they decided 
on an explicit criterion for determining cluster eligibility; in order to belong to the same 
cluster, two phage genomes must display sequence similarity spanning more the 50% of 
the smaller genome in a dot plot analysis
5
. Dot plot analysis according to this criterion 
resulted in nine clusters (designated A-I) with five singleton phages, which as noted 
above was three more clusters and four fewer singletons than initially described in 2006. 
Additionally, because some members of the same cluster display closer similarity to each 
other than to other genomes within the cluster, five clusters were further subdivided into 
a total of 12 subclusters.  
The other three methods were largely used to confirm these classifications and 
included comparison of average nucleotide identity values, gene content analysis using 
the phamily classifications as was done previously, and performing pairwise genome 
alignments of the genomes, which compare two or more nucleotide sequences while 
showing gene locations simultaneously (Figure 12). These three additional methods 
largely supported the classifications made based on the dot plot criterion. Finally, the 
authors noted the reclassification of several phages based on their new methodology, 
                                                          
5
 Dot plots are widely used in bioinformatics as a tool to visually compare two sequences.  The sequences 
are organized along the x and y axes, and a dot is placed on the graph wherever the two sequences match; 
consecutive matches form lines that illustrate the relationship between the two sequences.  
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including moving two phages previously excluded from cluster F and classified as 
singletons into the cluster. 
 
Figure 12: Pairwise Alignment of Two Mycobacteriophages. The figure depicts a section of a pairwise 
nucleotide alignment of G cluster mycobacteriophages Hope and Angel generated by the program 
Phamerator. The colored boxes represent putative genes, with colors and labels corresponding to the 
phamilies each gene belongs to. The purple areas between the two genomes show areas of high nucleotide 
homology, while white indicates little or no sequence homology. This particular segment shows evidence 
of an insertion in the Hope genome (putative gene 57) that is not present in the Angel genome but which is 
surrounded on both sides by areas of high sequence homology, a good example of the genetic mosaicism 
observed among mycobacteriophages. Source: Pope WH, Jacobs-Sera D, Russell D, et al. 2011. 
Expanding the diversity of mycobacteriophages: insights into genome architecture and evolution. PLoS 
One. 6(1): e16329. 
Since the publication of these papers, several additional clusters, subclusters, and 
singleton genomes have been added to the rapidly-expanding database of 
mycobacteriophage genomes. All of these are cataloged on the frequently-updated 
Mycobacteriophage Database at phagesdb.org, created and maintained by the Pittsburgh 
Bacteriophage Institute. As of May 2014, there were 21 clusters (A-U), variably divided 
into a total of 37 subclusters, and eight singleton genomes contained in the database, 
representing a total of 671 fully-sequenced mycobacteriophage genomes. Select 
characteristics of each cluster are displayed in Table 4. There are also 3995 phages 
contained in the database that have yet to be sequenced and thus cannot be rigorously 
clustered, although recent efforts have focused on developing sets of primers unique to 
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each cluster that would allow cluster assignment by Polymerase Chain Reaction (PCR), 
thereby eliminating the express need for whole-genome sequencing [104].  
A comparison of the average length and average GC content across each cluster is 
shown in Table 4. These data clearly showcase the wide diversity present among 
mycobacteriophages and highlights the utility of the clustering system in analyzing this 
diversity. The clustering system has also allowed researchers to identify and further 
investigate some of the unique characteristics specific to certain clusters. For example, 
intron splicing has been explored in the Cluster J phages [105], and the evolutionary 
history of a heteroimmune, exclusively virulent member of the K Cluster as well as the 
potential utility of K1 subcluster phages as genetic tools for M. tuberculosis have been 
elucidated through inter-cluster analysis [106].    
The cluster and gene phamily systems, while not perfect, have become 
conventional among the majority of mycobacteriophage researchers and will continue to 
develop as new genomes are elucidated. At the same time, it is clear from the rapid 
expansion of the clusters and prominence of singleton phages and orphams that 
researchers have just scratched the surface of the cache of mycobacteriophages present in 
the environment and that many more novel genes and genomes remain to be discovered 
[95].  
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Table 4: General Characteristics of the Mycobacteriophage Clusters. Source: phagesdb.org/clusters. 
Cluster Subclusters Members 
Avg Length 
(bp) 
Avg GC% 
Oldest 
Found 
Newest 
Found 
A 11 248 51,539 63.3 1954 2014 
B 5 119 68,661 67 2001 2014 
C 2 46 155,504 64.7 1990 2013 
D 2 10 64,795 59.4 2003 2013 
E - 44 75,487 63 2002 2013 
F 3 70 57,414 61.5 2002 2013 
G - 14 41,845 66.6 2003 2013 
H 2 5 69,469 57.3 2001 2013 
I 2 4 49,954 66.5 2002 2012 
J - 16 110,332 60.9 2005 2013 
K 5 33 59,720 66.8 1984 2013 
L 3 13 75,177 58.9 2008 2013 
M 2 3 81,636 61.3 2008 2011 
N - 7 42,888 66.2 2009 2013 
O - 5 70,651 65.4 2001 2012 
P - 10 47,784 67 2009 2014 
Q - 5 53,755 67.4 2005 2013 
R - 4 71,348 56 2009 2013 
S - 2 65,172 63.4 2009 2012 
T - 3 42,833 60.6 2008 2013 
U - 2 69,942 50.4 2009 2009 
Singleton - 8 66,405 66.2 1960 2013 
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C. FURTHER INSIGHTS FROM MYCOBACTERIOPHAGE COMPARATIVE 
ANALYSES 
 
The grouping of related mycobacteriophages into clusters and of related 
mycobacteriophage genes into phamilies make it relatively straightforward to conduct 
both inter and intra-cluster comparative analyses. Such comparative studies can reveal 
much about the diversity and evolution of mycobacteriophages [100]. The morphological 
and general genomic diversity of the mycobacteriophages, an important element of 
preliminary comparative analyses, was discussed in detail in Section A.  
The ubiquitous genetic mosaicism observed in the mycobacteriophages was also 
touched upon briefly in the previous section; this mosaicism is clearly visualized by 
pairwise genome alignments like the partial one shown in Figure 12 above. The genomes 
of these two phages display high sequence homology overall but have this homology 
interrupted intermittently by small, often single-gene regions of nucleotide sequence 
divergence where one of the pair has presumably added a gene to its genome from an 
outside source.  
Genetic mosaicism is also illustrated well by phamily circles, in which user-
selected mycobacteriophage genomes are arranged around the periphery of a circle by 
cluster (Figure 13). Lines whose thicknesses correlate with the strength of the 
relationship then connect all of the different phages that contain genes belonging to the 
pham under investigation. Phamily circles thus provide a visual depiction of evolutionary 
relationships both within and across clusters. For example, the existence of cluster-
identifier phams, i.e. phams represented in all genomes belonging to a particular cluster 
but not in any other genomes, has been observed through phamily circle analysis [100]. 
Pham 1707 in Figure 13 is an example of such a pham. 
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The construction of pairwise alignments and phamily circles as well as dot-plots 
can be accomplished using a specialized bioinformatics tool called Phamerator [107]. The 
program contains a database of protein-coding phage genes sorted into phamilies that it 
draws upon to generate these comparative graphics, thereby greatly facilitating both 
large-scale and more defined analyses.  
Figure 13: Mycobacteriophage Phamily Circle Diagrams. Pham 1707 is an example of a pham whose 
members are only observed in a single cluster, while pham 2942 is widely represented among the 
mycobacteriophages and has members observed in six different clusters. These diagrams are generated the 
program Phamerator. Source: Pope WH, Jacobs-Sera D, Russell D, et al. 2011. Expanding the diversity 
of mycobacteriophages: insights into genome architecture and evolution. PLoS One. 6(1): e16329. 
Besides the general genomic and genetic comparisons made possible through 
Phamerator, several other more specific comparative studies have been reported in the 
literature, including an investigation of the correlation between the isolation site and 
cluster classification/sequence similarity, the exploration of superinfection abilities 
among related phages, and the elucidation of possible mechanisms of host restriction 
among mycobacteriophage. These topics are treated in more detail in the following 
paragraphs. 
Geographic Analysis 
Mycobacteriophages have been isolated from geographic locations nearly as 
diverse as the phages themselves, ranging from various sites across the U.S. to 
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international sites in Canada, the Caribbean, China, Ireland, Finland, South Africa, 
Mozambique, Algeria, India, and Japan. In fact, 334 of the 4666 currently described 
mycobacteriophages were isolated outside the U.S., a small but important – and growing 
– group (phagesdb.org, May 2014). In their 2006 paper comparing 30 
mycobacteriophages, Hatfull et al. first suggested a lack of correlation between sequence 
similarity and location of isolation [101], an observation reinforced in a 2011 paper by 
Pope et al. that analyzed 80 mycobacteriophage genomes [95].  
This observation has interesting implications for the study of phage evolution and 
gene transfer, as it would seem likely that phages isolated from locations in closer 
geographic proximity would be genetically similar and that those separated by a vast 
geographical distance would be more divergent in accordance with decreased opportunity 
for genetic exchange. The observed lack of correlation between these two parameters is 
thus rather counterintuitive. The authors of the 2011 paper did take note of several 
possible non-random distribution patterns, but conceded that much more data is necessary 
to confirm these patterns. A more in-depth treatment of this topic as it relates specifically 
to phages in the A4 subcluster is provided in Chapter 8.   
Superinfection and Homoimmunity Studies 
In the same paper, Pope et al. also described an experiment in which they 
indirectly compared the immunity systems of Cluster A mycobacteriophages by 
investigating the ability of each phage to superinfect lysogens of each of the other 
members of the cluster. A prophage prevents expression of its lytic genes by the binding 
of a repressor protein to specific regulatory sites in the genome; often, this repressor can 
also block the expression of the lytic genes of closely related phages, barring them from 
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undergoing replication and thereby making the lysogenic host immune to superinfection. 
This phenomenon is known as homoimmunity. The observations made during this 
experiment yield insights into which portions of the repressor system are important for 
successful binding of the repressor as well as insights into bacteriophage immune 
specificity in general. Similar immunity studies involving three Cluster G phages have 
also been conducted [108].  
Sequence comparisons also revealed a unique example of “repressor theft” by an 
otherwise unrelated phage of Cluster C. This phage contains a putative repressor gene 
that is more than 99% identical to one of the A1 subcluster repressor sequences, although 
there is no binding site for the repressor within its genome and it is thus not utilized by 
the phage to form its own lysogens. Noting that the Cluster C phage is capable of 
superinfecting lysogens of the A1 subcluster phage, the authors came to the plausible 
conclusion that this gene, probably picked up through a horizontal gene transfer event 
somewhere in the phage’s evolutionary history, has been retained in the Cluster C 
phage’s genome as a defense mechanism against superinfection by cluster A1-like phages. 
If an A1-like phage were to superinfect a host already infected with the Cluster C phage, 
the repressor would bind to the A1-like phage and prevent it from replicating while 
allowing the Cluster C phage to continue replicating itself. The authors noted that this is, 
as far as they are aware, the first example of repressor theft observed in any type of 
bacteriophage.    
Mechanisms of Host Range Constraint  
Comparative analysis has also led to insights into phage-host interaction during 
infection, specifically mechanisms by which host range constraints are established for 
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mycobacteriophages. Several theories exist to account for the inability of a phage to 
successfully infect bacterial strains outside its host range. These include restriction-
modification, availability of appropriate receptors, various processes that result in 
abortive infection, Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPRs), and translational apparatus modification. In a 2012 Virology paper, Jacobs-
Sera et al. reported a series of experiments that strongly suggest host recognition or DNA 
injection barriers determine the host range for mycobacteriophage [99].  
As a prelude to these experiments, the authors first provided evidence for a 
correlation between cluster or subcluster designation and host preference. They tested 
221 sequenced mycobacteriophages representing clusters(subclusters) A(1-9), B(1-5), 
C(1), D, E, F(1-2), G, H(1-2), I(1-2), J, K(1-5), L(1-2), M, N, and O as well as seven 
singletons for ability to infect M. tuberculosis mc
2
7000 and found that infective ability 
was restricted to Cluster K phages and Subcluster A2 and A3 phages. Cluster G phages 
were also found to form plaques on M. tuberculosis at a reduced efficiency relative to M. 
smegmatis mc
2
155. Genome alignments yielded no obvious answers as to what merited 
this difference in host preference. 
Because M. tuberculosis is related rather distantly to M. smegmatis, it was not 
unreasonable to find so few examples of mycobacteriophage able to infect both strains in 
the almost exclusively M. smegmatis-derived database. Thus, to further probe patterns of 
host preference, the authors also tested the same 221 phages for their ability to infect M. 
smegmatis strains Jucho and MKD8 as well as the more distantly related M. aichiense, 
which exhibits a similar growth profile to M. smegmatis. Although none of the phages 
tested were able to infect M. aichiense, correlations between cluster/subcluster and 
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infective ability were once again observed for the two M. smegmatis strains. It is 
interesting to note that for these strains, differential plating efficiencies can be observed 
even among presumably very closely-related phages of the same subcluster. For example, 
the A4 Subcluster phages Peaches and TiroTheta9 share 99% sequence identity; however, 
according to the data presented in the article, TiroTheta9 plates on Jucho with an 
efficiency four orders of magnitude greater than Peaches (1.0 x 10
-1 
vs. 3.7 x 10
-5
, 
measured relative to M. smegmatis mc
2
155), while the opposite is true for MKD8 (<10
-9
 
vs. 1.1 x 10
-5
). A similar dichotomy is observed for MKD8 infection with Backyardigan 
and Wile, another pair of highly homologous A4 phages. 
With these host range constraints established, Jacobs-Sera et al. hypothesized that 
the observed ability of several phages to form plaques with reduced efficiency on some of 
the alternative hosts may be the result of mutations either expanding or altering the host 
range. To test this, they isolated plaques of two Cluster G phages grown on M. 
tuberculosis. Upon replating, the phages from these plaques were able to infect both M. 
smegmatis and M. tuberculosis with equal efficiency, suggesting that a mutation had 
occurred to expand the host range of the parent phages. The complete genome of one of 
the isolates derived from Mycobacterium phage Halo was sequenced, and the mutation 
was mapped to a non-synonymous point mutation within a gene belonging to a group of 
putative minor tail proteins. This mutation was confirmed through sequencing the same 
gene in the other isolates. The fact that mutations were exclusively found in a tail protein 
suggests that hindered surface interactions, including phage adsorption and DNA 
injection, rather than defects in the replicative process within the host are responsible for 
the low efficiency of M. tuberculosis infection observed in Cluster G phages.  
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Further support for this conclusion was provided by engineering two of the 
observed substitutions into wild-type Halo. The engineered phage showed an ability to 
infect M. tuberculosis equivalent to that of the mutants isolated previously. Additionally, 
when M. tuberculosis cells transformed with either wild-type or expanded-host-range 
mutant Halo DNA were plated on a lawn of M. smegmatis, equivalent numbers of 
plaques were observed. This indicated that the phage DNA was able to replicate normally 
within the M. tuberculosis cells, suggesting that replicative barriers are not what cause 
the differential infection abilities of the wild-type and expanded-host-range mutants. 
Unexpectedly, adsorption assays showed an increased ability of the mutant phage to 
adsorb to M. smegmatis (but M. tuberculosis adsorption rates remained the same) – this 
may suggest that the surface interactions affected by the mutation are not related to 
receptor recognition, but that subsequent events requiring participation of tail proteins, 
such as DNA injection into the host, somehow make the binding process irreversible. A 
similar minor tail protein point mutation was implicated in the increased ability of Cluster 
B2 phage Rosebush expanded-host-range mutants to infect M. smegmatis Jucho, and the 
same adsorption phenomena were observed for these mutants as well.  
The M. tuberculosis transfection results described above for Halo were replicated 
in another phage from Cluster Q (Giles) that cannot normally infect M. tuberculosis.  
Together, these results showed that it is largely surface interactions that prevent these 
phages from crossing the species barrier. To determine whether surface interactions also 
play a role in limiting cross-genus infections, the authors electroporated the DNA of the 
Streptomyces phage Zemlya into electrocompetent M. smegmatis cells and plated them 
onto a lawn of Streptomyces lividans, a known host of Zemlya. A small number of 
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plaques were recovered, supporting the conclusion that Zemlya is able to replicate in M. 
smegmatis post-DNA injection. Subsequently, twenty of these plaques were randomly 
picked and plated on both M. smegmatis and S. lividans; all formed plaques on S. lividans 
while none were able to do so on M. smegmatis, effectively ruling out the possibility of 
contamination or host range mutation and therefore strengthening the argument that 
surface interactions are responsible in large part for mycobacteriophage host range 
constraints. 
 
D. GENERATION OF MYCOBACTERIOPHAGE DIVERSITY 
 
A prevailing theme throughout the comparative study of mycobacteriophage 
genomes has been their striking mosaicism, with unique combinations of genes of clearly 
distinct evolutionary histories composing each genome. This feature is not restricted only 
to mycobacteriophages, but instead has been observed in all groups of double-stranded 
DNA (dsDNA) bacteriophages that have been studied thus far. Hendrix et al. [1] propose 
a model to explain these patterns in which all dsDNA phages share a common ancestor, 
from which they have diverged through access by horizontal exchange to a global pool of 
common genes; access is limited for each group of phages by parameters such as host 
range, leading to the development of unique mosaic patterns and non-uniform relatedness 
to other phages.  
This model is well-supported by examples from various phage groups, and given 
that there are an estimated 10
25 
phage infections, and thus opportunities for horizontal 
exchange between different types of phages and their bacterial hosts, occurring every 
second [96], it is also feasible. However, the model leaves the question of the precise 
mechanisms by which this horizontal exchange occurs. Hatfull et al. estimate that if 
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genetic exchange among mycobacteriophages occurred randomly, approximately 10
350
 
distinct mycobacteriophage genomes would be possible [101]. As the total number of 
global phage particles of all types is estimated at 10
31
, only a small portion of which are 
mycobacteriophages, it follows that exchanges must be non-random. This makes sense if 
one considers that in order to be viable, a genome would have to include all essential 
genes for successful infection and replication. In addition, some genes must be paired or 
co-translated with certain other genes in order to maintain functionality, and certain genes, 
such as those encoding head and tail proteins, can generally not exist in duplicate within a 
single genome. Two main models have been proposed to explain the majority of this non-
random mosaicism; although these models were developed for the global phage 
population in general, they apply to the generation of mycobacteriophage diversity, as 
well.  Both models are outlined in the following paragraphs. 
In lambdoid phages, mosaic boundaries tend to occur close to boundaries between 
genes [109], a tendency that has also been well documented in mycobacteriophages [98] 
[93]. Stemming from these observations, in 1978 Susskind et al. proposed an early 
“modular evolution” model in which they postulated the existence of short, conserved 
linker sequences between genes [110]. These intergenic linker sequences were 
hypothesized to facilitate recombination between modules of one or several genes 
through homologous recombination or a site-specific recognition system. In the absence 
of high-resolution DNA sequencing, these linker sequences seemed to provide a plausible 
explanation for how “healthy hybrids” could be continually produced as phage genomes 
recombine.   
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As the availability of high-resolution bacteriophage DNA sequences, including 
those of mycobacteriophages, increased, it became clear that this explanation was likely 
not correct. The existence of bacterial genes within phage genomes [98] as well as 
sequence evidence showing a lack of adequate space between genes to contain the 
hypothesized linker sequences [111] were incongruous with the modular evolution model. 
Additionally, little sequence similarity was observed among mosaic boundaries both 
between phages and even on the same phage [111] [96], and a few examples of 
recombination occurring not between genes but instead in the middle of single genes 
were also described [111], providing further evidence against the earlier model.  
Instead, a model of non-homologous, or illegitimate, recombination emerged to 
account for these new insights [111]. This model suggests that recombination occurs 
without discretion and essentially at random across the phage genome, giving rise to a 
variety of recombinant genomes. Most of these are non-viable due to incorrect length for 
packaging into the phage head or loss of essential gene function and thus are removed 
from the population. This leaves behind for our observation only those rare recombinants 
that have retained proper size and gene functions, the vast majority of which 
consequentially display recombination junctions between genes. Pedulla et al. cite an 
example of three recombination events in mycobacteriophages that occurred recently 
enough in evolutionary history that the original sequences at the recombination junctions 
are still well preserved [96]. Their observations provide definitive support for the 
illegitimate recombination model.   
Although illegitimate recombination has been widely accepted as the main 
mechanism by which the diversity of mycobacteriophage and bacteriophage in general 
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has been and continues to be established, there remain a few other mechanisms by which 
genomic diversity may be propagated in mycobacteriophage. For example, a novel class 
of small mobile elements apparently unique to mycobacteriophage genomes has been 
identified [108]; the shuffling of these mobile elements could play a role in the generation 
of new diverse mycobacteriophage genomes. Additionally, although transposons have 
generally not been observed in mycobacteriophage genomes, a Cluster F phage appears 
to include a transposon insertion 73% similar at the amino acid level to a putative 
transposase from the soil bacterium Norcardia farcinia [93]. 
Recently, Jacobs-Sera et al. have proposed a new model that works alongside the 
concept of illegitimate recombination but contains additional subtleties to explain the 
diversity of mycobacteriophage in environments where there exists a diverse bacterial 
population, such as in the soil [99]. Based on their studies of expanded-host-range 
mutants described in the previous section, in which mutants with expanded host range 
could be extracted after just one round of plating, the authors suggest that this switching 
or expanding of host range through random mutation occurs with much greater frequency 
than overall genetic exchange rates and much more quickly than changes in GC content 
to adapt to a new host. While expansion to more similar hosts, such as different strains of 
the same species, are more feasible, the authors present data that show cross-species 
switches can also occur and suggest that even cross-genus switches are not impossible. 
Given this model, different phages from a wide range of phylogenetic backgrounds (i.e. 
evolved to efficiently infect a wide range of different host bacteria) can arrive at a 
common host through a series of host range expansions in an environment of sufficient 
host diversity.  
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This model could explain the wide range of diversity observed among 
mycobacteriophages, the majority of which were isolated from microbe-rich soil 
environments; the distinct GC contents and genetic makeups observed among different 
clusters may be the result of the “arrival” at M. smegmatis mc2155 after a series of host 
expansion mutations by diverse phages originally adapted to infect other soil microbes. 
The model thus predicts that the diversity of phages isolated on any bacterial host will 
mirror the diversity of the bacterial population of the host’s natural environment. In line 
with the proposed model, the fact that a broad range of GC contents has been observed 
not only for mycobacteriophages but also for Pseudomonas and Staphylococcus phages 
supports the idea of diverse phylogenetic origins for these phages. Furthermore, as the 
model predicts, phages isolated from environments with restricted microbial diversity 
exhibit a similarly restricted degree of diversity. This is exemplified by the low diversity 
observed among phages of Propionibacterium acnes isolated from human sebaceous 
follicles, an environment of limited microbial diversity. Given the fact that this model 
allows expansion to extra-species and even extra-genus hosts, it highlights the great 
potential of phage to facilitate genetic exchange between different bacteria in 
environments of high microbial diversity, a concept introduced in Chapter 1D.     
        
E. SUMMARY AND CONCLUSIONS 
 
Comparative analysis of mycobacteriophage genomes has provided numerous 
insights into the diversity and evolutionary mechanisms of this dynamic group of phages. 
As covered in Section A, the observations reported in a number of papers indicate that the 
average mycobacteriophage is a siphoviridae with a long, flexible, non-contractile tail 
and isometric head about 55 nm in diameter and has a genome of approximately 114 
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protein coding genes that is about 70 kbp in length with a GC content of around 63%. 
However, enormous diversity has been observed among the mycobacteriophages, whose 
genomes range from  about 42 kbp to 165 kbp and which encompass a wide range of 
morphologies including prolate heads, tail lengths spanning a more than two-fold range, 
and both siphoviridal and contractile-tailed myoviridal morphotypes, although no stubby-
tailed podoviridae have been observed.   
Section B discussed two novel taxonomic systems based on sequence similarity 
and designed to alleviate some of the intrinsic difficulties in classifying phages by the 
classical Linnaean paradigm. These systems have resulted in 1) grouping of 
mycobacteriophages for which adequate sequence data exists into twenty clusters 
(designated A-T) containing 35 subclusters, plus eight singleton genomes that do not fit 
into any of the currently established clusters, and 2) the classification of 
mycobacteriophage genes into roughly 1,500 gene phamilies. A high percentage (~46%) 
of these are orphams containing only one member. These classification systems are not 
perfect, but they provide a relatively sound idea of the relationships among 
mycobacteriophage genomes and genes and greatly facilitate both intra and inter-cluster 
comparative analyses. 
Some examples of these analyses were detailed in Section C. Exploration of the 
pervasively mosaic nature of mycobacteriophage genomes has been mediated by the 
bioinformatics tool Phamerator. Geographic comparisons have revealed a distinct lack of 
correlation between genome sequence and geographic area of isolation. Immunity studies 
have yielded insights into immunity specificity and have described a unique instance of 
repressor theft. Additionally, host range preference studies have implicated surface 
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interaction barriers as the most likely mechanism for host range constraint among 
mycobacteriophages.  
Finally, Section D reviewed two major theories regarding the generation of the 
highly diverse mosaic genomes observed among the mycobacteriophages; the early 
“modular evolution” hypothesis, which maintains that short linker sequences between 
genes facilitate homologous recombination to generate diversity, has been discarded in 
favor of an illegitimate recombination model, whereby recombination happens randomly 
across a phage’s genome and only the small fraction of recombinant genomes that retain 
proper length and gene functions survive. Accordingly, most of these retained genomes 
display recombination between genes rather than in the middle of genes as has been 
observed in mycobacteriophages and bacteriophages in general. A new model of phage 
diversification that suggests high-frequency host range expansion mutations are 
responsible for the “arrival” of many different phages from diverse phylogenetic 
backgrounds, and that the diversity observed among groups of phages isolated on a single 
host strain accordingly reflect the bacterial diversity of the natural environment of that 
host, has also been proposed.  
Although much about the diversity and evolution of mycobacteriophages has been 
elucidated, it is clear from the large number of singleton genomes and orphams that 
researchers have only just begun to explore the enormous cache of undiscovered genetic 
information contained in the global mycobacteriophage population. More insights will be 
revealed through the isolation, characterization, and sequencing of additional 
mycobacteriophages, including those which utilize hosts other than Mycobacteriophage 
smegmatis. Illumination of the functions of the vast number of mycobacteriophage genes 
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for which there is currently no known function will help researchers to better understand 
the biology of these phages and make more accurate observations regarding their 
evolutionary patterns. Finally, the continued analysis of mycobacteriophages has great 
promise in terms of creating tools with which we can better understand and even 
manipulate their mycobacterial hosts with the eventual aim of challenging devastating 
pathogens like Mycobacterium tuberculosis. Although they are tiny in size, the advances 
that wait just around the corner with the continued study of mycobacteriophages promise 
to be immense. 
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CHAPTER 7 
 
 
ISOLATION AND SEQUENCING OF THE 
NOVEL MYCOBACTERIOPHAGE TIROTHETA9 
 
 
In this project, a novel mycobacteriophage, designated TiroTheta9 (TT9; see the 
footnote at end of this chapter for etymology), was isolated from the environment and 
completely characterized at both the phenotypic and genotypic levels. As covered 
extensively in previous chapters, in order to further our understanding of 
mycobacteriophage and bacteriophage in general, it is critical to develop a large database 
of phage and phage genes available for comparison and study. The phage characterized in 
this project, begun as a part of the previously described HHMI SEA-PHAGES program 
in its inaugural year at Western Kentucky University, contributes to the growing number 
of sequenced and characterized phages. The identity of TT9 as a mycobacteriophage 
additionally renders this data potentially valuable in aiding the efforts of researchers 
looking to develop phage-based tools for the study and treatment of Mycobacterium, 
including such prominent pathogens as M. tuberculosis, the agent of tuberculosis, and M. 
leprae, the agent of leprosy. 
 
A. MATERIALS AND METHODS 
 
Detailed recipes for all media, buffers, and reagents used in the following 
procedures are included in Appendix A and can also be found in the Science Education 
Alliance In Situ Resource Guide published by the HHMI [112].  
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Soil Sample Collection 
An environmental soil sample was collected by using a small spatula to scoop soil 
into a 15 mL conical tube (VWR, catalog no. 21008-670). The sample was capped to 
prevent drying and stored overnight at 4°C.  
Bacterial Culture Techniques 
The Mycobacterium smegmatis strain mc
2
155 used in the enrichment and growth 
of phage was initially cultured from a frozen stock stored at -80°C. A sample was 
streaked out for single conlonies on a standard Luria agar (L-agar) plate (Appendix A) 
and allowed to grow for 4-6 days at 37°C. Liquid M. smegmatis P1FF (passage 1 from 
frozen) stock cultures were prepared by using an inoculation loop to transfer M. 
smegmatis from a single colony to 50 mL of Middlebrook 7H9 liquid media Complete 
with Tween 80 (Appendix A) in a 250 mL baffled Erlenmeyer flask (Bellco, catalog no. 
2543-60250). The flask was then incubated with shaking at 250 rpm for 48-72 hours at 
37°C.  New P1FF stock cultures were started weekly from the same agar plate. Liquid 
cultures for use in phage experiments were prepared by adding a 1:1000 volume of P1FF 
culture to 7H9 Complete without Tween 80 (Appendix A) in a 250 mL baffled flask and 
incubating at 37°C with shaking at 250 rpm for 48 hours prior to use.  
Enrichment of Mycobacteriophages 
About one gram of soil was enriched for mycobacteriophages in a 250 ml baffled 
Erlenmeyer flask containing 40 mL of deionized water, 5 mL of 10X 7H9/glycerol broth, 
5 mL of AD supplement, 0.5 mL of 100 mM CaCl2, and 5 mL of late log/early stationary 
phase liquid M. smegmatis culture. The flask was incubated for 48 hours at 37°C with 
shaking at 220 rpm. The contents were then transferred to a 50 mL conical tube (VWR, 
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catalog no. 21008-690) and centrifuged for 10 minutes at 1300 g. One mL of supernatant 
was drawn off using a 1.0 mL luer-lock syringe (VWR, catalog no. BD-309628) and 
filter-sterilized by pushing through a 0.22 μm syringe filter (VWR, catalog no. 28145-
501) into a 1.5 mL microcentrifuge tube (VWR, catalog no. 20901-551). The tube was 
stored at 4°C. 
The filtrate was serially diluted by transferring 10 μL of undiluted (100) filtrate to 
a 0.2 mL microcentrifuge tube (Fisher, catalog no. AB-0620) containing 90 μL of phage 
buffer (Appendix A). After mixing, 10 μL from this 10-1 tube was transferred another 
tube containing to 90 μL of phage buffer, and so on until reaching 10-4 (Figure 14). Fifty 
μL of each dilution (100–10-4) were added to 0.5 mL aliquots of overnight liquid M. 
smegmatis culture in 9 mL glass culture tubes (VWR, catalog no. 47729-572) with caps 
(VWR, catalog no. 16199-003). After incubating for 20 minutes at room temperature to 
allow infection to occur, the aliquots were mixed with 4.5 mL of molten top agar 
(Appendix A) at 55°C and plated onto pre-warmed L-agar plates (Appendix A). The 
plates were inverted after the top agar was allowed to solidify for 20 minutes and 
incubated at 37°C for 48 hours. The plates were then examined for plaques, which are 
circular clearings where lysis of bacterial host cells has occurred as the result of lytic 
phage growth. 
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Figure 14: Phage Plating Protocol. A 10
0
 phage stock is serially diluted by transferring 10 μL to 90 μL 
phage buffer in a microcentrifuge tube, mixing, and repeating until reaching the desired dilution level (here, 
10
-4). Fifty μL of each dilution is transferred to 0.5 mL liquid M. smegmatis culture and incubated for 20 
minutes. Four point five mL of molten top agar is added to each tube. The tubes are mixed and plated on L-
agar plates. The plates are inverted after the top agar has cooled (~15 min) and incubated at 37°C. Petri dish 
picture source: http://www.clker.com/clipart-red-petri-dish-open.html.  
Purification of Single Phage Type 
 To isolate a single phage type from the plaques recovered through enrichment, a 
sterile micropipette tip was used to pick phage particles from an isolated plaque on the 
10
-2
 enrichment plate. The tip was swished in 100 μL phage buffer in a 0.2 mL 
microcentrifuge tube to make a 10
0
 phage solution. Serial dilutions to 10
-4
 were prepared 
and plated as described above for the enrichment filtrate. After 48 hours incubation at 
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37°C, an isolated plaque from these plates was picked, diluted, and plated as above; this 
was repeated two more times for a total of four rounds of purification.  
Obtaining a High-Titer Phage Stock 
   Plating assays of dilutions from an isolated plaque indicated that approximately 
8,000 plaque forming units per plate formed a “webbing pattern” of plaques sufficiently 
crowded so as to touch each other across the plate without achieving full lysis. Twenty 
μL of a 10-3 dilution from an isolated plaque (calculated to contain approximately 80,000 
plaque forming units, or 8,000 per plate) was added to 5.0 mL of liquid M. smegmatis 
culture in a 50 mL conical tube. After incubating for 20 minutes at room temperature, the 
contents were mixed with 45 mL of molten top agar and plated on 10 L-agar plates (5 mL 
per plate). The plates were inverted after the top agar was allowed to solidify for 20 
minutes and incubated at 37°C. After 24 hours, 4.5 mL of phage buffer was added to each 
plate and allowed to sit undisturbed for 2 hours at room temperature. The lysate from 
each plate was then collected in a 50 mL conical tube and sterilized by vacuum filtration 
using a Steriflip-GP filter unit with a pore size of 0.22 μm (Millipore, catalog no. 
SCGP00525). The filtered phage stock was stored at 4°C. 
Transmission Electron Microscopy 
 To prepare phage particles for imaging under the TEM, 1.5 mL of high-titer 
phage stock was added to a 1.5 mL microcentrifuge tube and centrifuged at 11,300 x g 
for 1 hour. The pellet was resuspended in 50 μL of phage buffer and stored overnight at 
4°C. Fine-point capillary tweezers (Pella, catalog no. 5620) were used to place a 3.0-mm-
diameter, carbon-stabilized, formvar-coated copper EM grid (Pella, catalog no. 01813) 
shiny-side-up on the edge of a sheet of Parafilm (Sigma-Aldrich, catalog no. P7668). A 
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10-μL droplet of resuspended phage stock was placed on top of the grid and allowed to 
adsorb for 2 minutes at room temperature. A Kimwipe (Kimtech, catalog no. 34120) was 
used to wick off excess fluid. The grid was washed twice by adding a 10-μL droplet of 
water, allowing it to sit for 2 minutes at room temperature, and wicking it off with a 
Kimwipe. The grid was stained with 10 μL of a 1.0% uranyl acetate solution (Appendix 
A), which was allowed to stain the grid for 2 minutes. After removing excess staining 
solution with a Kimwipe, the grid was allowed to air dry. Phage particles were visualized 
and photographed under a JEOL JEM 100CX TEM. The scale bar on the photographs 
was used to determine the average head and tail length of the phage particles.   
Isolation of Genomic DNA 
 Forty μL of nuclease mix (Appendix A) were combined with 10 mL of high-titer 
phage stock in a 50 mL Oak Ridge tube with a screw cap (VWR, 21009-342) to degrade 
nucleic acid contaminants in the stock. The solution was mixed by inversion, incubated at 
37°C for 30 minutes, and incubated again at room temperature for 1 hour. Four mL of 
phage precipitant (Appendix A) were added to the tube. The solution was mixed by 
inversion and incubated overnight at 4°C. To pellet the phage particles, the tube was 
centrifuged at 14,200 g for 20 minutes in a Sorvall SuperSpeed Centrifuge. After 
decanting the supernatant, the pellet was resuspended in 2 mL of DNA Clean Up Resin 
(pre-warmed to 37°C) from the Promega Wizard DNA Clean Up System (Fisher, catalog 
no. PR-A7280). The manufacturer’s instructions for purification without a vacuum 
manifold [113] were followed to isolate genomic DNA. DNA concentrations were 
quantified using a Nanodrop and preparations were stored at 4°C. 
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DNA Restriction Digests 
 Phage genomic DNA was digested with the restriction enzymes BamHI (NEB, 
catalog no. R0136S), ClaI (NEB, catalog no. R0197S), EcoRI (NEB, catalog no. 
R0101S), HaeIII (NEB, catalog no. R0108S), HindIII (NEB, catalog no. R0104S), SmaI 
(NEB, catalog no. R0141S), ApaI (NEB, catalog no. R0114S), PstI (NEB, catalog no. 
R0140S), XhoI (NEB, catalog no. R0146S), BglII (NEB, catalog no. R0144S), MspI 
(NEB, catalog no. R0106S), and KpnI (NEB, catalog no.R0142S). Each digest was 
prepared by combining 2 μL of the appropriate 10X reaction buffer (NEBuffer 1, 
NEBuffer 2, NEBuffer 3, NEBuffer 4, or NEBuffer EcoRI; NEB catalog no. B7001S, 
B7002S, B7003S, B7004S, B0101S) as detailed in Table 5, 0.5 μg phage genomic DNA, 
10X BSA (NEB, catalog no. B9000S) where appropriate (Table 5), 10 units of restriction 
enzyme, and deionized water to 20 μL in a 0.2 mL microcentrifuge tube. Digests were 
mixed and incubated for 2 hours at 37°C, then place on ice or stored at -20°C. 
Additionally, control digests of pUC18 plasmid DNA (Thermo Scientific, catalog no. 
SD0051) and Lambda genomic DNA (Thermo Scientific, catalog no. SD0011) were 
prepared to test the activity of BamHI, ClaI, EcoRI, HaeIII, and HindIII. 
 Point eight percent agarose gels were prepared from agarose gel powder (VWR, 
catalog no. EM-2090) and 1X TBE buffer (Appendix A).Digests were run in 1X TBE 
buffer at 100 V for approximately 45 minutes. Gels were stained in 0.5 μg/mL ethidium 
bromide solution for 10 minutes before photographing under UV light.  
 
 
 
99 
 
 
Table 5: Restriction Enzyme Reaction Conditions. Buffer and BSA requirements for each enzyme were 
determined from the NEB website (https://www.neb.com/products/restriction-endonucleases).  
Enzyme Buffer BSA 
BamHI NEBuffer 3 Yes 
ClaI NEBuffer 4 Yes 
EcoRI NEBuffer EcoRI Yes 
HaeIII NEBuffer 2 Yes 
HindIII NEBuffer 2 Yes 
SmaI NEBuffer 4 No 
ApaI NEBuffer 4 Yes 
PstI NEBuffer 3 Yes 
XhoI NEBuffer 2 Yes 
BglII NEBuffer 3 No 
MspI NEBuffer 2 No 
KpnI NEBuffer 1 Yes 
 
Genome Sequencing 
To assess quality before sequencing, phage genomic DNA was run against Lamda 
HindIII size standards (NEB, catalog no. N3012L) and Lambda DNA mass standards (15, 
31, 63, 125, 250, and 500 ng/5 μL; prepared in the Science Education Alliance lab). One 
percent agarose gels were prepared with Seakem LE agarose gel powder (VWR, catalog 
no. 12001-868) and 1X TAE buffer (Appendix A). One μL of phage genomic DNA 
(between 50 and 500 ng/μL; heated for 5 minutes in a 65°C heating block before loading) 
and the Lambda size and mass standards were run in 1X TAE buffer at 120 V for 
approximately 40 minutes. The gel was stained in 0.5 μg/mL ethidium bromide solution 
for 10 minutes before photographing under UV light. After confirming DNA quality, 
~10,000 ng of phage genomic DNA was sent to the sequencing facility at Virginia 
Commonwealth University and processed by Roche 454 pyrosequencing technology 
[114].  
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Sequencing the Genomic Ends 
a. Ligation of Phage Genomic DNA 
Many dsDNA bacteriophage genomes include at each extremity a single-stranded 
cohesive end, also referred to as a cos site. Usually around 10 base pairs in length, the cos 
site allows the genome to circularize upon injection into a host bacterium. Often, this cos 
site is not included in the raw genomic sequence data genome and must be sequenced 
separately. To determine the sequence of the cos site, one primer located close to the 
right end of the genome (P1) and two located close to the left end (P2, P3) were designed 
(Table 6) such that they would frame the cos site if the genome were circularized. 
Approximately 150 ng of phage genomic DNA was ligated overnight at 14°C in a 10 μL 
reaction with 1 μL of T4 ligase (NEB, catalog no. M0202S), 1X ligation buffer (NEB, 
catalog no. B0202S), and nanopure water to volume.  
Table 6: Primers for Sequencing the Genomic Ends. One forward primer located near the right end of 
the genome and two reverse primers located near the left end of the genome were designed to amplify 
across the ends of the ligated genomic phage DNA. The sequence of the primers is in the 5’ to 3’ direction.  
Primer Direction Sequence Location 
P1 Forward CTGGTCACAGGGCGTGTC 51,059-51,076 
P2 Reverse CGCTGAACGCCGCTACTC 129-148 
P3 Reverse CTGTACATACCTTCCTATTC 191-208 
 
b. PCR Reactions 
Polymerase Chain Reaction (PCR) reactions were prepared by combining 2 μL of 
ligated phage DNA, 2 μL of P1, 2 μL of either P2 or P3, 2 μL of dNTPs (10X stock 
mixture; NEB, catalog no. N0446S), 20 μL 5X GC buffer (NEB, catalog no. B0519S), 1 
μL Phusion polymerase (NEB, catalog no. M0530S), and nanopure water to 100 μL in a 
0.2 mL microcentrifuge tube. The reaction was run under the following thermocycler 
conditions: 1) 3 min at 98°C, 2) 10 s at 98°C, 3) 30 s at 55°C, 4) 2 min at 72°C, 5) Repeat 
101 
 
steps 2) – 4) 34 times, 6) 10 min at 72°C, 7) hold at 4°C. Upon completion of the PCR 
reactions, a 1% agarose gel prepared with 1X TBE buffer was run for approximately 1 
hour at 100 V to confirm the presence of a product of expected size (~500 bp).  
c. Gel Purification of PCR Products 
The PCR product was purified from agarose gel by the phenol-freeze method 
[115]. After electrophoresis and staining for 10 minutes in 0.5 μg/mL ethidium bromide 
solution, the band of expected size was excised from the gel using a UV light table using 
a razor blade. The extracted gel piece was placed in a 1.5 mL microcentrifuge tube and 
cut into small pieces using a needle. After adding 900 μL of phenol, the solution was 
vortexed and inverted to mix and frozen at -80°C for 10 minutes. The tube was 
centrifuged at 12,100 g in a tabletop centrifuge, and the aqueous layer was transferred 
into a clean tube. An equal volume of chloroform was added, mixed well by vortexting, 
and then centrifuged at 12,100 g. The top layer was transferred into a clean tube, and the 
chloroform process was repeated. The top layer was pipetted into a Microcon filter tube 
(Millipore, catalog no. MRCF0R100), and water was added to 0.5 mL. The tube was 
spun for 10 min at 550 g. Point five mL of water was added and the spin was repeated. 
Finally, the Microcon tube filter was inverted in a fresh 1.5 mL microcentrifuge tube and 
spun for 2 minutes at 550 g to recover the PCR product. Product recovery was verified on 
a 1% agarose/1X TBE gel, and the product was submitted to GENEWIZ (South 
Plainfield, NJ) for DNA sequencing.  
Annotating the Genome 
The FASTA-formatted DNA sequence file was uploaded to a bioinformatics 
workstation containing two DNA analysis programs called Glimmer [116] and GeneMark 
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[117]. These programs utilize different algorithms to identify genes ab initio in a DNA 
sequence. Briefly, Glimmer, which stands for Gene Locator and Interpolated Markov 
ModelER, utilizes an interpolated Markov model to call genes based on coding potential, 
while GeneMark makes gene predictions based on similarities to a user-specified species 
(the phage host M. smegmatis  in this case). In addition to the gene predictions made by 
Glimmer and GeneMark, tRNA genes were identified using a built-in program called 
“tRNA Scanner,” and translation starts were identified by looking for ribosome binding 
sites, known as Shine Dalgarno sequences, using another program called “SD finder.” A 
Java program called Apollo [118], also accessed through the workstation, was used to 
visualize Glimmer and GeneMark gene predictions simultaneously in order to locate 
discrepancies between gene calls and add annotations to predicted genes.  
The National Center for Biotechnology Information (NCBI) web-based Basic 
Local Alignment Search Tool (BLAST) [119] returned nucleotide and protein matches 
for each gene. Nucleotide BLAST (BLASTn) results, coupled with scores for possible 
Shine Dalgarno sequences detected by the programs and other information such as length 
and direction of the gene, were used to decide between Glimmer and GeneMark 
predictions when the programs did not agree. BLASTn results were also used to assess 
similarities between TiroTheta9 and other phages present in the database. Protein BLAST 
(BLASTp) results yielded insights into putative functions for each gene. After calling the 
most probable gene predictions and adding annotations regarding database matches and 
putative functions where applicable, the completely annotated genome was saved as a 
GenBank file for easy uploading to other mainstream bioinformatics programs such as 
Geneious [120] as well as for submission to NCBI’s GenBank database, an open-access 
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collection of all publically available DNA sequences [121]. Geneious and Phamerator 
were used to perform several alignments with other closely related phages. 
 
B. RESULTS AND DISCUSSION 
 
Bacteriophage have a variety of promising applications in diverse fields such as 
ecology, industry, and medicine. Because our current understanding of phage biology and 
diversity is relatively limited, the isolation and characterization of novel bacteriophages is 
essential for the continued development of these applications. Through the procedures 
described above, a novel bacteriophage, TiroTheta9 (TT9), was isolated from the 
environment and characterized both phenotypically and genotypically. The 
characterization of TT9 has enhanced our understanding of mycobacteriophages and their 
unique properties. Additionally, the data collected has expanded the growing knowledge 
base available to researchers and may contribute to groundbreaking discoveries in 
medicine, molecular biology, genetics, evolution, and beyond. 
Enrichment, Isolation, and Phenotypic Analysis 
Mycobacteriophages were enriched from a soil sample collected from Fairview 
Cemetery in Bowling Green, KY (GPS coordinates: 36° 59’ 34’’ N, 86° 25’ 15’’ W). A 
single phage type was purified from the sample after four successive rounds of 
purification by plating phage particles from isolated plaques on lawns of M. smegmatis. 
The purified phage was named TiroTheta9 (TT9; see Footnote at end of chapter). TT9 
forms clear, circular plaques with a diameter of 1-2 mm on a lawn of M. smegmatis 
bacteria (Figure 15a) after 24 hours of incubation at 37°C. The clarity of the plaques 
suggests that TT9 is primarily a lytic mycobacteriophage.  
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TEM analysis shows that TT9 is a member of siphoviridae and has an icosahedral 
capsid 58 ± 2 nm in diameter (average of 22 capsid measurements) and a noncontractile 
tail 174 ± 5 nm in length (average of 13 tail measurements) as measured from the TEM images 
shown in Figure 15b and c. TEM images were also useful in confirming the purity of the 
phage stock, as all particles present in the sample appeared to be identical.  
 
Figure 15: TiroTheta9 Plaques and TEM Micrographs. a.) TT9 forms clear plaques 1-2 mm in diameter 
on a lawn of M. smegmatis after 24 hours of incubation. b.) and c.) TEM images show TT9 is a member of 
siphoviridae, with an icosahedral capsid 58 ± 2 nm in diameter and a noncontractile tail 174 ± 5 nm in 
length.  
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Genotypic Analysis: Restriction Digest Results 
Genomic DNA was isolated from a high-titer stock of TT9 phage particles, and 
preliminary genotypic analysis was conducted by digesting the TT9 genomic DNA with 
various restriction enzymes. This was done primarily to determine if TT9 was a novel 
phage before sequencing by comparing the results with restriction patterns available for 
other mycobacteriophages as well as to identify a characteristic restriction pattern for 
TT9 DNA for future use in confirming DNA identity. The restriction patterns from 
digestion with BamHI, ClaI, EcoRI, HaeIII, and HindIII, visualized using gel 
electrophoresis, are shown in Figure 16. Additional digests were performed with XhoI, 
BglII, MspI, KpnI, SmaI, ApaI, and PstI; the results of the SmaI, ApaI, and PstI digests 
are shown in Figure 17a. The gel is badly smeared, which may be due to problems with 
the electrophoresis buffer used to run the gel, but general cutting patterns can still be 
discerned.  
The patterns produced by BamHI, ClaI, EcoRI, HindIII, XhoI, BglII, MspI, KpnI, 
SmaI, and ApaI all appear identical to the uncut genomic DNA, indicating that these 
enzymes did not cut the DNA. This result suggests that the TT9 genome does not contain 
the restriction sites for these enzymes. HaeIII, however, produced a multitude of 
fragments too small to be individually distinguished. This result demonstrated that the 
TT9 genome contains multiple instances of the HaeIII restriction site. Despite the 
smearing, it is evident from Figure 17a that the PstI digest produced multiple bands large 
enough to be individually discerned. As expected, subsequent genomic DNA stocks 
analyzed in this manner gave a similar restriction pattern (Figure 17b). 
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In order to confirm the functionality of the enzymes, digests of pUC18 plasmid 
and Lambda genomic DNA, both of known sequence, were performed. The results of 
these digests showed appropriate cutting patterns for each enzyme (results not shown), 
verifying the activity of the enzymes and supporting the conclusion that the TT9 genome 
does not contain restriction sites for the enzymes listed above. A comparison of the TT9 
restriction patterns for BamHI, ClaI, EcoRI, HindIII, and HaeIII with analogous patterns 
for 60 other mycobacteriophages yielded no matches to the patterns observed for TT9, 
suggesting that TT9 is a unique, previously uncharacterized phage.  
 
Figure 16: Restriction Digests of TiroTheta9 Genomic DNA.  The contents of each lane are as follows: 
1) 1-kb ladder (bands, top to bottom: 10.0, 8.0, 6.0, 5.0, 4.0, 3.0, 2.5, 2.0, 1.5, 1.0, 0.7 kb), 2) undigested 
TT9 genomic DNA, 3) BamHI digest, 4) ClaI digest, 5) EcoRI digest, 6) HaeIII digest, 7) HindIII digest. 
Only HaeIII produced a restriction pattern different from that of undigested DNA; thus, it can be concluded 
that the TT9 genome only includes the recognition site for this enzyme.  Furthermore, the fragments 
produced during the digestion are very small, indicating that the site is repeated many times throughout the 
genome. Comparison with a database of the restriction patterns using these five enzymes for 60 
mycobacteriophage genomes yielded no match, supporting the conclusion that TT9 is a unique and novel 
mycobacteriophage. Note: The ladder is marked in base pairs. 
 
107 
 
  
Figure 17: Additional Restriction Digests of TiroTheta9 Genomic DNA. a.) Additional restriction 
digest analysis of TT9 genomic DNA. The lane contents are as follows:1) 1-kb ladder (bands, top to 
bottom: 10.0, 8.0, 6.0, 5.0, 4.0, 3.0, 2.5, 2.0, 1.5, 1.0, 0.7, 0.5, 0.3 kb), 2) undigested TT9 genomic DNA, 3) 
undigested TT9 genomic DNA, 4) SmaI digest, 5) ApaI digest, 6) PstI digest. The smearing is mostly likely 
due to the compromised quality of the buffer used to prepare it. Lanes 4 and 5 ran identically to lanes 2 and 
3, indicating a lack of recognition sites in the TT9 genome for either SmaI or ApaI. However, multiple 
bands can be discerned in the PstI lane, leading to the conclusion that the TT9 genome contains several 
recognition sites for PstI. b.) After TT9 genomic DNA was isolated from a second high-titer stock of the 
phage, the DNA was digested with Pst1. The results of the digest were compared with the pattern produced 
by a Pst1 digest of the originally isolated DNA to confirm its identity. The lane contents are as follows: 1) 
1-kb ladder, 2) Pst1 digest of different preparation of TT9 genomic DNA, 3) Pst1 digest of original TT9 
DNA. Although the poor quality of the original gel makes it difficult to distinguish each individual band, 
overall they are discernable enough to confirm that the same pattern was produced by the digestion of both 
DNA samples with Pst1. Thus, the two DNA samples were isolated from the same phage.   
 
Genotypic Analysis: Sequencing and Genome Annotation Results 
The sequenced TT9 genome consists of a single contiguous sequence, or contig, 
and is 51,367 base pairs in length. Nucleotide BLAST (BLASTn) results returned 99% 
sequence similarity to Mycobacterium Phage Peaches [122]. After analyzing each gene 
prediction using BLAST and Apollo, the final TT9 genome was determined to contain 87 
genes, 24 of which were assigned putative functions based on Protein BLAST (BLASTp) 
matches. Spurred by the influx of phage genomic sequence information, functions for 
seven additional genes have been assigned since the TT9 genome was first annotated in 
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2010. Information for each predicted gene, including start and end position, gene length, 
orientation, gene product designation, corresponding amino acid length, and putative 
function where applicable, is summarized in Table 7, and the GenBank file showing the 
complete annotated genomic sequence can be found online [123] and in Appendix B. The 
data is also available on the Mycobacteriophage Database (http://phagesdb.org/ 
phages/TiroTheta9/). Based on sequence comparisons, TT9 was classified as a member 
of the A4 subcluster of mycobacteriophages. 
Identifying the Genomic Ends: 
A 10 base-pair cos site with sequence CGGCCGGTAA was identified by 
sequencing the PCR products amplified from ligated TT9 genomic DNA as shown in 
Figure 18. The cos site sequence matches that of most of the A4 mycobacteriophages 
included in the Mycobacteriophage Database as well as that of some phages from the A1, 
A3, and A10 subclusters. 
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Figure 18: Determining the TiroTheta9 cos Site Sequence. a.) Primers located at either end of the 
genome were combined with ligated TT9 genomic DNA in a PCR reaction to amplify the region between 
the ends of the ligated DNA containing the cos site. b.) The resulting PCR product was sequenced and 
aligned with the TT9 genomic sequence in Geneious to generate the figure. The components of the 
alignment are as follows: 1) the consensus identity across all sequences, 2) identity meter – green indicates 
homology between the aligned sequences, while the gap indicates the position of the cos site, which is not 
present in the genomic sequence data; 3) the sequence of the PCR amplified region containing the cos site 
sequence, 4) TT9 Genomic sequence; the gap between the ends is where the cos site belongs, 5) sequence 
verifying the left end of the TT9 genome. The peaks in 3 and 5 indicate that clear, unambiguous reads were 
obtained across the cos site, supporting the accuracy of the sequencing results. 
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Table 7: TiroTheta9 Gene Summary.  Putative genes were located in the raw TT9 genomic sequence 
using the ab initio gene calling programs Glimmer and GeneMark as well as NCBI’s BLAST. In total, 87 
genes were called. The table summarizes the start and end position (given in base pairs from the 5’ end of 
the genome), length in base pairs, direction, protein product designation (gp stands for gene product), 
translated length of the predicted protein product in amino acids, and putative function based on BLAST 
matches for each of TT9’s genes.   
Gene Start End Length Direction Designation AA Putative Function 
1 672 457 216 3' → 5' gp1 71 Protein coding 
2 803 1234 432 5' → 3' gp2 143 Protein coding 
3 1326 1640 315 5' → 3' gp3 104 Minor tail subunit 
4 1645 2718 1074 5' → 3' gp4 357 Protein coding 
5 2722 3384 663 5' → 3' gp5 220 Structural protein 
6 3384 3755 372 5' → 3' gp6 123 Protein coding 
7 3784 3921 138 5' → 3' gp7 45 Protein coding 
8 3921 5423 1503 5' → 3' gp8 500 LysA 
9 5420 5881 462 5' → 3' gp9 153 Protein coding 
10 5881 6861 981 5' → 3' gp10 326 LysB 
11 6884 8581 1698 5' → 3' gp11 565 Terminase 
12 8578 10029 1452 5' → 3' gp12 483 Portal Protein 
13 10026 10886 861 5' → 3' gp13 286 Capsid maturation protease 
14 10939 11451 513 5' → 3' gp14 170 Scaffolding protein 
15 11479 12411 933 5' → 3' gp15 310 Major capsid protein 
16 12475 12681 207 5' → 3' gp16 68 Protein coding 
17 12685 13041 357 5' → 3' gp17 118 Protein coding 
18 13038 13205 168 5' → 3' gp18 55 Protein coding 
19 13202 13564 363 5' → 3' gp19 120 Protein coding 
20 13566 13958 393 5' → 3' gp20 130 Protein coding 
21 13958 14395 438 5' → 3' gp21 145 Protein coding 
22 14385 14975 591 5' → 3' gp22 196 Major tail subunit 
23 15095 15466 372 5' → 3' gp23 123 Tail assembly chaperone 
24 15095 15963 869 5' → 3' gp24 289 Tail assembly chaperone 
25 15882 18482 2601 5' → 3' gp25 866 Tape measure protein 
26 18487 19827 1341 5' → 3' gp26 446 Minor tail protein 
27 19824 21602 1779 5' → 3' gp27 592 Minor tail protein  
28 21624 22070 447 5' → 3' gp28 148 Protein coding 
29 22079 22525 447 5' → 3' gp29 148 Protein coding 
30 22515 22943 429 5' → 3' gp30 142 Protein coding 
31 22957 24813 1857 5' → 3' gp31 618 Protein coding 
32 25094 24876 219 3' → 5' gp32 72 Protein coding 
33 26634 25120 1515 3' → 5' gp33 504 Serine integrase 
34 26713 27132 420 5' → 3' gp34 139 Protein coding 
35 27801 27205 579 3' → 5' gp35 198 Protein coding 
36 27956 27798 159 3' → 5' gp36 52 Deoxycytidylate deanimase 
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37 28108 27956 153 3' → 5' gp37 50 Protein coding 
38 28371 28105 267 3' → 5' gp38 88 Protein coding 
39 28454 28368 87 3' → 5' gp39 28 Protein coding 
40 28708 28451 258 3' → 5' gp40 85 Protein coding 
41 29061 28705 357 3' → 5' gp41 118 Protein coding 
42 29323 29048 276 3' → 5' gp42 91 Protein coding 
43 29553 29320 234 3' → 5' gp43 77 Protein coding 
44 29717 29550 168 3' → 5' gp44 55 Protein coding 
45 31564 29738 1827 3' → 5' gp45 608 DNA polymerase I 
46 31874 31572 303 3' → 5' gp46 100 Protein coding 
47 32047 31874 174 3' → 5' gp47 57 Protein coding 
48 32775 32056 720 3' → 5' gp48 239 ThyX 
49 33382 32843 540 3' → 5' gp49 179 Protein coding 
50 35442 33409 2034 3' → 5' gp50 677 Ribonucleotide reductase 
51 36323 35439 885 3' → 5' gp51 294 Protein coding 
52 37106 36339 768 3' → 5' gp52 255 Metallophosphoesterase 
53 37374 37099 276 3' → 5' gp53 91 Protein coding 
54 37678 37367 312 3' → 5' gp54 103 Protein coding 
55 38133 37474 660 3' → 5' gp55 219 DNA primase 
56 38362 37949 414 3' → 5' gp56 137 DNA primase 
57 38480 38346 135 3' → 5' gp57 44 Protein coding 
58 38972 38502 471 3' → 5' gp58 156 Endonuclease VII 
59 39860 39036 825 3' → 5' gp59 274 Hydrolase 
60 40237 39857 381 3' → 5' gp60 126 Protein coding 
61 40458 40234 225 3' → 5' gp61 74 Protein coding 
62 41052 40516 537 3' → 5' gp62 178 Phosphoribosyltransferase 
63 41878 41072 807 3' → 5' gp63 268 DnaB-like helicase 
64 41966 41886 81 3' → 5' gp64 26 Protein coding 
65 42157 41963 195 3' → 5' gp65 64 Protein coding 
66 42351 42154 198 3' → 5' gp66 65 Protein coding 
67 43152 42361 792 3' → 5' gp67 263 AddAB recombination protein 
68 43571 43149 423 3' → 5' gp68 140 Protein coding 
69 44165 43653 513 3' → 5' gp69 170 Immunity repressor 
70 44504 44376 129 3' → 5' gp70 42 Protein coding 
71 44874 44626 249 3' → 5' gp71 82 Protein coding 
72 45185 44871 315 3' → 5' gp72 104 Protein coding 
73 45342 45202 141 3' → 5' gp73 46 Protein coding 
74 45641 45342 300 3' → 5' gp74 99 Protein coding 
75 45796 45638 159 3' → 5' gp75 52 Protein coding 
76 45947 45804 144 3' → 5' gp76 47 DNA methylase 
77 46742 46158 585 3' → 5' gp77 194 Protein coding 
78 47253 46720 534 3' → 5' gp78 177 Protein coding 
79 47420 47250 171 3' → 5' gp79 56 Protein coding 
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80 47893 47423 471 3' → 5' gp80 156 SprT 
81 48060 47890 171 3' → 5' gp81 56 Protein coding 
82 48410 48057 354 3' → 5' gp82 117 Protein coding 
83 48583 48407 177 3' → 5' gp83 58 Protein coding 
84 48797 48585 213 3' → 5' gp84 70 Protein coding 
85 49095 48889 207 3' → 5' gp85 68 Protein coding 
86 50002 49118 885 3' → 5' gp86 294 Protein coding 
87 50150 50031 120 3' → 5' gp87 39 Protein coding 
 
Gene Content and Organization 
A schematic diagram of the TT9 genome is shown in Figure 19. From the 
diagram, it can be seen that TT9 has a very closely-packed genetic architecture, with little 
to no space between genes and many genes overlapping with those adjacent to them. This 
compact genomic structure is characteristic of phage genomes, as well as viral genomes 
in general.  
The overlap phenomenon is taken to a notable extreme in the case of gene 23, 
which overlaps entirely with gene 24; the two genes share a start position, but gene 23 
terminates 497 base pairs earlier than gene 24, resulting in a gene product 166 amino 
acids shorter in length. Given the identification of these two genes as tail assembly 
chaperones, this likely represents a unique frame-shift event that has also been 
documented in the tail assembly chaperone genes of E. coli phage Lambda. In such a case, 
the two genes would be transcribed together as a single transcript. Translation would 
normally result in the production of the shorter gene product due to the presence of 
translation terminators in the reading frame of gene 23. However, a “slippery” sequence 
near the end of gene 23 would occasionally cause the ribosome to shift backwards or 
forwards by a fixed number of bases (in Lambda, the shift is -1, but shifts of +1 and -2 
have been observed in other phages [phagesdb.org/glossary]) and continue translating in 
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a different reading frame, resulting in the production of a longer gene product in 
accordance with the entire length of gene 24.  
The overall orientation of TT9’s genes is also of note. As reflected in Figure 19 
and Table 7, except for gene 1, the first 31 TT9 genes are transcribed from the bottom 
strand, while the remaining 56 plus gene 1 are transcribed from the complementary top 
strand and are thus oriented in the opposite direction. This organization scheme is 
common for phage genomes, where groups of genes of opposite orientation are often 
expressed at different times during the phage replication cycle. For example, in the 
Lactococcus phage sk1, middle and late transcripts are oriented opposite to early genes 
[125]. A similar setup is observed in phage Lambda [41]. 
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As noted above, putative functions have been identified for 31 of the 87 TT9 
genes. Although this represents only 35.6% of the gene content, it allows several 
important conclusions to be drawn regarding TT9’s genomic architecture. For example, 
the genes involved in forming and assembling the phage capsid are grouped together, as 
are those involved in forming the tail. In particular, genes 11, 12, 13, 14, and 15 have 
been identified as a putative terminase
6
, portal protein
7
, capsid maturation protease
8
, 
scaffold protein
9
, and major capsid subunit respectively. Located downstream of the 
capsid genes are genes 22, 23, 24, 25, 26, and 27, which comprise a putative major tail 
subunit, two tail assembly chaperones
10
, a tapemeasure protein
11
, and two minor tail 
proteins respectively. This organization reflects a synteny in structural and assembly 
genes that is highly conserved among all siphoviridae, even among those with no 
detectable nucleotide or amino acid sequence similarity [126].  
An interesting anomaly that breaks from the traditionally tight grouping of related 
structural genes is the presence of a putative minor tail subunit, gene 3, upstream of the 
capsid genes. BLAST results yield nucleotide and protein matches to other A cluster 
phages, including phages from the A4, A3, and A7 subclusters; however, these matches 
                                                          
6
 The ATP-driven terminase enzyme is responsible for packaging genetic material into the capsid during 
assembly. 
 
7
 Twelve portal proteins form a ring called the portal at one vertex of the phage capsid. During assembly, 
the portal serves as a binding site for terminase and later for the tail to form a complete phage particle.  
 
8
 Capsid maturation protease functions to degrade intermediate scaffolding proteins as the capsid matures 
during phage assembly. 
 
9
 Scaffolding proteins aid in the early formation of the capsid. They are degraded by capsid maturation 
protease as the capsid matures and are thus not present in the mature phage particle. 
 
10
 The two tail assembly chaperones help to assemble the major tail proteins in a spiral pattern around the 
core of the tail. 
 
11
 The tapemeasure protein, typically encoded by the longest gene in a siphoviridae phage genome, forms 
the core of the tail and is thus directly proportional to the tail length. 
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are located in a similar position apart from the other tail genes in these phages, as well, 
suggesting that 1) the gene may have been acquired by a recent common ancestor of 
these subclusters, and 2) the phage from which the gene originated has yet to be 
discovered. Given its ambiguous evolutionary origins and anomalous position, it also 
remains to be shown whether this gene actively functions as a minor tail subunit in the A 
cluster phages that have it in their genomes.  
Although the relative order of phage structural genes is highly conserved among 
virtually all siphoviridae, the location of other genes tends to be more varied. Lysis genes 
in the mycobacteriophages, for example, are generally found either upstream of the 
capsid genes or downstream of the tail genes [126]. TT9 exhibits the former pattern, with 
two putative lysin genes located immediately 5’ of the capsid genes. In particular, gene 8 
is a putative Lysin A gene. LysA has been shown to function in peptidoglycan hydrolysis 
and serves as the major lysis enzyme. Gene 9 is a putative Lysin B gene. LysB proteins, 
found only in mycobacteriophage, function as mycolylarabingalactan esterases to 
disconnect the unique mycobacterial outer membrane from the peptidoglycan cell wall 
for efficient lysis [127].  
Gene 33, a putative integrase gene, lies near the center of the genome. The 
presence of this gene in conjunction with the putative immunity repressor represented by 
gene 69 indicates that TT9 is a temperate phage capable of forming lysogens. Phenotypic 
analysis of TT9 suggested a lytic classification for the phage, with clear plaques free of 
the peripheral turbidity often associated with lysogen formation observed after incubation 
at 37°C for 24 hours. It may be that the laboratory conditions were not optimal for TT9 
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lysogen formation, or that 24 hours was not enough time for lysogens to grow in high 
enough quantities to be observed.    
Other genes of interest that have been identified in the TT9 genome are likely to 
be involved in the synthesis of phage DNA during replication; these include DNA 
polymerase I (gene 45); two DNA primases (genes 55 and 56); a DnaB-like helicase 
(gene 63); and a deoxycytidylate deaminase (gene 36), the thymidylate synthase ThyX 
(gene 48), and ribonucleotide reductase (gene 50), which function in the de novo 
biosynthesis of deoxynucleotides. Unlike the structural genes, these genes are not 
localized to a single region of the genome, but instead are scattered throughout the 
second half of the genome and read in a direction opposite to that of the structural genes, 
perhaps reflecting a distinct expression profile from the structural genes.  
A putative endonuclease VII (gene 58) likely functions to resolve branch points in 
newly synthesized DNA to prepare the genome for packaging, a function that has been 
attributed to an analogous enzyme in E. coli phage T4 [128]. Gene 67 is a putative 
AddAB DNA recombination protein that repairs double-stranded DNA breaks through 
homologous recombination. A putative DNA methylase represented by gene 76 likely 
constitutes an antirestriction mechanism to protect the phage DNA from digestion by the 
host’s restriction-modification defense system. The specific roles of a putative 
metallophosphoesterase (gene 52), hydrolase (gene 59), phosphoryltransferase (gene 62), 
and SprT-like zinc metallopeptidase (gene 80) in the TT9 lifecycle have yet to be fully 
elucidated. The function of these and the remaining 57 genes of unknown function that 
comprise the TT9 genome could represent the subject of future investigations.   
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Similarity to Other Mycobacteriophages  
At the time of initial sequencing in 2010, TT9’s closest match in the BLAST 
database was Mycobacterium Phage Peaches, another A4 phage. The Mycobacteriophage 
Database local BLAST server contains an extended library of phage genomes, including 
some that have not yet been published to GenBank. Unsurprisingly, current nucleotide 
BLAST results of the entire TT9 genome on this server reveal closest similarity to other 
A4 mycobacteriophages, with Broseidon, TygerBlood, and Flux making up the top three 
matches. However, the top 100 matches also include, in order of first appearance in the 
list, phages from the A10, A3, A1, A7, and A2 subclusters.  
BLAST results for the entire TT9 genome on the general NCBI BLASTn server 
show that TT9 displays 99% identity across 100% of its genome with six A4 phages 
(Flux, Sabertooth, Dhanush, Meezee, Peaches, and Shaka). These genomes are nearly 
identical at the nucleotide level, but the differences in their sequences could provide 
tantalizing insights into the evolution of the phages as well as the structure of their 
proteins. These and other important insights are derived from the comparative analysis of 
related phage genomes, a topic that is explored for the A4 subcluster in the next chapter.  
Footnote – What’s in a Name? 
As bacteriophage are not considered living organisms due to the fact that they 
require the assistance of a host cell to replicate, they are not assigned conventional 
scientific names. Although several generally accepted guidelines have been put in place 
by the Pittsburgh Bacteriophage Institute (phagesdb.org/namerules), novel phages can 
more or less be named arbitrarily by their discoverers, which was the case for TT9. The 
first part of TiroTheta9’s name, Tiro, is a Latin word meaning “beginner” or “new 
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recruit.” It denotes the beginning of the discoverer’s journey in the world of scientific 
research. Theta is a Greek letter which was used to symbolize death in ancient Athens, 
akin to the skull-and-crossbones symbol used today. It alludes to the graveyard site where 
the soil sample that contained TT9 was collected, as well as to the deadly relationship 
TT9 and all lytic phages share with their hosts. Theta also symbolizes the number 9, 
which was included again as an Arabic numeral at the end of TT9’s name to represent the 
month and year in which TT9 was discovered (September 2009). 
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CHAPTER 8 
 
 
COMPARATIVE ANALYSIS OF TIROTHETA9 AND THE A4 SUBCLUSTER 
 
 
TT9, the novel mycobacteriophage described in the previous chapter, is a member 
of the A4 subcluster of mycobacteriophages. Although the A4 phages necessarily share 
many characteristics, they differ in important ways that may yield insights into phage 
gene structure and function as well as the evolutionary history of the group that can be 
extended to mycobacteriophage and even bacteriophage in general. The following 
chapter outlines the general characteristics of the subcluster before delving into the 
geographic distribution of the A4 phages and making genomic comparisons among them. 
  
A. GENERAL CHARACTERISTICS OF THE A4 SUBCLUSTER 
 
The A4 subcluster currently has 46 sequenced and verified members registered in 
the Mycobacteriophage Database. It is the second largest subcluster of Cluster A, which 
itself is the largest among the 20 mycobacteriophage clusters. The earliest member of the 
subcluster was discovered in 2008, while the newest was added in 2013. All have the 
siphoviridae morphotype, although a survey of the available micrographs on the 
Mycobacteriophage Database server shows that capsid and tail dimensions vary. The 
genome sizes and GC contents of members of the A4 subcluster are relatively consistent; 
the genome sizes range from 51,131 bp to 51,813 bp and average 51,375 bp, and the GC 
contents range from 63.7% to 64.1% with an average of 63.9%. 
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Of the 46 sequenced and verified A4 phages, 18 have been annotated and 
published on GenBank as of March 2014. Interestingly, although the genome size does 
not differ dramatically among these 18 phages (51,236 bp-51,813 bp, ~600 bp difference), 
the number of genes ranges from 85 to 91 (average 87.4). This suggests that the sizes of 
individual genes may also vary rather significantly among subcluster members. TT9, with 
87 genes, a genome size of 51,367 bp, and a GC content of 63.9%, falls right at the 
average values for the subcluster. The names, genome lengths, GC contents, year of 
isolation, and sampling location for all 46 A4 phages are summarized in Table 8; the 
number of genes for each of the published phage genomes (indicated by bolded and 
boxed names in Table 8) is also included along with statistics across applicable categories. 
Table 8: Basic Characteristics of the A4 Subcluster Phages. The table includes the 46 members of the 
A4 subcluster that have been sequenced and verified as of March 2014. The names of the 18 members that 
have been published on GenBank are bolded and boxed. Source: phagesdb.org/subclusters/A4. 
Name 
Size 
(bp) 
GC% Genes Year State 
Abdiel 51381 63.9 - 2011 MO 
Achebe 51433 63.7 - 2012 KY 
Arturo 51500 64.1 - 2011 VA 
Backyardigan 51308 63.7 84 2009 KY 
BellusTerra 51236 63.9 89 2012 PA 
Broseidon 51374 63.9 - 2011 MO 
Bruiser 51374 63.9 - 2011 MA 
BubbleTrouble 51397 63.9 - 2012 MA 
Burger 51371 63.9 - 2013 AR 
Caelakin 51374 63.9 - 2013 MN 
Camperdownii 51131 63.9 - 2012 MA 
Clarenza 51372 63.9 - 2011 MA 
Dhanush 51373 63.9 88 2011 AL 
Eagle 51436 63.9 87 2008 VA 
Eris 51386 64 - 2012 MA 
Flux 51370 63.9 89 2011 PA 
Funston 51372 64 - 2012 CT 
Gadost 51376 64 - 2012 NJ 
HamSlice 51370 63.9 - 2012 PA 
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Holli 51162 63.9 - 2012 MS 
ICleared 51440 63.9 88 2011 LA 
Kampy 51378 63.9 - 2012 VA 
KFPoly 51365 63.9 - 2012 MA 
Kratark 51407 63.9 - 2012 MA 
Lemur 51370 63.9 - 2012 IN 
LHTSCC 51813 63.9 91 2009 MA 
LittleGuy 51178 63.9 - 2011 MO 
Maverick 51372 63.9 - 2010 VA 
Medusa 51384 63.9 87 2011 LA 
MeeZee 51368 63.9 87 2010 NY 
Melvin 51369 63.9 91 2011 PA 
Millski 51374 63.9 - 2012 MA 
Morpher26 51294 63.7 - 2011 KY 
Mundrea 51257 64 - 2011 GA 
Nyxis 51250 63.9 87 2011 MO 
Obama12 51797 64 89 2012 NC 
Peaches 51376 63.9 86 2008 LA 
Phighter1804 51470 64 - 2011 GA 
Pipcraft 51376 63.9 - 2013 AR 
Sabertooth 51377 63.9 88 2011 MO 
Shaka 51369 63.9 86 2008 VA 
TinaFeyge 51367 63.9 - 2011 KY 
TiroTheta9 51367 63.9 87 2009 KY 
TygerBlood 51373 63.9 - 2011 AL 
Wander 51366 63.9 - 2011 MA 
Wile 51308 63.7 85 2009 VA 
Average 51,375 63.9 87.6 - - 
Minimum 51,131 63.7 84 2008 - 
Maximum 51,813 64.1 91 2013 - 
Range 682 0.4 7 5 - 
 
 
B. GEOGRAPHIC DISTRIBUTION 
 
The A4 phages originate from a remarkable diversity of locations, as illustrated 
by Figure 20. Although all current members were isolated in the United States, they 
represent 16 states across about 2,200 km from Louisiana to Massachusetts and covering 
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an area of about 1,840,000 km
2
. Even subsets of especially similar phages within the 
subcluster display wide geographic diversity – for example, TT9 and the six phages with 
which it shares 99% sequence identity (Flux, Sabertooth, Dhanush, MeeZee, Peaches, 
and Shaka; red icons in Figure 20) were all isolated in different states (KY, PA, MO, AL, 
NY, LA, and VA). 
With so many miles between them, and given the huge diversity of the 
bacteriophage population, it is remarkable that these seven phages, and the members of 
the A4 subcluster in general, bear such strong sequence similarity, sharing a surprisingly 
large amount of highly conserved sequence. In addition, the continued isolation and 
characterization of new mycobacteriophages promises to uncover novel A4 subcluster 
members from an increasing diversity of locations. These intriguing observations, which 
reinforce previously published observations by Hatfull et al. in 2006 and Pope et al.in 
2011, raise new questions about how phages evolve and are distributed. The observed 
sequence similarity could be the result of convergent evolution to infect a common host, 
but given the high degree of homology across the genomes of A4 phages, it is more likely 
that A4 phages share a common ancestor. Where this putative ancestor first arose and 
how it spread to the diverse locations from which its descendants have been isolated, 
however, remains to be elucidated, as does the full extent of the geographic distribution 
of A4 subcluster phages.  
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Figure 20: Geographic Distribution of the A4 Phages. Despite their high degree of sequence similarity, 
the A4 subcluster phages were isolated across a wide range of geographic locations, spanning from 
Louisiana to Minnesota to Massachusetts. Even subsets of phages within the subcluster that display 
particularly high homology – for example, TT9 and the six phages with which it shares 99% sequence 
identity, indicated by the red icons in the figure – are found in diverse locations. These observations 
indicate that there is little correlation between genomic sequence and geographic area of isolation. Figure 
generated by Google Earth. 
 
C. GENOME COMPARISONS 
 
General Observations 
As discussed earlier in this chapter, the 18 published genomes in the A4 
subcluster vary somewhat in terms of genome size and number of genes. Despite these 
minor variations, the general organization of the genome is very similar across the entire 
subcluster. This is exemplified in Figure 21, which shows schematics of four 
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representative A4 subcluster genomes. Given that there is a well-conserved relative order 
for structural genes among all siphoviridae, one might suspect that perhaps a roughly 
similar genome organization is observed for all mycobacteriophages and not just among 
the A4 phages. However, a schematic comparison of these A4 genomes with the A1 
subcluster phage Bxb1 and I1 subcluster phage Babsiella, also included in Figure 21, 
shows that this is not the case. Although Babsiella is similar in length to the average A4 
phage (48,420 bp vs. 51,375 bp), its genes are arranged in a very different manner. In 
addition, despite belonging to the same cluster as the A4 phages, Bxb1 also shows 
differences in genome organization, although much less dramatic than for Babsiella. This 
suggests that the organization pattern observed for the A4 phages is subcluster-specific.  
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Although the general organization of the genomes is similar across the A4 
subcluster, there remains a considerable amount of sequence diversity. In general, this 
diversity is spread across the genome, as can be seen in Figure 22, which shows an 
alignment of TT9 and Flux. Although the two phages share 99% overall sequence 
identity across 100% of their genomes, the figure clearly shows areas of sequence 
divergence. Different divergence patterns are observed when TT9 is compared with each 
of the other A4 members. 
Many of these areas of divergence take the form of single nucleotide substitutions. 
While most of these substitutions correspond to synonymous changes that do not alter the 
amino acid sequence of the translated gene product due to the inherent degeneracy of the 
genetic code, others are nonsynonymous, meaning the codons are translated into different 
amino acids. Figure 23 shows a partial alignment of the TT9 and Flux tapemeasure 
proteins. Of the 17 nucleotide differences shown, ten are synonymous while the 
remaining seven are nonsynonymous.  
As the substitution of even a single amino acid can radically alter the form and 
function of the protein synthesized, these seemingly insignificant variations can 
potentially produce two very different phage at the phenotypic level; an example of this 
was discussed in Chapter 7C, where host range mutants were generated by the 
substitution of a single amino acid in a minor tail protein. Alternatively, an amino acid 
substitution may have little or no effect on the ultimate functioning of the resulting 
protein, especially if the amino acids in question have similar properties. Studying these 
small differences can thus unlock a new understanding of how evolution works to create 
128 
 
viable phages as well as enhance our knowledge of how amino acid sequence is related to 
protein structure and function in general.  
These single amino acid substitutions provide evidence for a vertical model of 
phage evolution, whereby new phages diverge from a common ancestor through the 
gradual acquisition of random mutations. The genomes of the A4 phages also show 
evidence of evolution on a larger scale through horizontal gene transfer, whereby whole 
genes from diverse evolutionary origins can be incorporated into the genome. Support for 
both of these models will be presented in the following paragraphs. 
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Evidence for Vertcal Evolution 
The abundance of nucleotide substitutions that pepper the A4 genomes can 
potentially offer clues into the evolutionary history of the subcluster. These substitutions, 
which vary in location among different phages, are likely evidence of random mutations 
acquired gradually in a vertical manner, similar to the way evolution proceeds in 
macroscopic organisms such as animals and plants. A comparison of the putative 
scaffolding and capsid proteins of TT9 with those of Flux, Shaka, and Peaches in Figure 
24 illustrates this idea. Overall, the figure shows a high degree of sequence homology 
among the two genes in TT9 and the analogous genes in each of the other three phages, 
suggesting a common evolutionary origin. However, the genes vary in the number and 
location of nucleotide substitutions they contain relative to TT9. Peaches differs the most, 
displaying sequence differences in both genes. Fewer differences are seen for Shaka, and 
they appear only in the capsid gene. Finally, Flux is identical to TT9 in both genes. If we 
consider a model of vertical descent from a common ancestor, this would suggest that 
Flux is most closely related to TT9, with Shaka a close second and Peaches a slightly 
more distant relation as there has been more evolutionary time for random mutations to 
accumulate.  
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Figure 24: Evidence for Vertical Evolution in Peaches, Shaka, Flux, and TiroTheta9 Scaffolding and 
Capsid Protein Genes. Alignments of the Peaches, Shaka, and Flux scaffolding and capsid protein genes 
(genes 14 and 15 respectively) with the same genes in TiroTheta9 show varying degrees of sequence 
divergence relative to TT9, with Peaches showing nucleotide substitutions in both genes, Shaka showing 
fewer and only in the capsid gene, and Flux displaying complete sequence identity with TT9 across both 
genes. If a vertical model of evolution for this set of genes is assumed, these observations would indicate 
that Flux is most closely related to TT9, with Shaka a close second and Peaches more distantly related. In 
the figure, phage genomic sequences are represented by gray lines. Black stripes on these lines highlight 
areas of sequence dissimilarity for the pair of genomes under comparison. Genes are represented by green 
arrows that point in the direction of transcription. Figure generated by Geneious.    
A comparison of the minor tail proteins of TT9, Shaka, and Eagle reveals a 
nucleotide sequence difference that is potentially related to the differential host 
preferences of these phages. As discussed in the last chapter, Jacobs-Sera et al. identified 
a single amino acid change in a minor tail protein of G cluster phages that allows host-
expanded mutants to infect M. tuberculosis with higher efficiency [99]. The same paper 
also reported infection efficiencies on the Jucho and MKD8 strains of M. smegmatis for 
eight A4 mycobacteriophages. Compared to TT9, Shaka and Eagle showed much greater 
infectivity on both strains (for Jucho, 3.3 and 1.0 vs. 1.0 x 10
-1
,
 
respectively, and for 
MKD8 3.3 x 10
-1 
and 3.3 x 10
-1
 vs. <10
-9
, respectively; reported relative to infectivity on 
M. smegmatis mc
2
155). The observations made by Jacobs-Sera et al. for G cluster phages 
suggest that a difference in the structure of their minor tail proteins may be responsible.  
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An examination of the two minor tail protein genes located downstream of the 
tapemeasure gene in the three genomes (Figure 25) reveals a single nonsynonymous 
amino acid change near the middle of the second minor tail protein (gp 26 in Eagle and 
gp 27 in TT9 and Shaka). The same substitution – a methionine residue for a leucine 
residue – occurs for both Shaka and Eagle, suggesting that this change may play a role in 
their increased ability to infect the Jucho and MKD8 M. smegmatis strains. Although 
methionine and leucine both have hydrophobic side chains, the structures of the two 
amino acids differ rather significantly, meaning that such a substitution could have 
significant effects on protein functionality. As Jacobs-Sera et al. showed through their 
expanded host-range mutant experiments, single amino acid substitutions can occur 
through random mutation as phage replicate; it is thus reasonable to suspect that such a 
process also led to the divergence of Shaka and Eagle from TT9 in regards to the minor 
tail protein gene. 
 
Figure 25: A Nonsynonymous Amino Acid Substitution in Minor Tail Protein Genes of Shaka/Eagle 
and TiroTheta9. An alignment of Shaka gene 27 and Eagle gene 26 with TiroTheta9 gene 27, all 
identified as putative minor tail proteins, reveals the same nonsynonymous nucleotide substitution in Shaka 
and Eagle relative to TT9. Reports indicate that TT9 exhibits a much lower plating efficiency on M. 
smegmatis strains Jucho and MKD8 relative to Shaka and Eagle, which have a similar plating efficiency for 
both strains [99]. Given that all other nucleotide substitutions between Shaka/Eagle and TT9 in the gene are 
synonymous, the differential host range observed could be attributable to this change. Figure generated by 
Geneious.  
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Evidence for Horizontal Gene Transfer: Constructing a Genetic Mosaic 
While much of the sequence diversity across the subcluster takes the form of 
nucleotide substitutions as described above, other areas of difference encompass entire 
genes. Offering a more generalized comparison than Geneious alignments, the 
Phamerator program alignment of several representative A4 phages in Figure 26 shows 
that genes bearing little or no similarity to the other A4 phages often appear sandwiched 
between long stretches of highly homologous sequence. Although not found in other A4 
phages, these genes are often homologous to sequences found in members of other 
subclusters – for example, Wile gp62 matches genes found in several A2 subcluster 
phages. This suggests that the genes were obtained through horizontal gene transfer 
rather than derived from a common ancestor. This could potentially occur through a 
coinfection event by two different phages.  
These observations are consistent with the genetic mosaic model of phage 
evolution proposed by Hendrix et al., which suggests that “all dsDNA phage genomes are 
mosaics with access, by horizontal exchange, to a large common genetic pool” [1] (see 
Chapter 6 for further background). A potent illustration of this mosaicism is given by the 
following examination of the integrase genes of the A4 subcluster phages. 
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Figure 2623: Phamerator Alignment of Four A4 Phages. The complete genomes of TiroTheta9, Wile, 
Nyxis, and Eagle are compared in the figure. Purple shading between genomes indicates areas of high 
sequence homology, while blue and orange indicate areas of less homology and white represents little or no 
homology. Phage genomic sequences are represented by ruler-like lines, with colored blocks representing 
genes placed above for genes transcribed in the forward direction and below for genes transcribed in the 
reverse direction. The figure shows that although the four phages display a high degree of sequence 
homology across the lengths of their genomes, there are several areas where one or more phages possesses 
a gene not shared by the others. This observation is consistent with the mosaic model of phage evolution. 
Figure generated by Phamerator.   
Integrase Diversity in the A4 Subcluster 
Figure 27 is a schematic of the 18 published A4 genomes generated through a 
BLASTn nucleotide search using the full TT9 genome. This analysis shows a clear 
sequence difference that occurs midway through the genomes. Closer examination 
reveals that this region encompasses the integrase gene, and that the integrase genes 
represented by members of the A4 subcluster can be divided into three groups of 
apparently distinct evolutionary origin. 
135 
 
 
Figure 27: Integrase Diversity in the A4 Subcluster as Visualized Through BLAST. BLAST results 
using the entire TiroTheta9 genomic sequence as the query show a curious dichotomy located mid-genome 
for the 18 published A4 subcluster phages. This divergence occurs in the integrase gene; the BLAST results 
depicted in the figure indicate that that the integrase genes of Flux, Sabertooth, Dhanush, MeeZee, Peaches, 
Shaka, Wile, and Backyardigan are similar to that of TT9, while those of Melvin, Medusa, Icleared, 
BellusTerra, Eagle, Nyxis, Arturo, LHTSCC and Obama12 are not. Further examination reveals three 
integrase groups of distinct evolutionary origin represented across the A4 subcluster, lending support to the 
mosaic model of phage evolution. The phage genomes represented in the figure are as follows: 1) TT9, 2) 
Flux, 3) Sabertooth, 4) Dhanush, 5) MeeZee, 6) Peaches, 7) Shaka, 8) Melvin, 9) Medusa, 10) ICleared, 11) 
BellusTerra, 12) Eagle, 13) Nyxis, 14) Arturo, 15) Wile, 16) Backyardigan, 17) LHTSCC, 18) Obama12. 
Figure generated by NCBI BLASTn. 
In general, phage integrases work by facilitating site-specific recombination 
between the attP attachment site on the phage genome and the attB site on the bacterial 
chromosome (Figure 28). Although the attP and attB sites often differ significantly in 
sequence, the attB site contains a short stretch of identity to attP, called the overlap 
region, where crossing over occurs. Two major families have been identified for phage 
integrases, the tyrosine integrases and serine integrases. These are named for the amino 
acid responsible for effecting catalytic activity in each. The two families of integrase 
operate by completely different mechanisms and also differ in other key aspects, detailed 
in Table 9. 
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Figure 28: General Mechanism of Phage Integrases. To integrate into a bacterial chromosome, a phage 
integrase mediates site-specific recombination between the attP attachment site on the phage genome and 
the attB attachment site on the bacterial chromosome. Excision requires an additional enzyme called 
exisase. The specific mechanism by which integration occurs depends on the integrase family (Tyrosine or 
Serine). Source: http://2010.igem.org/wiki/index.php?title=Team:Paris_Liliane_Bettencourt/Project/Memo-
cell/Design&oldid=208629. 
Table 9: Comparison of Tyrosine and Serine Integrases. Source: Groth AC, Calos MP. 2004. Phage 
integrases: biology and applications. J. Mol. Biol. 335:667-78. 
Characteristic Tyrosine Integrases Serine Integrases 
Mechanism 
Formation and resolution of 
Holliday Junction 
2-bp staggered cut followed by 180° 
rotation and ligation 
attP site 
Short; overlap region flanked 
by imperfect inverted repeats 
Short; overlap region sometimes 
flanked by imperfect inverted repeats 
attB site 
Extended; multiple binding 
sites for cofactors 
Short; overlap region sometimes 
flanked by imperfect inverted repeats 
Overlap region 6-8 bp 3-12 bp 
Host factors required? Yes No 
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Despite the fact that these two families of integrases operate by entirely different 
mechanisms and have likely arisen from distinct evolutionary backgrounds [38], both are 
represented in the A4 subcluster. Six of the 18 published genomes (33%) – Eagle, 
BellusTerra, LHTSCC, Medusa, Melvin
12
, and Obama 12 – have tyrosine integrases, 
while the remaining twelve (67%) have serine integrases. All six of the tyrosine 
integrases are similar in sequence and closely resemble the integrases of primarily A3 
subcluster phages, displaying 85% identity with 92% coverage to the A3 phage HelDan 
among other A3 phages. However, BLAST analysis of the twelve serine integrases 
reveals that they are comprised of two distinct groups. The first includes the integrase 
genes of TT9, MeeZee, Peaches, Dhanush, Flux, Sabertooth, Shaka, Wile, and 
Backyardigan, for which BLAST results show nucleotide matches only to each other. 
This suggests that the integrase of these nine phages is currently unique to the A4 
subcluster and perhaps originated from a phage ancestor that has yet to be discovered.  
The remaining three integrases – those of Nyxis, Arturo13, and ICleared14 – are 
also serine integrases based on protein matches, but interestingly do not display 
significant sequence similarity to the other A4 serine integrases. This is clearly illustrated 
in Figure 29, which shows a representative integrase from each of the three groups. 
                                                          
12
 The annotations published on GenBank (http://www.ncbi.nlm.nih.gov/nuccore/KF841476) identify 
Mycobacterium Melvin gp 33 as a serine integrase. However, BLASTp results for this gene reveal a 
putative conserved domain associated with tyrosine phage integrases. In addition, BLASTn and BLASTp 
matches are to tyrosine integrases. Thus, the gene is identified as a tyrosine integrase here. 
 
13
 The annotations published on GenBank (http://www.ncbi.nlm.nih.gov/nuccore/JX307702) identify 
Mycobacterium Arturo gp 32 as a tyrosine integrase. However, BLASTp results for this gene reveal a 
putative conserved domain from the serine recombinase superfamily. Furthermore, BLASTn and BLASTp 
matches are to serine integrases. Thus, the gene is identified as a serine integrase here.  
 
14
 The annotations published on GenBank (http://www.ncbi.nlm.nih.gov/nuccore/JQ896627) do not classify 
ICleared gp 33 as either a tyrosine or serine integrase. However, BLASTp results reveal a putative 
conserved domain from the serine recombinase superfamily. In addition, BLASTn and BLASTp matches 
are to serine integrases. Thus, the gene is identified as a serine integrase here. 
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Instead, these integrases appear to be related to integrases from the A5 subcluster, with 
which they display partial sequence identity; nucleotide BLAST results show 
approximately 75% identity with 50% coverage to the A5 phage ElTiger69, Airmid, and 
Benedict.  
Figure 29 also shows that the sequences surrounding the integrase genes are 
highly homologous. This strongly suggests that these diverse integrases were obtained 
through horizontal gene transfer with phages of other subclusters, providing further 
evidence in support of the mosaic model of phage evolution.  
 
Figure 29: Phamerator Alignment of A4 Subcluster Phage Integrase Genes. A Phamerator alignment 
of four A4 phages shows that three distinct groups of integrase genes, contained in the red box, are 
represented in the A4 subcluster. TiroTheta9 and Wile have serine integrases that are very similar in 
sequence, as indicated by the purple shading between them. Nyxis also has a serine integrase, but the 
absence of purple shading shows that this integrase is distinct from that of TT9 and Wile. The gene is also 
somewhat shorter than the TT9/Wile integrase. Eagle has a tyrosine integrase that is distinct from both the 
TT9/Wile integrase and the Nyxis integrase. Figure generated by Phamerator.  
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CHAPTER 9 
 
 
CONCLUSIONS 
 
 
This project resulted in the successful isolation and phenotypic and genotypic 
characterization of a novel mycobacteriophage, designated TiroTheta9 (TT9), from an 
environmental soil sample collected in Bowling Green, Kentucky. TT9 was found to be a 
primarily lytic phage, forming clear plaques 1-2mm in diameter on a lawn of M. 
smegmatis after 24 hours of incubation at 37°C. Although phenotypic analysis did not 
yield evidence for TT9 lysogens, genomic analysis showed that TT9 contains an 
integrase gene and is thus a temperate phage. This suggests that laboratory conditions 
were not optimal for TT9 lysogen formation or that plates were not allowed to incubate 
for long enough to observe plaque turbidity associated with lysogen formation. TEM 
images revealed that the phage has an average capsid diameter of 58 ± 2 nm and a tail 
length of 174 ± 5 nm. Its genome is comprised of 87 putative genes spanning 51,367 base 
pairs, including a 10 base pair overhanging cos site.  
Based on sequence similarities, TT9 was classified into the A4 subcluster of 
mycobacteriophages, which currently contains 46 sequenced and 18 published genomes. 
Comparative analysis of these genomes revealed a general lack of correlation between 
geographic distribution and sequence similarity and provided insight into the 
evolutionary mechanisms that govern the emergence of new phage types. In particular, 
evidence for both vertical divergence from a common ancestor and acquisition of genes 
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from distinct evolutionary origins through horizontal gene transfer from phages of other 
clusters/subclusters was observed in the genomes of the A4 phages. The identification of 
three groups of integrases of distinct origin among the otherwise highly homologous 
members of the A4 subcluster provided strong support for the genetic mosaic model of 
phage evolution proposed by Hendrix et al [1].  
Notably, in their original 1999 paper proposing the mosaic model, the authors 
comment that “the veracity of this view of bacteriophage population genetics and 
evolution…will only be determined… after substantially more data are determined of 
sequences and genetic organization of phages and their hosts.” Thus, the characterization 
of TT9 adds an additional piece to this massive puzzle of phages, their hosts, and their 
genes as we move closer to figuring out how these pieces integrate with each other. 
Future Directions 
Given that only 31 of TT9’s 87 genes (35.6%) are currently assigned putative 
functions, elucidating the functions of the remaining genes and clarifying functions of 
others that currently have only vague descriptions (such as gp 5, identified only as a 
structural protein) is a logical direction for future experiments. Such experiments could 
involve deleting, altering, or tagging the protein products of certain genes and observing 
phenotypic effects. Such studies could potentially reveal new gene functions. These 
products could be of potential use in basic or applied research and may contribute greatly 
to our continued understanding of phage biology. 
Comparative analysis of the A4 phages should also be continued as more 
mycobacteriophages are added to the database. It would be interesting to observe which 
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integrase group newly classified A4 members fall into. The expansion of the database as 
a whole may reveal new links to other clusters.  
Finally, the isolation and sequencing of additional phage genomes is another area 
in which future efforts could be concentrated. To maximize chances of discovering 
unique phages, different types of environmental samples beyond soil from a wide variety 
of geographic locations and conditions could be considered. During the isolation process, 
the purification of plaques with uncommon morphologies such as “bulls eye” patterns or 
unusual size could yield diverse phage types. For instance, small plaques, while harder to 
work with, are generally formed by larger phage that take longer to diffuse through the 
agar when released upon cell lysis. Additionally, different isolation techniques could be 
considered to potentially obtain phages with unique characteristics. This could potentially 
include ssDNA and RNA phages.   
Although TT9 and its analysis in the context of the A4 subcluster has yielded 
important insights into mycobacteriophage genome structure and evolution, many 
questions still remain. What is the function of the many unknown genes present in the 
genomes of TT9 and other mycobacteriophages? How can such similar phages as the 
members of the A4 subcluster be found in such geographically dissimilar areas? 
Ultimately, can mycobacteriophages be developed into tools to manipulate and even 
combat human pathogens such as M. leprae and M. tuberculosis? The answers to these 
and many other important questions will only be revealed through the continued 
expansion and study of this remarkably diverse group of phages. 
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APPENDIX A 
 
 
RECIPES FOR STOCK SOLUTIONS, MEDIA, AND REAGENTS 
 
 
The following recipes were adapted from the Science Education Alliance In Situ 
Resource Guide published by the HHMI [112]. 
I. Stock Solutions 
 
AD Supplement (2 L)     
Ingredient Amount Final Concentration   
NaCl 17 g 145 mM 
 
Albumin (Fraction V) 100 g 5.0% 
 
Dextrose 40 g 2.0% 
 
ddH2O To 2 L     
To Prepare 
   
1 Weigh out NaCl and albumin and place in 4 L Erlenmeyer flask 
2 While stirring, slowly add 1800 mL of ddH2O until the albumen 
and NaCl are dissolved 
3 While still stirring, slowly add the dextrose 
4 Once the dextrose is dissolved, transfer solution to 2 L graduated 
cylinder and bring the volume to 2 L with ddH2O 
To Sterilize Filter-sterilize; do not autoclave 
Store at 4°C 
 
20% Tween 80 (100 mL) 
  Ingredient Amount Final Concentration   
Tween 80* 20 mL 20%  
ddH2O To 100 mL     
To Prepare 
   
1 Measure 60 mL ddH2O and place in a medium-sized beaker 
2 Slowly add 20 mL Tween 90 while stirring  
3 Once the Tween 80 has completely dissolved, transfer to graduated 
cylinder and bring to 100 mL with ddH2O 
To Sterilize Filter-sterilize; do not autoclave 
Store at room temperature 
*VWR, catalog no. 97063-806 
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Carbenicillin (CB; 10 mL 50 mg/mL stock solution) 
Ingredient Amount Final Concentration 
Carbenicillin powder* 500 mg 50 mg/mL  
ddH2O 10 mL     
To Prepare 
   
1 Weigh out carbenicillin and place in 15 mL conical tube 
2 Add ddH2O and mix until dissolved 
To Sterilize Filter-sterilize (pore size 0.22 μm) 
Store at 4°C for ≤ 60 days 
*VWR, catalog no. 101384-990 
   
Cycloheximide (CHX; 10 mL 10 mg/mL stock solution) 
Ingredient Amount Final Concentration   
Cycloheximide powder* 100 mg 10 mg/mL  
ddH2O 10 mL     
To Prepare 
   
1 Weigh out cycloheximide and place in 15 mL conical tube 
2 Add ddH2O and mix until dissolved 
To Sterilize Filter-sterilize (pore size 0.22 μm) 
Store at 4°C for ≤ 60 days 
*VWR, catalog no. 97064-724 
   
40% Glycerol (1 L)     
Ingredient Amount Final Concentration   
Glycerol (glycerin) 400 mL 40% 
 
ddH2O To 1 L     
To Prepare 
   
1 Measure 500 mL ddH2O and place in a 1 L graduated cylinder 
2 Slowly add 400 mL gycerol 
3 Place parafilm on the top of the cylinder and shake thoroughly to 
mix 
4 Once the glycerol has completely dissolved, bring the volume to 1 
L with ddH2O and mix 
To Sterilize Filter-sterilize or autoclave in 250 mL or 500 mL bottles 
Store at room temperature 
 
1 M Tris, pH 7.5 (1 L) 
   Ingredient Amount Final Concentration 
Trizma base* 121.1 g 1 M  
ddH2O To 1 L     
To Prepare 
   
1 Weigh out Trizma base and place in a large beaker 
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2 Add approximately 975 mL of ddH2O and stir 
3 Once the Trizma base has dissolved, bring the pH to 7.5 with HCl 
4 Transfer to a graduated cylinder and add ddH2O to 1 L 
To Sterilize Autoclave in 250 mL or 500 mL bottles 
Store at room temperature 
*Sigma-Aldrich, catalog no. T1503-500G 
   
50X Tris-Acetate-EDTA (TAE; 1 L)     
Ingredient Amount Final Concentration   
Trizma base*  242 g 2 M  
500 mM EDTA 100 mL 50 mM  
Glacial acetic acid 57.1 mL 1 M  
ddH2O To 1 L     
To Prepare 
   
1 Weigh out Trizma base and place in a large beaker 
2 Add approximately 800 mL of ddH2O and stir until the Trizma base 
is dissolved 
3 Add the EDTA stock while stirring 
4 Slowly add the glacial acetic acid while stirring 
5 If necessary, adjust the pH to 8.5 with additional glacial acetic acid 
and trasfer to a graduated cylinder 
6 Bring the volume to 1 L with ddH2O  
To Sterilize No sterilization necessary; do not autoclave 
Store at room temperature 
*Sigma-Aldrich, catalog no. T1503-500G 
   
10X Tris-Boric Acid-EDTA (TBE; 1 L)     
Ingredient Amount Final Concentration   
Trizma base* 108 g 890 mM  
Boric acid 55 g 890 mM  
EDTA disodium salt dihydrate 7.44 g 20 mM  
ddH2O To 1 L     
To Prepare 
   
1 Weigh out Trizma base, boric acid, and EDTA and place in a large 
beaker 
2 Add 980 mL of ddH2O and stir until all ingredients are dissolved 
3 Adjust the pH to 8.3 and transfer to a graduated cylinder 
4 Bring the volume to 1 L with ddH2O 
To Sterilize Autoclave 
Store at room temperature 
*Sigma-Aldrich, catalog no. T1503-500G 
   
 
 
155 
 
II. Media 
 
Middlebrook 7H9 Liquid Medium, Neat (900 mL) 
 Ingredient Amount Final Concentration   
7H9 broth base* 4.7 g 
 
 
40% glycerol stock** 5 mL 0.2%  
ddH2O To 900 mL     
To Prepare 
   
1 Place broth base and 850 mL of ddH2O in an Erlenmeyer flask 
2 While stirring, add the glycerol and stir until the broth base powder 
is completely dissolved 
3 Transfer to a graduated cylinder and bring up to 900 mL with 
ddH2O 
4 Aliquot into 90 mL, 450 mL, or 900 mL portions as needed 
To Sterilize Autoclave 
Store at room temperature 
*VWR, catalog no. 90003-876 
  ** Recipe included in this appendix 
   
Middlebrook 7H9 Liquid Medium, Complete without Tween 80 (100 mL) 
 Ingredient Amount Final Concentration 
7H9 liquid medium, neat* 89 mL 1X  
AD supplement* 10 mL 10%  
CB stock* 100 μL 50 μg/mL  
CHX stock* 100 μL 10 μg/mL  
100 mM CaCl2 1 mL  1 mM   
To Prepare 
   
1 Add all ingredients to sterile bottle or flask aseptically and mix 
To Sterilize All ingredients sterile; do not autoclave or filter sterilize 
Store at 4°C 
*Recipe included in this appendix 
   
Middlebrook 7H9 Liquid Medium, Complete with Tween 80 (100 mL) 
 
Ingredient Amount 
Final 
Concentration 
  
7H9 liquid medium, neat* 89 mL 1X  
AD supplement* 10 mL 10%  
CB stock* 100 μL 50 μg/mL  
CHX stock* 100 μL 10 μg/mL  
100 mM CaCl2 1 mL 1 mM  
20% Tween 80 stock* 250 μL 0.05%   
To Prepare 
   
1 Add all ingredients to sterile bottle or flask aseptically and mix 
To Sterilize All ingredients sterile; do not autoclave or filter sterilize 
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Store at 4°C 
*Recipe included in this appendix 
   
10X 7H9/Glycerol Media (500 mL) 
  Ingredient Amount Final Concentration   
7H9 broth base* 23.5 g 
 
 
40% glycerol stock** 25 mL 2%  
ddH2O To 500 mL     
To Prepare 
   
1 Place broth base and 400 mL of ddH2O in an Erlenmeyer flask 
2 
While stirring, add the glycerol and stir until the broth base 
powder is completely dissolved 
3 
Transfer to a graduated cylinder and bring up to 500 mL with 
ddH2O 
4 Aliquot into 50 mL or 100 mL portions as needed 
To Sterilize Autoclave 
Store at room temperature 
*VWR, catalog no. 90003-876 
  ** Recipe included in this appendix 
   
Middlebrook Top Agar (TA; 1 L) 
  Ingredient Amount Final Concentration   
7H9 broth base* 2.35 g 
 
 
Agar** 4 g 0.8%  
ddH2O 0.5 L 
 
 
7H9 liquid medium, neat*** 0.5 L 
 
 
100 mM CaCl2 10 mL 1 mM   
To Prepare 
   
1 Place broth base, agar, and ddH2O  in an Erlenmeyer flask 
2 Stir until broth base powder is complete dissolved 
3 Autoclave the flask 
4 Once cooled to handling temperature, aliquot in 25 mL volumes 
into sterile 100 mL bottles and add 25 mL 7H9 liquid medium 
(neat) to each bottle 
5 Before use, heat to boil in microwave and cool to 55°C in water 
bath 
6 Add 0.5 mL  100 mM CaCl2 to each bottle   
To Sterilize 
Add all ingredients aseptically after autoclaving in step 3; do not 
autoclave or filter-sterilize final medium 
Store in 55°C water bath ≤ 7 days 
*VWR, catalog no. 90003-876 
  ** VWR, catalog no. 100370-088 
  ***Recipe included in this appendix 
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Luria Agar (L-Agar) Plates (1 L) 
  Ingredient Amount Final Concentration   
L-Agar base* 30.5 g 
 
 
CB stock** 1 mL 50 μg/mL  
CHX stock** 100 μL 10 μg/mL  
ddH2O To 1 L     
To Prepare 
   
1 Add L-Agar base to 1 L ddH2O and stir to mix 
 
2 
Heat while stirring and boil for up to 1 minute to completely 
dissolve the L-Agar base 
3 Autoclave at 121°C for 10 minutes 
 
4 Cool to 55°C in a 55°C water bath 
 
5 Aseptically add the CB and CHX stock solutions 
 
6 Mix well by swirling, avoiding bubbles 
 
7 Use aseptic technique to pour agar into Petri dishes 
To Sterilize Plates sterile after autoclaving; keep lids on to maintain sterility 
Store at 4°C 
*VWR, catalog no. 90003-250 
  **Recipe included in this appendix 
   
III. Reagents 
 
Phage Buffer (PB; 1 L) 
   Ingredient Amount Final Concentration 
1 M Tris, pH 7.5* 10 mL 10 mM 
1 M MgSO4 10 mL 10 mM 
NaCl 4 g 68 mM 
100 mM CaCl2 10 mL 1 mM  
ddH2O 970 mL     
To Prepare 
   
1 Place all ingredients except CaCl2 in Erlenmeyer flask 
2 Stir until the NaCl is completely dissolved 
3 Autoclave and cool to 55°C in 55°C water bath 
4 Aseptically add the CaCl2 and mix well by swirling 
5 Aliquot into sterile bottles or tubes in 50 mL or 100 mL portions 
To Sterilize Autoclave 
Store at room temperature 
*Recipe included in this appendix 
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Phage Precipitation Solution (100 mL) 
  Ingredient Amount Final Concentration 
Polyethylene glycol (PEG) 
8000* 
30 g 30% 
 
NaCl 19.3 g 3.3 M  
ddH2O To 100 mL     
To Prepare 
   
1 Place NaCl and 60 mL ddH2O in a glass bottle with a screw cap 
and swirl until NaCl is completely dissolved 
2 Slowly add PEG 8000 a few grams at a time, alternatively 
swirling and heating in a microwave until all the PEG is dissolved 
3 Add ddH2O to 100 mL and stir until homogeneous 
To Sterilize Filter-sterilize 
Store at room temperature 
*Sigma-Aldrich, catalog no. P2139-500G 
   
Nuclease Mix (10 mL) 
  Ingredient Amount Final Concentration 
NaCl 0.088 g 150 mM  
DNase I* 500 μL of 5 mg/mL stock 10 mM  
Rnase A** 250 μL of 10 mg/mL stock 68 mM  
Glycerol 5 mL 50%  
ddH2O 4.25 mL     
To Prepare 
   
1 Dissolve the NaCl in the ddH2O in a sterile 15 mL conical tube 
2 
Add the Rnase and DNase stock solutions and mix with gentle 
inversion 
3 
Add the glycerol slowly to a final volume of 10 mL and mix with 
gentle inversion until the solution is homogeneous 
4 Aliquot into microcentrifuge tubes   
To Sterilize No sterilization necessary 
Store at -20°C 
*Sigma-Aldrich, catalog no. D4527-40KU 
  **Sigma-Aldrich, catalog no. R6513-10MG 
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1.0% Uranyl Acetate Stain (10 mL) 
  Ingredient Amount Final Concentration   
Uranyl acetate* 0.1 g 1.0%  
ddH2O To 10 mL     
To Prepare 
   
1 Weigh out the uranyl acetate and place it in a beaker 
2 Add approximately 9 mL ddH2O and stir 
 
3 
When the uranyl acetate has dissolved, bring the final volume up 
to 10 mL with ddH2O 
To Sterilize Filter-sterilize (0.22 μm pore size) 
Store at room temperature in the dark 
*SPI Supply, catalog no. 02624-AB 
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APPENDIX B 
 
 
GENBANK PROFILE AND COMPLETE GENOMIC SEQUENCE OF 
MYCOBACTERIOPHAGE TIROTHETA9 
 
 
The following is the GenBank profile for Mycobacterium TiroTheta9 as 
determined through the procedures described in this work and published on GenBank 
under accession number JN561150.1 (http://www.ncbi.nlm.nih.gov/nuccore/JN561150). 
Mycobacterium phage TiroTheta9, complete genome 
GenBank: JN561150.1 
LOCUS JN561150     51367 bp  DNA   linear PHG 03-FEB-2012 
DEFINITION Mycobacterium phage TiroTheta9, complete genome. 
ACCESSION JN561150 
VERSION JN561150.1  GI:343197866 
KEYWORDS . 
SOURCE Mycobacterium phage TiroTheta9 
ORGANISM Mycobacterium phage TiroTheta9 
 Viruses; dsDNA viruses, no RNA stage; Caudovirales; Siphoviridae. 
REFERENCE 1  (bases 1 to 51367) 
AUTHORS Hatfull,G.F. 
CONSRTM the Science Education Alliance Phage Hunters Advancing Genomics and Evolutionary 
Science Program; the KwaZulu-Natal Research Institutefor Tuberculosis and HIV 
Mycobacterial Genetics Course Students; the Phage Hunters Integrating Research and 
Education Program 
TITLE Complete Genome Sequences of 138 Mycobacteriophages 
JOURNAL J. Virol. 86 (4), 2382-2384 (2012) 
PUBMED 22282335 
REFERENCE 2 (bases 1 to 51367) 
AUTHORS Schrader,S.M., Parthasarathy,P.T., King,R.A., Rinehart,C.A., Serrano,M.G., Lee,V., 
Hendricks,S.L., Sheth,N.U., Buck,G.A., Bradley,K.W., Khaja,R., Lewis,M.F., 
Barker,L.P., Jordan,T.C., Russell,D.A., Pope,W.H., Jacobs-Sera,D., Hendrix,R.W. and 
Hatfull,G.F. 
TITLE Direct Submission 
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JOURNAL Submitted (05-AUG-2011) Pittsburgh Bacteriophage Institute and Department of 
Biological Sciences, University of Pittsburgh, 365 Crawford Hall, Pittsburgh, PA 15260, 
USA 
COMMENT Isolation, DNA preparation, and annotation analysis performed at Western Kentucky 
University, Bowling Green, KY 
 Sequencing performed at Virginia Commonwealth University, Richmond, VA 
 Supported by Science Education Alliance, Howard Hughes Medical Institute, Chevy 
Chase, MD and The Gatton Academy for Mathematics and Science, Bowling Green, 
KY. 
FEATURES Location/Qualifiers 
source 1..51367 
 
/organism="Mycobacterium phage TiroTheta9" 
 
/mol_type="genomic DNA" 
 
/strain="TiroTheta9" 
 
/isolation_source="soil" 
 
/db_xref="taxon:1074829"  
 
/lab_host="Mycobacterium smegmatis mc2 155" 
 
/country="USA: Bowling Green, KY" 
 
/lat_lon="36.99 N 86.42 W"  
 
/collection_date="01-Oct-2009" 
 
/collected_by="S. Schrader" 
 
/identified_by="S. Schrader" 
gene complement(457..672) 
 
/gene="1" 
 
/locus_tag="TIROTHETA9_1" 
cds complement(457..672) 
 
/gene="1" 
 
/locus_tag="TIROTHETA9_1" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp1" 
 
/protein_id="AEM05952.1"  
 
/db_xref="GI:343197950" 
 
/translation="MAAVARCLEIAATVVVAAPDVVNIGCLPEATGTLNLTLVARCFEH
GLPVVLVPVRREPAGAVGGAPAPPRI" 
gene 803..1234 
 
/gene="2" 
 
/locus_tag="TIROTHETA9_2" 
cds 803..1234 
 
/gene="2" 
 
/locus_tag="TIROTHETA9_2" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp2" 
 
/protein_id="AEM05869.1"  
 
/db_xref="GI:343197867" 
 
/translation="MGERGPIGKRSDQRVRRNKTDNPVTKLPARGPVKQPQIGIPDAHP
VVTQLWDSLAHSAQAQFYEPSDWAYARMALHFANQLLWSEKPNGQILATVNS
MLNGLLVSEGDRRRVQLEIERNQADAVVVDVAAMFAQQLGAQQRSG" 
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gene 1326..1640 
 
/gene="3" 
 
/locus_tag="TIROTHETA9_3" 
cds 1326..1640 
 
/gene="3" 
 
/locus_tag="TIROTHETA9_3" 
 
/note="minor tail subunit" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp3" 
 
/protein_id="AEM05870.1"  
 
/db_xref="GI:343197868" 
 
/translation="MPVIGAQLESDTLVLTRGRDFKWSFENLDATGQPVAFPAGSLFFEF
ENGTKWTFSIEGALATIKIESEQVALIAARTKWQLVFLPEGEELGGDPIALGQVQ
IQG" 
gene 1645..2718 
 
/gene="4" 
 
/locus_tag="TIROTHETA9_4" 
cds 1645..2718 
 
/gene="4" 
 
/locus_tag="TIROTHETA9_4" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp4" 
 
/protein_id="AEM05871.1"  
 
/db_xref="GI:343197869" 
 
/translation="MRLRGFPTDGRPAVSYVGSPTGSILGIPQNLIGKVSVSQQRPRSLLSI
PTDTPRGVISRHPTTGRLLAVPGRPGPQGPQGPKGDGLRIDGQVPTYAELPGSAS
DGDVWLAGGKLYRYDNGWPDESAGTQVQGQEGPRGPQGIAGPQGPVGPQGP
QGLKGDTGPRGPEGPEGPEGPRGLQGEQGVQGPQGPKGDTGSQGPKGDVGPQ
GERGLQGIQGPVGPKGDKGDKGDTGNQGPQGPQGPRGFTGDTGQTGDDGPPG
PEGPPGPEGPQGPAGPKGDLGPQGPQGLQGPKGDKGDKGDTGSQGPQGIQGPQ
GIQGPQGPYGYLSSDATVLDFRRMTQAQYNALGAGRPATTFYVIVG" 
gene 2722..3384 
 
/gene="5" 
 
/locus_tag="TIROTHETA9_5" 
cds 2722..3384 
 
/gene="5" 
 
/locus_tag="TIROTHETA9_5" 
 
/note="structural" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp5" 
 
/protein_id="AEM05872.1"  
 
db_xref="GI:343197870" 
 
/translation="MPVRIGDATPSGFRFGDLTATKIYLGDVLVFPAFTVVSQTFSTVGN
WTFNIPAECGAIDIILLGGGGGGSSGNAGLGNGGGGDGGLWETLTLIRGIDFPST
ALQITGTVGDGGTGGAGGWIPINGADGNPTTANIPGVGLVQALGGGGGVWTSG
SRPGKGPGNRVHNGINYTGGANTGDSAANGNPPGGGAGGGNSGFFGFPAGGG
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GKGARGQAWVRAYV" 
gene 3384..3755 
 
/gene="6" 
 
/locus_tag="TIROTHETA9_6" 
cds 3384..3755 
 
/gene="6" 
 
/locus_tag="TIROTHETA9_6" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp6" 
 
/protein_id="AEM05873.1"  
 
/db_xref="GI:343197871" 
 
/translation="MTQTAPYPTELEELVDGVRYRPGWAFQLVEAPRNDGVNGLALVI
VVQTVDAYGEETHRPVSIYFPFMVPPEVRSRDGWKRWLYDRIEDAERHERGEF
FEVDGEKPFAPRHYPEADGYLRLPPT" 
gene 3784..3921 
 
/gene="7" 
 
/locus_tag="TIROTHETA9_7" 
cds 3784..3921 
 
/gene="7" 
 
/locus_tag="TIROTHETA9_7" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp7" 
 
/protein_id="AEM05874.1"  
 
/db_xref="GI:343197872" 
 
/translation="MTALQGKLAVFALKQGVKFLKNHPDLIPGEIDDAIVKVLALALGV
" 
gene 3921..5423 
 
/gene="8" 
 
/locus_tag="TIROTHETA9_8" 
cds 3921..5423 
 
/gene="8" 
 
/locus_tag="TIROTHETA9_8" 
 
/note="LysA" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp8" 
 
/protein_id="AEM05875.1"  
 
/db_xref="GI:343197873" 
 
/translation="MARRLFRGRAFSENGWPYVDQGSCTWDEVVPGVWLQIQNGAPFT
IMRAFARDFHAHVEPLRDYDSACWTQDNTVDTSNHPGGTGMDLNWNGADQK
TFRYGITKERAYPGDKARKLDELLAFYEDVIYCGGYWSIRDWMHFQMGYGTY
DSKADRPTEKTLDFIRRKIRPDGFSTFNRGGGTTVPNGASVLARATGIPLDRAERI
LPALREGLILAECNTFPRIAMFLAQTCWESDQYRATEEYANGPAHEERWIYKGR
TWIQLTWRSAYEGFGKWCHARGLVNDPMVFVNNPRSLADLKWAGLGAAYY
WTTTVRNTRKYPTLNQASDARDVLVATQIVNGGTNHLAERTAIYNRAIALGDE
LLQLVQEEDGFLSALNSAEQREVLDLLRWLAAPEYGELRKLFASRAMYRDSDD
RFETLAGFVLACDAMQWEDRVEGAAMLGEPEYLERVLRLAAGRGPGAKNPDG
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SPRQWAINHARAVLADIEAKNPQALQRYLAQKGAA" 
gene 5420..5881 
 
/gene="9" 
 
/locus_tag="TIROTHETA9_9" 
cds 5420..5881 
 
/gene="9" 
 
/locus_tag="TIROTHETA9_9" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp9" 
 
/protein_id="AEM05876.1"  
 
/db_xref="GI:343197874" 
 
/translation="MSPKVRQTIYYLGTIIPGVLGIALIWGGIDAGAAQSIGDIIAGAVALL
GASAPAVAAKKVNEQRKDGTLVPQAPVEQVVNGVQAVIAAQQAAQAELDRV
RDVVTGAIGIVPGIVPQLGPLAQQAVDALNSFAPPTAYSQAAQFADPYRAPWDR
" 
gene 5881..6861 
 
/gene="10" 
 
/locus_tag="TIROTHETA9_10" 
cds 5881..6861 
 
/gene="10" 
 
/locus_tag="TIROTHETA9_10" 
 
/note="LysB" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp10" 
 
/protein_id="AEM05877.1"  
 
/db_xref="GI:343197875" 
 
/translation="MLKLGSSGLMVSAWTAVMRLRFASYALGVNGQPIKVDGYFGYDE
EKVQKEYQLRTGQFPSGQVSREDLHRLGLLPTLLSIHGTGQADPFGIGYPADIAR
RVLDLYWWQPVGNWPAKAVPMNGSVDAGERECVRLISNPLIVPGPTAFVDYS
QGSVIGGRVRNRMRRKELRGELVAAASFGNPMRLRGHYAGNVDPGGEGIDPR
QELAAEPFRIELAAKGDLYTTCPGGQSGEMERAIYHAVFSRFIGEDSLIEQVWEL
ARNPWVEVPAAVKAIVRGGMFAIRGTGPHVRYHIDECPGTGMTYYEYAIKHLR
DTAEARLRRIVASVT" 
gene 6884..8581 
 
/gene="11" 
 
/locus_tag="TIROTHETA9_11" 
cds 6884..8581 
 
/gene="11" 
 
/locus_tag="TIROTHETA9_11" 
 
/note="terminase" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp11" 
 
/protein_id="AEM05878.1"  
 
/db_xref="GI:343197876" 
 
/translation="MSLANHHPVPLLPQPPHKIGPVWQVREDGSWHLPERTLGWGILN
WLAKYVRSPAGGGPFLPTLEQARFILWWYAVDERGVYAYREGVLRRMKGWG
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KDPLCAAIALAELCGPVAFSHWDLEGNPVGQTRHAAWITIAAVSQDQTKNTFSL
FPVMISKDLKTDYGLDVNKFVIYSEVGGRIEAATSSPASMEGNRPTLVIENETQ
WWGVGPDGNVNDGVDMDDVIEGNVAKIPGARKLAICNAHIPGNDTVAEKAYD
HWQDVQTGKAVDTGILYDALEAPADTPVSEIPSEKEDPEGYAEGIAKLMDGLQ
VARGDSYWLPLEEILGSVLNTRNPVSESRRKFLNQVNAHEDSWIAPTEWDRLAL
TDKVFCLKKNDRITLGFDGSKSNDWSALVACRVEDGMLFVLKTWNPEDHPHN
EVPREDVDAYVRSAFQRYDVVGFRADVKEFEAYVDQWGRDFKRKIKVNATPG
NPIAFDMRGQTKRFALDCERFLDAVLEREVYHDGNPVLRQHVLNARRHPTTYD
AISIRKESKDSSKKIDAAVCAVLAYGARQDFLMSKKSRTGRAVVIR" 
gene 8578..10029 
 
/gene="12" 
 
/locus_tag="TIROTHETA9_12" 
cds 8578..10029 
 
/gene="12" 
 
/locus_tag="TIROTHETA9_12" 
 
/note="portal" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp12" 
 
/protein_id="AEM05879.1"  
 
/db_xref="GI:343197877" 
 
/translation="MTSPTEQQNVNPEERLEPLLNAFEEKIRPLADNTAYYESERRPDAI
GIAVPPEMRKLLAHVGYPRLYVNSIADRLELEGFRIAGESDADEQLWDWWSAN
DLDVESTLGHVDALVHGRSFVTVSAPDPAIDLGVDPTVPMIRVEPPTNLHAVIDP
RTRQVKEAIRAIYDEEGNEIVGATIYLPNATAYFDKVEGEWTQGRPTVNHGLEM
VPVVPIPNRNRLSDLYGTSEITPELRSVTDAAARTLMLMQSTAELMGVPLRLLF
GIKRSEIGLPDDPDEPVSPRQAFEAYYARILGFEDEMGKAYQFDAAELRNFVDA
LDALDKKAAAYTGLPPQYLSFSSDNPASAEAIRSSESRLVMNCERKARIFGGAW
EQVMRVAYRVMNPGAEIPPNMYRLEALWADPSTPTYAAKADAATKLYGQGM
GVIPREQARIDMGYSVETRRQMREWDKEENPVGQLAGLYAPTDKTGGSETPNE
PAAEEVPEE" 
gene 10026..10886 
 
/gene="13" 
 
/locus_tag="TIROTHETA9_13" 
cds 10026..10886 
 
/gene="13" 
 
/locus_tag="TIROTHETA9_13" 
 
/note="capsid maturation protease" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp13" 
 
/protein_id="AEM05880.1"  
 
/db_xref="GI:343197878" 
 
/translation="MNAEEYAARQAVVSAAVANYILQIGKLFLGPRLSVQDWIGFLQAL
YPEVYRHRLEAAELARQFHDSERRRHGKAFQPRFLVEYDFKEFVKDMEPTRDR
MSRELAPQSALGDVALRAVRSVENAGRKQIIRAVEDDSETGTVKGWARVATGR
ETCAWCLMLISRGPVYSSAESAGLDLDDQSAADVFRASGGDLNKLAAYVDENE
LMKEWHTGCDCKVVPVYDRANWPGRDAYKRAEQFWIEATKEARRLIDSGKSK
SDNLNREAQNALRRRLERGDLSMTRFALAA" 
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gene 10939..11451 
 
/gene="14" 
 
/locus_tag="TIROTHETA9_14" 
cds 10939..11451 
 
/gene="14" 
 
/locus_tag="TIROTHETA9_14" 
 
/note="scaffolding" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp14" 
 
/protein_id="AEM05881.1"  
 
/db_xref="GI:343197879" 
 
/translation="MADNDTQTPDTTPGNDGGTDTGQAPAPEVFSREYVEELRRENAK
ARTSKNQAVEDAKAEVRKEYEAKLAEKDTAYTELQNQLGEAWIELEKVYTTID
AKVPSDRVRAFAAILQGSDKESISESAKSAKQLFGGMTGTVPAVDPTQGSGGGK
HTPLNGDPILDALRKAVGA" 
gene 11479..12411 
 
/gene="15" 
 
/locus_tag="TIROTHETA9_15" 
cds 11479..12411 
 
/gene="15" 
 
/locus_tag="TIROTHETA9_15" 
 
/note="major capsid" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp15" 
 
/protein_id="AEM05882.1"  
 
/db_xref="GI:343197880" 
 
/translation="MAQGTTFQVDHAQIAQTGDSMFKGYLEPEQAQDYFAEAEKTSIVQ
RVARKIPMGSTGVKIPHWTGDVAAAWIGEGDMKPITKGDMTVNQVEPHKIATI
FIASAETVRANPANYLGTMRVKVGTAIALAFDDAALHGTDSPFDQFVDQTTKS
VDITPAAPATTYDAIGVNALSLLVNDGKKWQATLLDDIAEPVLNGAKDANGRP
LFVESTYEGLTTPYREGRILGRTTILSDHVATGTTVGYQGDFSQIVWGQVGGLSF
DVTDQATLNLGTMEEPKFVSLWQHNLVAVRVEAEFGLLINDVEAFVKLTNA" 
gene 12475..12681 
 
/gene="16" 
 
/locus_tag="TIROTHETA9_16" 
cds 12475..12681 
 
/gene="16" 
 
/locus_tag="TIROTHETA9_16" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp16" 
 
/protein_id="AEM05883.1"  
 
/db_xref="GI:343197881" 
 
/translation="MKIRNKDNGGVAEVTEDYGKALIELGRWEPADAPRRQRAKKSSP
KPPEPAPAEAPEPETPTEVTTTEE" 
gene 12685..13041 
 
/gene="17" 
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/locus_tag="TIROTHETA9_17" 
cds 12685..13041 
 
/gene="17" 
 
/locus_tag="TIROTHETA9_17" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp17" 
 
/protein_id="AEM05884.1"  
 
/db_xref="GI:343197882" 
 
/translation="MAIATAQDVENRWVRELSEEETTLVNTRLNDAERMLKRRIKNLD
AVDPEDVKQVEADMVLRLLRNPEGYTQETDGNYTYMLSQALASGKLEVLPEE
WEALGIRRSGMFVLTPTFEMPT" 
gene 13038..13205 
 
/gene="18" 
 
/locus_tag="TIROTHETA9_18" 
cds 13038..13205 
 
/gene="18" 
 
/locus_tag="TIROTHETA9_18" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp18" 
 
/protein_id="AEM05885.1"  
 
/db_xref="GI:343197883" 
 
/translation="MSASDRQPPGPYPEGFTEAVRPEDVDVSKCDHEFGVCFCVHDWRI
HWGNLDRSGL" 
gene 13202..13564 
 
/gene="19" 
 
/locus_tag="TIROTHETA9_19" 
cds 13202..13564 
 
/gene="19" 
 
/locus_tag="TIROTHETA9_19" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp19" 
 
/protein_id="AEM05886.1"  
 
/db_xref="GI:343197884" 
 
/translation="MSLLDHCPDDVIVYPQVVTTDDDGNTITKPSDEGIPTKARLQVLGQ
SGTSSRRQEQDNEGFESERVYTIRFTRKFDREHGILGMQSQVEWEGVRWALFGE
PAYYNSSRRTRHITYTVKRY" 
gene 13566..13958 
 
/gene="20" 
 
/locus_tag="TIROTHETA9_20" 
cds 13566..13958 
 
/gene="20" 
 
/locus_tag="TIROTHETA9_20" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp20" 
 
/protein_id="AEM05887.1"  
168 
 
 
/db_xref="GI:343197885" 
 
/translation="MAKLIPRRRLNHIVAHLAETKAAIRREAREVEGRARRNLAEARAS
TTHSKIVGPGHLTKIGSAADDPDVLVYMDAPNPMAIEYGHGPSGYFDPDKYGK
VTKAPAGLYILNRAAGIAGSMVTPSMGRRGVK" 
gene 13958..14395 
 
/gene="21" 
 
/locus_tag="TIROTHETA9_21" 
cds 13958..14395 
 
/gene="21" 
 
/locus_tag="TIROTHETA9_21" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp21" 
 
/protein_id="AEM05888.1"  
 
/db_xref="GI:343197886" 
 
/translation="MTFPRIQSVVIPLLRDALVPDKAKKVGSWIENIDYREFPLVNVRRIG
GGRHPNRPTQFATPVIELTVYHTKGLIECEQLYEDCLDVLYDAVKTQKQTPKGY
LHSIRETMGATQFSSPFMDSWRVQGLIALGLRPPRNKGVTPNGT" 
gene 14385..14975 
 
/gene="22" 
 
/locus_tag="TIROTHETA9_22" 
cds 14385..14975 
 
/gene="22" 
 
/locus_tag="TIROTHETA9_22" 
 
/note="major tail subunit" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp22" 
 
/protein_id="AEM05889.1"  
 
/db_xref="GI:343197887" 
 
/translation="MALNDEAVLTAAVGYVYTGPVGTAAPSAAELDDLDLESPSSWTA
TSWDSIGHTSRGDMPEFGFDGGDSEIKGTWQRKKLREVTTEDPVDYLTLFLHQF
DEDALSLYYGKNASTTAGEFAVSGKSDPTEKAFFVVIEDGDVRIGFHSAKASVK
RDDAIQLPVDDFASLPIRATFLDHPGFPLFKWVNEDLFPNVQTP" 
gene 15095..15963 
 
/gene="24" 
 
/locus_tag="TIROTHETA9_24" 
cds join(15095..15442,15442..15963) 
 
/gene="24" 
 
/locus_tag="TIROTHETA9_24" 
 
/ribosomal_slippage 
 
/note="tail assembly chaperone" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp24" 
 
/protein_id="AEM05891.1"  
 
/db_xref="GI:343197889" 
 
/translation="MSNVFTLDSLREEADKQFAPFKVRLSDGTEVVLRNLLRLNKNDRK
TVLASIEALKTEDESEEGRTLDDIDRMVDTVSKILELAAGKDSRKLLKELDGDL
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GLLMGVLEGWLEATSPGGSAELAGLIDRYGEHLVPDLKHYYGIDLRELFSEANP
LSPQYVLIHIKHLPIESAFVAAIRGGQEFRGWNADRYALAAIINSIRAGNYMFVM
ANSDPRKGKPPLPSPWPVPQENKAEKKYAPNSFAGIVAAQVIAARKRKQQKKE
AEWQAQEASKSAGFLSGSSQTSTGSTES" 
gene 15095..15466 
 
/gene="23" 
 
/locus_tag="TIROTHETA9_23" 
cds 15095..15466 
 
/gene="23" 
 
/locus_tag="TIROTHETA9_23" 
 
/note="tail assembly chaperone" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp23" 
 
/protein_id="AEM05890.1"  
 
/db_xref="GI:343197888" 
 
/translation="MSNVFTLDSLREEADKQFAPFKVRLSDGTEVVLRNLLRLNKNDRK
TVLASIEALKTEDESEEGRTLDDIDRMVDTVSKILELAAGKDSRKLLKELDGDL
GLLMGVLEGWLEATSPGEAQNSPA" 
gene 15882..18482 
 
/gene="25" 
 
/locus_tag="TIROTHETA9_25" 
cds 15882..18482 
 
/gene="25" 
 
/locus_tag="TIROTHETA9_25" 
 
/note="tapemeasure" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp25" 
 
/protein_id="AEM05892.1"  
 
/db_xref="GI:343197890" 
 
/translation="MAGAGGVEVGRISIRVVPDLDGFYRELKTKLEGIEKTLKAKIKVEP
DMDGFAGVVAQKAKNLKAKVKLDGDSTDLQKAVDAVNAKGPKKIKLELDPE
FDYRLRQRLAKLKPKVEVDVDFKRGMLDRLSNSLSKIQMPSFGSGINPMGWAV
ILAGVAAVTPLISGLLGAITTAIVALPGLITSILVPVAALALGMDGLKKAAEVLK
GPFDDLKATMSSAVEEQFTPVFEKLGTIFPMLKEALPGVTDGLAAMAQSFADA
VTSPQGMEKVRGVIDDIANALKQAAPGIGDFTTGLLDLVKGFTGNLPSVADWF
NDTGKSFKDWAKDFTEKGPDGTSKFDRALEGLGWTLKELGGGLVDIGGKALD
FFSDPEKIRSFKTELDGVVATVSTLVDLSNQLASNMSKIPGFRDGEANGPMDFAP
IQIQLIKEQFDKIDWSGIWGNMKSTAAGAFAEVTMFAANTAITIGAKFRGIWDGI
STNAGTAWNGVVTIVSGVIANILRIAAQLPGQIASVWANIPSMTAGVWNTVVST
AAPIITQILTTFINVGVGVMNEVSSWPGKIVGALGSLASTLAEIGSRAAQALVSA
LAAGIRAGIGPIGQAVGALMSAARALIPNSPAKEGPFSGSGWRAVEGFGDALGD
ALASGIPGQEDKIVSKIRAIMQAIKDVFGDASKLNLNFNFGSLESGLNSVASAAT
DTSRALGNTVSGAMPNKLSDEAKQQKDLLELKKDELEVERQKLQNQKNGLDP
KDKAGRAAIQQQIDQLNLQKKQIDLEKEQLDYAGKYTDQVAETDSVMGDMGK
KIYDATKNVAQAASGQLMSDLGISGNGALSQFLEQGLALGEQFIFNVGSMDDA
VAGQQTIQNKKALQFDRR" 
gene 18487..19827 
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/gene="26" 
 
/locus_tag="TIROTHETA9_26" 
cds 18487..19827 
 
/gene="26" 
 
/locus_tag="TIROTHETA9_26" 
 
/note="minor tail protein" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp26" 
 
/protein_id="AEM05893.1"  
 
/db_xref="GI:343197891" 
 
/translation="MDTLVELEGVNGEWFTLAGPGEGDRGVYLGTDVKGLYDPPVKV
VYEEPGNYPGARYLNHRILRRDITFGVEILNDAAIGPNSWLSRESEWRKAWAFD
RDCKLYITTPESGTRYLKVRLGESPEVSWFTDPRGNKINRTVMVVIAGDPFWYQ
DDVVYSAVTQTDTTFDPNPLPWPWPQEALPTETLSITVDPADGKGGLNPTDQYS
WVKWILPGSTQVPAEPYVPGIPWLGAPKSPAVIWTVPDYSFEDESLSNRRVRMP
GLIGGLRTAEVQIVSLIGDPKSGTFKLGRDSSLTSSIAYNATAATMKTRLEAVYG
AGNIRVDGGPTLLSPRQPWRVSFIGALAGSPQPLMLTESSLGNGGRVQVTRATE
GATAPAENALIDTDPREEQVTSENGSQLWARMNGVRFRHPIPPWTKSATFELTV
SGAVPGQMAVLRIPRAWTRPWGLE" 
gene 19824..21602 
 
/gene="27" 
 
/locus_tag="TIROTHETA9_27" 
cds 19824..21602 
 
/gene="27" 
 
/locus_tag="TIROTHETA9_27" 
 
/note="minor tail protein" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp27" 
 
/protein_id="AEM05894.1"  
 
/db_xref="GI:343197892" 
 
/translation="MSTSTITSLEDAERVWNTAMARRALREQERLKPVLTRLWDGDMR
LRGHVAGERGGDFEFIENDTGTASLQLSLDHHLAKWVMNFRGREKRNVIVTFD
KQGARWSGFMDHYRVVREENGDVYLDIVFKHDYEQAKHILCWCNPFLRPELQ
FPKLWIIFGPAKWCLLLTLFVNILRLETSLWTLPDNPLDPTEWMPLSFNISNWRNI
VKPFPLIGDNSNLTMVFSRFQSFHDIAKSTLEDAQLTIVCRRYLKGEDPHPFEDL
RGELNIGPLEDLLSLIPIRHGCLVWDIVDNSGWGSETSFGGSWLTGFIRAVVNIAS
DGMTEGVDVFTGDPTFPGEYYTPWFLGTSPQAPWIVFEEGPYTGIKSSEFKYFE
ATDTSFVAGGESMPGVNEGISAGVNMGGDFLTSMINQALGGFIDLPPLGGTMD
AIAKPLYENVFLAFQEWPTLRAMGSPIPIPLLEASQNGLGDFHYYEGWVENATK
AFTLSAFLATRAKIYATRAHTAHTIKVSDAAPYYVGEPGYGHFWLGSRVGTSVL
GFPIPHTVFVERVSKISYSWGADGPKGWELDIGYRDPKDPLLKLFELVMRFNGA
MGQLGIL" 
gene 21624..22070 
 
/gene="28" 
 
/locus_tag="TIROTHETA9_28" 
cds 21624..22070 
 
/gene="28" 
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/locus_tag="TIROTHETA9_28" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp28" 
 
/protein_id="AEM05895.1"  
 
/db_xref="GI:343197893" 
 
/translation="MIKPQEEVDWNKPEEHFAWALRNMPMLAGVGAVTHPGFLVQWS
KHLWECGFAHRDYLERLADEDGNIHVSKLPKQRIRWQAPFRGPRSNYNNAAR
WVSKNTPAPQPVRLPDVSKMTQQEQEFMLGQFRELGLIQDYIPQPDVAQELND 
gene 22079..22525 
 
/gene="29" 
 
/locus_tag="TIROTHETA9_29" 
cds 22079..22525 
 
/gene="29" 
 
/locus_tag="TIROTHETA9_29" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp29" 
 
/protein_id="AEM05896.1"  
 
/db_xref="GI:343197894" 
 
/translation="MTFRYVPAWGLRGLQLAVLFEAAMRGLMYLLMPQMALSSDSLTE
LERSAPLYVWGLVFVAAAAFGLFGETLMSGTENYMGSSSQNNPRAWPSFVAH
AALMILYVTLALAYGASLYDAGAAHFAIIPYDLLMIAYLHWLFARRRKSHVH" 
gene 22515..22943 
 
/gene="30" 
 
/locus_tag="TIROTHETA9_30" 
cds 22515..22943 
 
/gene="30" 
 
/locus_tag="TIROTHETA9_30" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp30" 
 
/protein_id="AEM05897.1"  
 
/db_xref="GI:343197895" 
 
/translation="MSTEILQYLPQQWVGLFAVIMFIGYITMQVIEKYPTFAKIMPFGTW
WHERQKTKRGKRNAWVAEDNEVIQALQAQVSAIAADLAAVNEKVRTFTAWS
VYDARWHHKVSVTWAGSETCLLPDHLDYFAFERLWRDDPVGASRL" 
gene 22957..24813 
 
/gene="31" 
 
/locus_tag="TIROTHETA9_31" 
cds 22957..24813 
 
/gene="31" 
 
/locus_tag="TIROTHETA9_31" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp31" 
 
/protein_id="AEM05898.1"  
 
/db_xref="GI:343197896" 
 
/translation="MTTPHQIPDQGVLEKWLGSGAFELGGGDSSWGQDYTENAVRALF
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EVPIGSVLTAFDVLEEQLLKLPLEALRYFKPLIPGATENDFVDVYTAVAKIIDNLT
DLPMALLKGEFLEWLGGTYAVLSTEVRQILEILSGLIVTPINAAVQGVKDWWNL
ITGKTSKLGTDGKLAADQLTGTVPTDKVGGFGGTANLADGLTTLVDNTVKAA
GNILGSGFGLQDLFDSLKGMQSNIADANAALAQLQADWAGSVNSGKKFFVNFG
DFDNANSVPSILTEVVNTGPGSVATVDGQLQWLDSGNAFAQRMYLYNVEPLM
DDYFEVQFVMPRRSEDELFGFANPPYNYAIGRSNASGSRFCFARVGYQRARIGC
MVDGTMTLFGTQDISYQAPAGARIKFRGGTSGGVRVFQLLVNNQIIGTVTDTGN
VSYAGAGYRMIGIGFEAQPRGNGQGTPGTISALSANDNTPQAVVGTSFRAYRA
ATGSISKGSGANVLPANCIDTLDHISSDLTWTPATQRLTYNGERPKTFLVGMRV
KSNSIIPSGGTWRQVLYKNGSLYARLEGHEGMVDTSTNNDNENRLSFVGGGTP
MVQMNPGDYISFGFENTSSVGIVGSGDGSQTWVNAIGLG" 
gene complement(24876..25094) 
 
/gene="32" 
 
/locus_tag="TIROTHETA9_32" 
cds complement(24876..25094) 
 
/gene="32" 
 
/locus_tag="TIROTHETA9_32" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp32" 
 
/protein_id="AEM05951.1"  
 
/db_xref="GI:343197949" 
 
/translation="MSNPVPYPYPVPSKRKPAPNPLFLTLSILSGFPTAFFLLLFVTGGTSI
FVMIGFLWSAMWTWVWALMANRYR" 
gene complement(25120..26634) 
 
/gene="33" 
 
/locus_tag="TIROTHETA9_33" 
cds complement(25120..26634) 
 
/gene="33" 
 
/locus_tag="TIROTHETA9_33" 
 
/note="integrase (S-int)" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp33" 
 
/protein_id="AEM05950.1"  
 
/db_xref="GI:343197948" 
 
/translation="MPQPLRALVGARVSVVQGPQKVSQQAQLETARKWAEAQGHEIVG
TFEDLGVSASVRPDERPDLGKWLTDEGASKWDVIVWSKMDRAFRSTKHCVDF
AQWAEERQKVVMFAEDNLRLDYRPGAAKGIDAMMAELFVYLGSFFAQLELNR
FKSRAQDSHRVLRQTDRWASGLPPLGYKTVPHPSGKGFGLDTDEDTKAVLYD
MAGKLLDGWSLIGIAKDLNDRGVLGSRSRARLAKGKPIDQAPWNVSTVKDALT
NLKTQGIKMTGKGKHAKPVLDDKGEQIVLAPPTFDWDTWKQIQDAVALREQA
PRSRVHTKNPMLGIGICGKCGATLAQQHSRKKSDKSVVYRYYRCSRTPVNCDG
VFIVADEADTLLEEAFLYEWADQPVTRRVFVPGEDHTYELEQINETIARLRRESD
AGLIVSDEDERIYLERMRSLITRRTKLEAMPRRSAGWVEETTGQTYGEAWETED
HQQLLKDAKVKFILYSNKPRNIEVVVPQDRVAVDLAI" 
gene 26713..27132 
 
/gene="34" 
 
/locus_tag="TIROTHETA9_34" 
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cds 26713..27132 
 
/gene="34" 
 
/locus_tag="TIROTHETA9_34" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp34" 
 
/protein_id="AEM05899.1"  
 
/db_xref="GI:343197897" 
 
/translation="MLSPVRVATAGTVAVGGLAFALSFTALSELSADNGVSQAWMVPL
VVDGGIIVATTATLALRTQWYAWTLLIVGSLVSVAGNVAHASPHGAIAMVIAAI
PPLWLLAATHLTVLLYRGTQESRSASISEPLFSRAFAENAA" 
gene complement(27205..27801) 
 
/gene="35" 
 
/locus_tag="TIROTHETA9_35" 
cds complement(27205..27801) 
 
/gene="35" 
 
/locus_tag="TIROTHETA9_35" 
 
/note="deoxycytidylate deaminase" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp35" 
 
/protein_id="AEM05949.1"  
 
/db_xref="GI:343197947" 
 
/translation="MRPTWDEYFLGIARAAAERSDCERSKVGAVVVKDRRVRATGYNG
APAGRPGCGTCPRRTSNARPGVDSYSSGGTRCVAVHAEANALLYCDREDLRGA
ALYITRAPCGDCSKLIDAAGIERVVYPFEWEKPEGCVCAGPTDPYHGWCDPCSK
LPKIVVQEQDRWERNEYTVRMEPGMLPDEPWRLGFINLRDEVGKTIE" 
gene complement(27798..27956) 
 
/gene="36" 
 
/locus_tag="TIROTHETA9_36" 
cds complement(27798..27956) 
 
/gene="36" 
 
/locus_tag="TIROTHETA9_36" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp36" 
 
/protein_id="AEM05953.1"  
 
/db_xref="GI:343197951" 
 
/translation="MAKHRFDTPRSANTPVVFRYGGRANGTGGVFVRYKNGNLEPLVG
PWVPRRPR" 
gene complement(27956..28108) 
 
/gene="37" 
 
/locus_tag="TIROTHETA9_37" 
cds complement(27956..28108) 
 
/gene="37" 
 
/locus_tag="TIROTHETA9_37" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp37" 
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/protein_id="AEM05948.1"  
 
/db_xref="GI:343197946" 
 
/translation="MKLVTALVLLALVLGLTACEGDSGGSDYDGPNGVIFMPVQGNPV
GIPIFF" 
gene complement(28105..28371) 
 
/gene="38" 
 
/locus_tag="TIROTHETA9_38" 
cds complement(28105..28371) 
 
/gene="38" 
 
/locus_tag="TIROTHETA9_38" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp38" 
 
/protein_id="AEM05947.1"  
 
/db_xref="GI:343197945" 
 
/translation="MSAGDVYLQIVEDDKGRPIMHFNGREFGVLEEPRIEFNSVPYGIYG
RARADISVSIRAVLIEPEPTPPPKPKRTWASAMGLRKPRGNR" 
gene complement(28368..28454) 
 
/gene="39" 
 
/locus_tag="TIROTHETA9_39" 
cds complement(28368..28454) 
 
/gene="39" 
 
/locus_tag="TIROTHETA9_39" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp39" 
 
/protein_id="AEM05946.1"  
 
/db_xref="GI:343197944" 
 
/translation="MKGVIVLLYLLAWLIVGFGVPITLDALL" 
gene complement(28451..28708) 
 
/gene="40" 
 
/locus_tag="TIROTHETA9_40" 
cds complement(28451..28708) 
 
/gene="40" 
 
/locus_tag="TIROTHETA9_40" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp40" 
 
/protein_id="AEM05945.1"  
 
/db_xref="GI:343197943" 
 
/translation="MTVQATSIESYHQIKPLLPKREVEALAWLQRGRPLCNLELAGLLDL
PINSVTPTVFRLRERGLVVESHRAKYEPTNRTVIYWTAA" 
gene complement(28705..29061) 
 
/gene="41" 
 
/locus_tag="TIROTHETA9_41" 
cds complement(28705..29061) 
 
/gene="41" 
 
/locus_tag="TIROTHETA9_41" 
 
/codon_start=1 
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/transl_table=11  
 
/product="gp41" 
 
/protein_id="AEM05944.1"  
 
/db_xref="GI:343197942" 
 
/translation="MEDRDFFDLLYQQWSKTTGAQDTYWMVEEDTEHYAGGPGTFLV
LAVDKENERKFIASFEREEDADFIAGLHGCLADLVRKLHMALDEADNADYDRD
SRECRIAELELENAELRKELGR" 
gene complement(29048..29323) 
 
/gene="42" 
 
/locus_tag="TIROTHETA9_42" 
cds complement(29048..29323) 
 
/gene="42" 
 
/locus_tag="TIROTHETA9_42" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp42" 
 
/protein_id="AEM05943.1"  
 
/db_xref="GI:343197941" 
 
/translation="MKWMHGGEGDSPAIAPLRPPSTTVELYITLPDQSSIPEFGENHRLTV
QKLALGVENMSQVERNWAIRTLIESVVEAAITELEEKGILRGGS" 
gene complement(29320..29553) 
 
/gene="43" 
 
/locus_tag="TIROTHETA9_43" 
cds complement(29320..29553) 
 
/gene="43" 
 
/locus_tag="TIROTHETA9_43" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp43" 
 
/protein_id="AEM05942.1"  
 
/db_xref="GI:343197940" 
 
/translation="MKAAVALPAPDGLTEELMGKAIYELNKLGTIMPHPLSGEGALEVY
LIPDAMKPAGAPKELTFLRFVADLMPYVGKRP" 
gene complement(29550..29717) 
 
/gene="44" 
 
/locus_tag="TIROTHETA9_44" 
cds complement(29550..29717) 
 
/gene="44" 
 
/locus_tag="TIROTHETA9_44" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp44" 
 
/protein_id="AEM05941.1"  
 
/db_xref="GI:343197939" 
 
/translation="MDGIKLTLTVENGKRTATAEAVIDRLWLNEVFVDLAYDAAVAAM
KEALKAEGVLP" 
gene complement(29738..31564) 
 
/gene="45" 
 
/locus_tag="TIROTHETA9_45" 
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cds complement(29738..31564) 
 
/gene="45" 
 
/locus_tag="TIROTHETA9_45" 
 
/note="DNA pol I; DNA polymerase I" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp45" 
 
/protein_id="AEM05940.1"  
 
/db_xref="GI:343197938" 
 
/translation="MIEHRHEVDGDEVVINVVDRESDLDGFMDFIRAHQGFLGLDSETT
GLDIYNDGFRCRLVQFGTPSEAWVVPVERGGPYAGDVKRALEMVQGFVLHNA
AYDLQVFERTLGVPMETMWPKVKDTRILAHLIDPRGKDEGGSGHSLEDLTRRYI
DSAVADNVKTLMADLAKANKTTKVNVWKKVPFEDPHYQLYSGMDPILAARLI
QKLAPLVKVSDELVDNEHKLAAICSYMERTGFLLDVEYTEELSLDLQVKESHY
NEIALNYGCEKVNSTDQVADVLESMGVRIKGRTPSGKRKVDDAVLSELTEHEK
AGEFATAVIEAKKAGKWRKTWVDGFLKQRDSQNRCHAAINPLRARTARMSIT
GIPAQTLPAGDSTIRRCFLADEGHRIASVDYQAQELRVLAALSKDQRMIQAFLD
DADLHLMTARAAFGEHIQKDDPERKYAKVVNFGRVYGGGAKTVAEQTGLDM
ATAQKVVAGFDRAYPEVQKLSQRLQREAIRNGYITTPFIDGLGGRRLPVDPQRA
YSALNYLIQSSSRDVTCRALLRLHDAGFTPYLRLPIHDEILASVPAEQAEWGANR
IGELMAEQMGPVLIGTDPEVGGRSWGSLYGANY" 
gene complement(31572..31874) 
 
/gene="46" 
 
/locus_tag="TIROTHETA9_46" 
cds complement(31572..31874) 
 
/gene="46" 
 
/locus_tag="TIROTHETA9_46" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp46" 
 
/protein_id="AEM05939.1"  
 
/db_xref="GI:343197937" 
 
/translation="MRKKELKRALREANLSIDALASSNTTLWEQREELARQNRELRAKL
ETKGPNRPNRPKLDKTEVAFIKDLVRAGVSRRDVARSFDVNPSTISRIVRGQYH
R" 
gene complement(31874..32047) 
 
/gene="47" 
 
/locus_tag="TIROTHETA9_47" 
cds complement(31874..32047) 
 
/gene="47" 
 
/locus_tag="TIROTHETA9_47" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp47" 
 
/protein_id="AEM05938.1"  
 
/db_xref="GI:343197936" 
 
/translation="MKEVTVLLIDGTIIRTQGEVNVDPIENTLVITGDSGAYLSFYRPNLM
YYAVSPLEGI" 
gene complement(32056..32775) 
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/gene="48" 
 
/locus_tag="TIROTHETA9_48" 
cds complement(32056..32775) 
 
/gene="48" 
 
/locus_tag="TIROTHETA9_48" 
 
/note="ThyX" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp48" 
 
/protein_id="AEM05937.1"  
 
/db_xref="GI:343197935" 
 
/translation="MKVKLIAATEVDPYVLESLGYKPSPYETAGGIGDWDADELAEFAG
RNCYRSFDRPNPATRENEDYLAHILEVGHESVLEHASATFYIEASRSVLTELERH
RHLSFSVVSQRYVDPTPLGGHTPPVVWELPENQYRDAAHFLAEAWDSAESYYK
RLLAVLENAGLPRKKAREAARAVLPNMTNSPMVVTGNHRAWRYVIKARYHEA
ADAEIRELAGELLAQLREIAPNTYQDIPNEPYSY" 
gene complement(32843..33382) 
 
/gene="49" 
 
/locus_tag="TIROTHETA9_49" 
cds complement(32843..33382) 
 
/gene="49" 
 
/locus_tag="TIROTHETA9_49" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp49" 
 
/protein_id="AEM05936.1"  
 
/db_xref="GI:343197934" 
 
/translation="MQDPFASAPATDEAQAAPEPQESAFDAPPPEAPKKAPAKKAAAKA
APKPAAAPGEGKVVLTFKGGSGFDAPWIVIHAEDLDDALDQVTNQGATLGAL
MERVQNAGQHFAGMAPAKASGGNSGGGGGGRSNAPRGAQEPPAGTPPAPGPD
WVYKSGTGKNGKPWSAWMPPRGSDEKPVWL" 
gene complement(33409..35442) 
 
/gene="50" 
 
/locus_tag="TIROTHETA9_50" 
cds complement(33409..35442) 
 
/gene="50" 
 
/locus_tag="TIROTHETA9_50" 
 
/note="ribonucleotide reductase" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp50" 
 
/protein_id="AEM05935.1"  
 
/db_xref="GI:343197933" 
 
/translation="MTTEVNWGPTGEIVYNRTYSRVKPDGSSETWPETVERVVDGNLA
LVDARYQQPGEREELIRLITEFKMLPAGRHLWASGVKNAQHLFNCWVSGWTE
KPSDHFEFTFMRLMEGGGVGANYSNRFIDYGPVPQELYVHIVCDEEHPDYQAM
KDAGVLSTEYDPEWAGAFVIEDSREGWAAALVDLIDTHYRDEVSHFQRVYDVS
RVRPFGAKLKTFGGRASGPLPLARMLIDVCEVLSEIATVGGSLNGIAAMEIDHAI
AQCVVAGGVRRSARMSMMHWQDPQIEEFVRCKQETGKHWTTNISVVVDDLF
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WTALNMPNQVSIMVRDQAHKALTWITDGMVANGEPGFWDSSLSNQGEPNEVV
CTNPCGEITLQEWEPCNLGHINLAAFVKDNGKVDTIDLIRSHRLMARFLIRATFS
PVGDPKSREVLDRNRRIGVGHLGVASYLAMTGRRYSKAPLDKHFRKTLRELAK
EVEQSAQQFSHELRIPVPVKTRTVAPTGTIAKMPGVSEGIHPIFAKYFYRRIRFSK
GDPQIEELREQGYEVEDDLYAQNTVVVTIPTKDTLVQEVVDRFGRDAEEIVESA
EDLTLNQLLAFQAMYQMLWADNAVSFTANVDPDRYKPHVVGEQLRTFGGLLK
GATIFPESSMPQAPYERITKKQFEAATAQAVADSVDEECASGACPIR" 
gene complement(35439..36323) 
 
/gene="51" 
 
/locus_tag="TIROTHETA9_51" 
cds complement(35439..36323) 
 
/gene="51" 
 
/locus_tag="TIROTHETA9_51" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp51" 
 
/protein_id="AEM05934.1"  
 
/db_xref="GI:343197932" 
 
/translation="MVKVMEAAAKSALVTWGREGGLDDLVQDLWVWYLERPATQRK
LEELSKPEAIATVRRAAIQILTEQVLAGNKFNGRNLYSSEAVKDVLKDRSNNRY
LKDIMPTAMAALEKQHAVYAEALRSRYDDGVIPQDGPSQDALKNAHKAITEHV
NIIVITAGDVSSAAVQAETRKSSGGRSDPTADAAIALIEKGDEELELTDQEGNVT
GTTTYRTELANVFDDWITQSTGDSSEVRLDIFDGMFNGDDRMAMYRAQVFPEL
FPDEKPMLIDNWPAEDRELYCGGEYTPGYLRLVKGGK" 
gene complement(36339..37106) 
 
/gene="52" 
 
/locus_tag="TIROTHETA9_52" 
cds complement(36339..37106) 
 
/gene="52" 
 
/locus_tag="TIROTHETA9_52" 
 
/note="metallophosphoesterase" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp52" 
 
/protein_id="AEM05933.1"  
 
/db_xref="GI:343197931" 
 
/translation="MSKRIVIVSDTQIPYEDRRAVRAVLRFIGDYQPDQVIHIGDLMDFPQ
PSRWNKDTRGEFEGSVFTDAEKAKLRFLAPLRTIYVGPVGVHEGNHDERPRTYL
SKYAPALAESKAFHLETLLDFDGFGIDLLPEFYKVAPGWVTTHGHRGQISLSRIA
GNTALNAARKFDTSVIMGHTHRQGILSHTSGYGGISKKIVTGVEVGNLMDMRQ
ADYLKGGTGNWQSGFGLLTIEGRHVKPEIIPITNGRFTVDGHTWEV" 
gene complement(37099..37374) 
 
/gene="53" 
 
/locus_tag="TIROTHETA9_53" 
cds complement(37099..37374) 
 
/gene="53" 
 
/locus_tag="TIROTHETA9_53" 
 
/codon_start=1 
 
/transl_table=11  
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/product="gp53" 
 
/protein_id="AEM05932.1"  
 
/db_xref="GI:343197930" 
 
/translation="MSESILEEAQRLIHGERNKNYGHPRENFSDIAALFSGYLERPISDIDV
ANLMILMKIARVKGTGYHRDSFTDIAGYAGCVERIYEEEPEVE" 
gene complement(37367..37678) 
 
/gene="54" 
 
/locus_tag="TIROTHETA9_54" 
cds complement(37367..37678) 
 
/gene="54" 
 
/locus_tag="TIROTHETA9_54" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp54" 
 
/protein_id="AEM05954.1"  
 
/db_xref="GI:343197952" 
 
/translation="MEALHARAVHRIPNRLRPRGRRRARSRVRQPCGTDPAEQQGDPDA
TWRGCQLASHQQRQIRSAGKDVMTQPNEYTETEFLGLDPDAPWWEGIHDYVH
EGEDDE" 
gene complement(37474..38133) 
 
/gene="55" 
 
/locus_tag="TIROTHETA9_55" 
cds complement(37474..38133) 
 
/gene="55" 
 
/locus_tag="TIROTHETA9_55" 
 
/note="DNA primase" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp55" 
 
/protein_id="AEM05931.1"  
 
/db_xref="GI:343197929" 
 
/translation="MQRLSESQKSFLREATERYRRSLNGSPAEEYLATRGLMFDSVRDE
VDRFMLGYVDDPLPGHEMFRGFMAIPYLRWSREHGWIVVAIRYRCIQDHDHRG
HGKYMTAPGDQPWLYNTLALLREVPDVAITEGEIDAITAQVCGLPAVGVPGAN
MWKPYMRELFIGYRTVYVLADGDEPGAEFANRVALTLPNSRVIPMPPGEDVNS
LVISRGKSALLERMS" 
gene complement(37949..38362) 
 
/gene="56" 
 
/locus_tag="TIROTHETA9_56" 
cds complement(37949..38362) 
 
/gene="56" 
 
/locus_tag="TIROTHETA9_56" 
 
/note="DNA primase" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp56" 
 
/protein_id="AEM05955.1"  
 
/db_xref="GI:343197953" 
 
/translation="MPSTDEPLIVQAIHRYHPDWEPPKDTGKDWIKCLCPFHAEEVPSAA
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VSFVRQAFNCLACGVKGDVLGLIKKQEEVSYAEAERIAEELSPGGNRTVPAKSE
RQSSRRVFGDKGTDVRQRQGRSRPVHARVRGRPTPWS" 
gene complement(38346..38480) 
 
/gene="57" 
 
/locus_tag="TIROTHETA9_57" 
cds complement(38346..38480) 
 
/gene="57" 
 
/locus_tag="TIROTHETA9_57" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp57" 
 
/protein_id="AEM05930.1"  
 
/db_xref="GI:343197928" 
 
/translation="MRYRVEAIIRSDEDEAKFAEKFDELINDTYKTGVEDTVVYAING" 
gene /gene="58" 
 
/locus_tag="TIROTHETA9_58" 
 
/note="Endo VII; endonuclease VII" 
cds /codon_start=1 
 
/transl_table=11  
 
/product="gp58" 
 
/protein_id="AEM05929.1"  
 
/db_xref="GI:343197927" 
 
/translation="MTTTRRKPTVRSQDRAHKRKPCIDCTAEGIVTKRKAPHPGPRCVT
HHRAKRLQRRTLTQEQRWMDVYGITADEYWAIYEHQGGCCYICRRANGKRKR
LSVDHDHATGIVRGLLCTACNRNVLGHLRDSVEAAQRIIDYLDDPPAVQAIGER
VVPDP" 
gene complement(39036..39860) 
 
/gene="59" 
 
/locus_tag="TIROTHETA9_59" 
cds complement(39036..39860) 
 
/gene="59" 
 
/locus_tag="TIROTHETA9_59" 
 
/note="hydrolase" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp59" 
 
/protein_id="AEM05928.1"  
 
/db_xref="GI:343197926" 
 
/translation="MNLKHQTLVLDDGYRVAVTTAGHSAGVPLVFMHGLSVSAIAYEE
LFEELSYLGFYVIAPDAANHGDSGSLPWGHTVEDMANIIARALTSLKVDKAVIA
GHSMGGAMAVEFSAMFPDRVHAAILIDAAAGKEHHEGIAIAPGRNLPTRAARF
AVGGLVDILGDGYRAMRSRTRRERLSLLSSLQESVSGLRFVRAAYALTKADTVP
LLEKMRANSVPTAVLHAECDQIVPYAAGVSAAALAGGKLFTVKGFHSWLLVD
PEFAADLIKTAMWDVIA" 
gene complement(39857..40237) 
 
/gene="60" 
 
/locus_tag="TIROTHETA9_60" 
cds complement(39857..40237) 
 
/gene="60" 
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/locus_tag="TIROTHETA9_60" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp60" 
 
/protein_id="AEM05927.1"  
 
/db_xref="GI:343197925" 
 
/translation="MRRVLVTGSRDWRDRPEVWRTLQDELDKSPDGIVVVHGAARGA
DDIADRWAWGMHQMGYKVEPEDHPADWDTYGKSAGHRRNAEMVALGADV
CHAFPLEESIGTFGCMELAEAAGIPVVNHGYIKE" 
gene complement(40234..40458) 
 
/gene="61" 
 
/locus_tag="TIROTHETA9_61" 
cds complement(40234..40458) 
 
/gene="61" 
 
/locus_tag="TIROTHETA9_61" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp61" 
 
/protein_id="AEM05926.1"  
 
/db_xref="GI:343197924" 
 
/translation="MPKPTPKMNIIHQQALSALIATKPVSWDRKSLVKDENGKESVVKT
KVTREGLRFPLAQNVSEFNVDLAARRWVP" 
gene complement(40516..41052) 
 
/gene="62" 
 
/locus_tag="TIROTHETA9_62" 
cds complement(40516..41052) 
 
/gene="62" 
 
/locus_tag="TIROTHETA9_62" 
 
/note="phosphoribosyltransferase" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp62" 
 
/protein_id="AEM05925.1"  
 
/db_xref="GI:343197923" 
 
/translation="MTLADAIFAPWDTVQYQAVAPRPEKKVLDLTDETYLRVVHKPDR
LLELANQYLSNVDYDTLVGTGLSGTIAATTLARLLDKNYLVVRKPNDGSHTSM
KAEGRIGKRWVFVDDLVATGRTFGRVWDAVHLITQDWKFETKFVGSFLYSDG
GWYDHDFVPADDERTERWLMNNSEYYSQP" 
gene complement(41072..41878) 
 
/gene="63" 
 
/locus_tag="TIROTHETA9_63" 
cds complement(41072..41878) 
 
/gene="63" 
 
/locus_tag="TIROTHETA9_63" 
 
/note="DnaB-like helicase" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp63" 
 
/protein_id="AEM05924.1"  
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/db_xref="GI:343197922" 
 
/translation="MYTPMQSLRVKGSAGDPLPPVFQALEMKGTRFLRGQLALVCAGP
GTGKSAFVLTYALKARVPTLYFSADSDAFTQLNRMVSIQTAWSMERSARAVRN
SDLTEVAEEFEDIPIRFNYNASPSLDQIEDSMKAYCQGYGDYPDLVVVDNITNVR
SGGGEDDDPFSGLESMMDYLHTMARNTGACVVGLHHVTGSYNDADKPIPLSG
VKGQITRVPELVLTLHRVSEEFGPEALRVSTVKNRAGRMDPSGLDFVELEFIGDT
MQIRDPSNQ" 
gene complement(41886..41966) 
 
/gene="64" 
 
/locus_tag="TIROTHETA9_64" 
cds complement(41886..41966) 
 
/gene="64" 
 
/locus_tag="TIROTHETA9_64" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp64" 
 
/protein_id="AEM05923.1"  
 
/db_xref="GI:343197921" 
 
/translation="MIAEVIVFGFIIALGALGGWLCFTKL" 
gene complement(41963..42157) 
 
/gene="65" 
 
/locus_tag="TIROTHETA9_65" 
cds complement(41963..42157) 
 
/gene="65" 
 
/locus_tag="TIROTHETA9_65" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp65" 
 
/protein_id="AEM05922.1"  
 
/db_xref="GI:343197920" 
 
/translation="MRNVQMEMNVAKQRRKLTQLCAEAPPSHQGYIEHLIRLFDKDCE
AGLPRPASEFIPMYHEEFGL" 
gene complement(42154..42351) 
 
/gene="66" 
 
/locus_tag="TIROTHETA9_66" 
cds complement(42154..42351) 
 
/gene="66" 
 
/locus_tag="TIROTHETA9_66" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp66" 
 
/protein_id="AEM05921.1"  
 
/db_xref="GI:343197919" 
 
/translation="MTQSYRKSLTLSTESEYWFVELGSGDSEYPFPSVAAATRFAQGHT
HRAPVIRYPDGRRWNGKEWV" 
gene complement(42361..43152) 
 
/gene="67" 
 
/locus_tag="TIROTHETA9_67" 
cds complement(42361..43152) 
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/gene="67" 
 
/locus_tag="TIROTHETA9_67" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp67" 
 
/protein_id="AEM05920.1"  
 
/db_xref="GI:343197918" 
 
/translation="MTEERKHRSVSQLKQYEKCPYSYKLSRLDKAWQRPAAWTAQGSA
VHEAIEAWERSGRTMSLEAAQAVFRESYQKYINAACAITPNFEYWFASGRYGG
RLDIARRYDIGLEQVGKYIDWATSHTEEVIWIAPDGTPGIELGFDIDLDGVLVRG
FIDAVIETDEGLIVRDHKTGKQPGDDFQLAVYAVALAEEYGIEPPELGDYWMG
QSGKATYPYNLTDWTKEAITEKFKELDANVRAGKFDPNPSEDNCRFCDVSFAC
EFSAG" 
gene complement(43149..43571) 
 
/gene="68" 
 
/locus_tag="TIROTHETA9_68" 
cds complement(43149..43571) 
 
/gene="68" 
 
/locus_tag="TIROTHETA9_68" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp68" 
 
/protein_id="AEM05919.1"  
 
/db_xref="GI:343197917" 
 
/translation="MPLAIVCHQLALAAPVIRVARPGWLFAESINLLGVTLLLTYRSSAV
RDTDPMFADVKALLDRAKAVKRICLQSLPDQGIMFGEGYWESSLVYDGALDPT
EPLDPRAQAVVDFITKGKYPVHPTEVPAQIRKHLHTLEVAS" 
gene complement(43653..44165) 
 
/gene="69" 
 
/locus_tag="TIROTHETA9_69" 
cds complement(43653..44165) 
 
/gene="69" 
 
/locus_tag="TIROTHETA9_69" 
 
/note="immunity repressor" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp69" 
 
/protein_id="AEM05918.1"  
 
/db_xref="GI:343197916" 
 
/translation="MKTDKPYKNQPELTLAVVEDLKGKGYTQSEIARMYGVTRQYVSW
IKHYYGGRLTPREIVLQHFPFQVPVPMQQGVSPYRRLREHGEYMATGGVGMDD
LKLKRLRGFYNKLRDHVLEFDPNIPPEEGVSKAGGWAYRPRRPEDKDLLIRVND
YTDLTEEGAMIWRFPPREP" 
gene complement(44376..44504) 
 
/gene="70" 
 
/locus_tag="TIROTHETA9_70" 
cds complement(44376..44504) 
 
/gene="70" 
 
/locus_tag="TIROTHETA9_70" 
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/codon_start=1 
 
/transl_table=11  
 
/product="gp70" 
 
/protein_id="AEM05917.1"  
 
/db_xref="GI:343197915" 
 
/translation="MYVEDMDLDEAIEWEAELSGSDDPQDIMDLEDVRARIEELEG" 
gene complement(44626..44874) 
 
/gene="71" 
 
/locus_tag="TIROTHETA9_71" 
cds complement(44626..44874) 
 
/gene="71" 
 
/locus_tag="TIROTHETA9_71" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp71" 
 
/protein_id="AEM05916.1"  
 
/db_xref="GI:343197914" 
 
/translation="MRKLAFALAMAGIGVAIVATPPYAEAAPGMCANHGTGPGLIYKH
ACASGRGGWGWVDISETQQEYKSPSGQSQTPPRVRDKG" 
gene complement(44871..45185) 
 
/gene="72" 
 
/locus_tag="TIROTHETA9_72" 
cds complement(44871..45185) 
 
/gene="72" 
 
/locus_tag="TIROTHETA9_72" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp72" 
 
/protein_id="AEM05915.1"  
 
/db_xref="GI:343197913" 
 
/translation="MAVTLVDDTVQGLNARIEELEAELALARAVREAHIPEEPSVDGTVI
RFVKYNLSYTFAAIRVLGRWYITQDGTRSPRQGHAPKAWDELLAWIGERNWH
RIEVLS" 
gene complement(45202..45342) 
 
/gene="73" 
 
/locus_tag="TIROTHETA9_73" 
cds complement(45202..45342) 
 
/gene="73" 
 
/locus_tag="TIROTHETA9_73" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp73" 
 
/protein_id="AEM05914.1"  
 
/db_xref="GI:343197912" 
 
/translation="MKLTKSDIAYREALGLSTTDPLPAEIGMVTRRANRLKRPRKTARFR
" 
gene complement(45342..45641) 
 
/gene="74" 
 
/locus_tag="TIROTHETA9_74" 
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cds complement(45342..45641) 
 
/gene="74" 
 
/locus_tag="TIROTHETA9_74" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp74" 
 
/protein_id="AEM05913.1"  
 
/db_xref="GI:343197911" 
 
/translation="MKARYILAGLCGAIVLGNAPAIIAEARADVTAECYAHLSDKQSHT
TPAADRRFHLERGEPSPCTEQDAKDGLPKASSDSGKPKEDRDKKSRHCRKHWY
C" 
gene complement(45638..45796) 
 
/gene="75" 
 
/locus_tag="TIROTHETA9_75" 
cds complement(45638..45796) 
 
/gene="75" 
 
/locus_tag="TIROTHETA9_75" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp75" 
 
/protein_id="AEM05912.1"  
 
/db_xref="GI:343197910" 
 
/translation="MSNIHREDWHLGVDDEFNVGESRPKTPRWLTNAVNGPEYYKDRK
FQRRKRTR" 
gene complement(45804..45947) 
 
/gene="76" 
 
/locus_tag="TIROTHETA9_76" 
cds complement(45804..45947) 
 
/gene="76" 
 
/locus_tag="TIROTHETA9_76" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp76" 
 
/protein_id="AEM05911.1"  
 
/db_xref="GI:343197909" 
 
/translation="MARNYRRRPYGSKYKPKTHTIVLNSGAVLSVNAKGRCEDAPCCG
CCT" 
gene complement(46158..46742) 
 
/gene="77" 
 
/locus_tag="TIROTHETA9_77" 
cds complement(46158..46742) 
 
/gene="77" 
 
/locus_tag="TIROTHETA9_77" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp77" 
 
/protein_id="AEM05910.1"  
 
/db_xref="GI:343197908" 
 
/translation="MPTPVATDAKGTRNSTANRTPKEVPAHAGDTLTDAMWKLFPTPA
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ARDGKGPNPNKREGGMDLPGAVALLPTPLTTDSQGGGHHGDGGMDLRTTATH
LYGTSEWGKFEPAIRRWEGIVGREVPVPTEPNKNGNPRLNAAFSEWMMGWEE
GWVTDLIETSGRRAPEGKISRTAAMKIIGNGVVVQQAAAAIRDLLA" 
gene complement(46720..47253) 
 
/gene="78" 
 
/locus_tag="TIROTHETA9_78" 
cds complement(46720..47253) 
 
/gene="78" 
 
/locus_tag="TIROTHETA9_78" 
 
/note="DNA methylase" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp78" 
 
/protein_id="AEM05909.1"  
 
/db_xref="GI:343197907" 
 
/translation="MSHGPRIGSLFSGAGGLDLAVEEVFGGQTIWQVEVEKAAATLLAK
RFGVPNLGDVSKVNWHEVPAVDILCGGFPCQDVSPAGLKAGIGQGTRSGLWAH
FAEAIDILRPRVVVIENVRGLLSAKATDASGLQMRAMGRVLRDLSDLGYDAKW
KTLAAGAIGAPHKRERVFIVAHPGRD" 
gene complement(47250..47420) 
 
/gene="79" 
 
/locus_tag="TIROTHETA9_79" 
cds complement(47250..47420) 
 
/gene="79" 
 
/locus_tag="TIROTHETA9_79" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp79" 
 
/protein_id="AEM05908.1"  
 
/db_xref="GI:343197906" 
 
/translation="MAPDATLEELRLLMSDYDRHGLAVGQEAIDRMVELMTALDEWIT
KGGFLPADWRAA" 
gene complement(47423..47893) 
 
/gene="80" 
 
/locus_tag="TIROTHETA9_80" 
cds complement(47423..47893) 
 
/gene="80" 
 
/locus_tag="TIROTHETA9_80" 
 
/note="SprT" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp80" 
 
/protein_id="AEM05907.1"  
 
/db_xref="GI:343197905" 
 
/translation="MTAMLDRPTTMTPPQARFQARSLMDEHGLDDWHLRFDNAKRRA
GQCNYRTRTISLSLHLMRLRSAEDTMQTITHEIAHALVGGSHGHDAVWAAKHR
ELGGNGQRCFEMEDIDPTAPWIGTCSHGKQFARYRQPKRLEGWRCRCRPSSSPV
VWKKRG" 
gene complement(47890..48060) 
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/gene="81" 
 
/locus_tag="TIROTHETA9_81" 
cds complement(47890..48060) 
 
/gene="81" 
 
/locus_tag="TIROTHETA9_81" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp81" 
 
/protein_id="AEM05906.1"  
 
/db_xref="GI:343197904" 
 
/translation="MTSHKEQAMSTRATPEQLEARLGLRQSNAAQPHRNRKREMKRPG
KGHRKAWKRDEQ" 
gene complement(48057..48410) 
 
/gene="82" 
 
/locus_tag="TIROTHETA9_82" 
 
complement(48057..48410) 
cds /gene="82" 
 
/locus_tag="TIROTHETA9_82" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp82" 
 
/protein_id="AEM05905.1"  
 
/db_xref="GI:343197903" 
 
/translation="MRVFVYFNLHKHMWSVKALEGPDKGRVITRSHYVILRNVEGKVS
EAGRQRVLREGRKNVHAGLVGELVQGEAVDLDVNARLVTYNPRKYSTFVYAD
DETPFAGADLAVMTHKRVYAA" 
gene complement(48407..48583) 
 
/gene="83" 
 
/locus_tag="TIROTHETA9_83" 
cds complement(48407..48583) 
 
/gene="83" 
 
/locus_tag="TIROTHETA9_83" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp83" 
 
/protein_id="AEM05904.1"  
 
/db_xref="GI:343197902" 
 
/translation="MSDAAFKQWMRLVDAQLLKRMGVTTRDIADRCYRDMHDDGLRP
FEVVSEIMSEGIDAL" 
gene complement(48585..48797) 
 
/gene="84" 
 
/locus_tag="TIROTHETA9_84" 
cds complement(48585..48797) 
 
/gene="84" 
 
/locus_tag="TIROTHETA9_84" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp84" 
 
/protein_id="AEM05903.1"  
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/db_xref="GI:343197901" 
 
/translation="MIIAALIALGIGPTVDLSDIDIDMLPECVEEDCSDQPGQVGMWLDE
DTGNWYLSLGESSVLVVDDTVEEG" 
gene complement(48889..49095) 
 
/gene="85" 
 
/locus_tag="TIROTHETA9_85" 
cds complement(48889..49095) 
 
/gene="85" 
 
/locus_tag="TIROTHETA9_85" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp85" 
 
/protein_id="AEM05902.1"  
 
/db_xref="GI:343197900" 
 
/translation="MKRDTIVQITGKSSTGSPHGLLVEAEPTGGLRFTVTGHDGKKRHA
AVILPVGEVSAALVSIIDHLTES" 
gene complement(49118..50002) 
 
/gene="86" 
 
/locus_tag="TIROTHETA9_86" 
cds complement(49118..50002) 
 
/gene="86" 
 
/locus_tag="TIROTHETA9_86" 
 
/codon_start=1 
 
/transl_table=11  
 
/product="gp86" 
 
/protein_id="AEM05901.1"  
 
/db_xref="GI:343197899" 
 
/translation="MTTRVETILSKADFGAAVIAGLEGSTDVRWARQVWAELRESVGY
RKASAALLTSGASQQKLSKNSLPSFGLMLTPERGMMAASLRDVREAFGLSGAIN
LCPMASKGCAAACLSRSGQSGMPAQQRAQAVRTAFLLSHPVLAGLLIGAEIRSA
LRRHGRINLRLNTTSDIRWEIVAPHMVQALAEAGVLMYDYTAWSPRDRAESSD
YSLTYSAKEPSHTSDEYLQGILASGGNVAMPFTTRRGEALPEEWNGYRVIDGDE
SDERRNDPRGVVVGLRAKGHEWKKDNTAGFIRATA" 
gene complement(50031..50150) 
 
/gene="87" 
 
/locus_tag="TIROTHETA9_87" 
cds complement(50031..50150) 
 
/gene="87" 
 
/locus_tag="TIROTHETA9_87" 
 
/codon_start=1 
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ORIGIN      
        1 tgcgcctggc cgatcatgta cgggttttca gatttgagtc acaggagtcc cgccaggcac 
       61 gcgagggaaa agcccaggtc gacgttccat gcgcggtgat ccgcgccaca cttgtcatct 
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      121 cacacgccga ataggaaggt atgtacaggg tagaggccca acgtaagggg gaacctctaa 
      181 ggagggggtt gagtagcggc gttcagcgcc gccccaggag gcagcggcct tcacccccca 
      241 ccggccgctg ccgacaggga gcgccccgca gggcgctcgg gtaagtaaga gaggcccgcg 
      301 aatcggcgcg ggccgactag acatagtaca agggaccgcc tcagagcggt cccgttggtt 
      361 gaggtcgaag acctccttct cagtcggtct tctccctgtc ggcagccgcc gcccacaggc 
      421 ggctgcctct actagggagg tactcaaatt tcaccctcag atgcgaggag gagctggagc 
      481 tcctccgacc gcgccagcag gctcccgcct gactgggacg agaactaccg gcagcccgtg 
      541 ctcgaagcag cgggctacca gtgtcagatt cagggtcccg gttgcctcag gaaggcaacc 
      601 gatgttgacc acatcaggcg cggcgacgac cacagtcgcc gcaatctcca ggcagcgtgc 
      661 aaccgctgcc acggcagaaa gtcatccgca gaaggccacg cccgcaagcg gcagttacga 
      721 gcaatgagga ggcgacctat cgagcgccat cccggctctc ggtagcgggc caggtgcccg 
      781 cttttcaccc aggaggtgtc aagtgggcga aagaggccct atcggcaagc gatcggatca 
      841 gcgcgtccga cgcaacaaga cagacaaccc ggtcaccaag ctcccagcgc gtggaccggt 
      901 gaagcaaccg cagatcggta tccccgacgc acacccggtc gtcacgcagt tgtgggactc 
      961 cctggcgcat tcagcgcagg cgcagttcta cgagccgagc gactgggcct acgcccgcat 
     1021 ggcgctgcac ttcgccaacc agctcctctg gtctgagaag cccaacgggc agattctcgc 
     1081 gaccgtcaac tcgatgttga acggtctgct cgtgtccgaa ggcgaccgcc gacgggtgca 
     1141 actcgagatc gagcggaacc aggccgacgc cgtcgtggtc gacgtagcgg cgatgttcgc 
     1201 tcagcagttg ggcgctcagc agcgttccgg ctgagcccac agacccccgg agggggttga 
     1261 gcgcgtttcc tctcggcgca gctccctcct ccggggatag accccccacc tttgaaagga 
     1321 atcccatgcc agtcatcggc gctcagcttg agtccgacac cctcgtcctg actcgcggcc 
     1381 gcgacttcaa gtggtcgttc gagaacctcg acgcgaccgg tcagccggtg gccttcccgg 
     1441 ccgggtccct gttcttcgag ttcgagaacg gcacgaagtg gaccttcagc atcgaaggcg 
     1501 cactcgccac gatcaagatc gaatccgagc aggtcgcgct gatcgctgcc cgcacgaagt 
     1561 ggcagctcgt cttcctcccc gagggtgagg agctcggcgg cgatcccatc gcgctcggcc 
     1621 aagtccagat tcaggggtga tcgcatgagg ctgcgcggat tcccgactga cggtcggccg 
     1681 gcggtctcct acgtcggctc ccccaccggt tccatcctcg gaatccctca gaacctgatc 
     1741 ggcaaggtct cggtgtcgca gcagcggccc cgcagcctgc tgtcgatccc gactgacacg 
     1801 cctcgcggcg tcatcagccg ccacccgacc acaggtcgac tgctcgcggt gcccggtaga 
     1861 ccgggcccgc aaggaccaca aggtcccaag ggcgacggcc tccgcatcga cggccaggtc 
     1921 cccacgtatg cagagcttcc tggttcagcc tcggacggag atgtgtggct cgcgggcggc 
     1981 aagctgtacc gctacgacaa cggctggccc gacgagtctg ccggaaccca ggtccaaggc 
     2041 caggagggac cgcgaggacc gcaaggtatc gcgggcccgc agggcccagt cggcccgcag 
     2101 gggccgcagg gtctcaaggg tgataccggt cctcgaggcc cggaaggtcc ggaaggaccg 
     2161 gagggcccgc gtggtctgca gggtgagcag ggtgtccaag ggccgcaagg cccgaagggt 
     2221 gacaccggct cccagggacc taagggtgac gtaggccccc agggtgagcg aggtctccaa 
     2281 ggcattcagg ggccggtcgg cccgaagggc gacaaaggcg acaagggcga cacgggcaac 
     2341 caaggcccgc aagggccgca gggcccgcgt ggcttcacag gcgacaccgg tcagaccggc 
     2401 gatgacggtc ctcccggacc cgaaggccca ccaggaccgg aaggtccaca aggtcctgcg 
     2461 ggaccgaagg gcgacctcgg accgcaagga cctcagggcc tgcagggtcc gaagggtgat 
     2521 aagggcgaca agggtgatac gggatcgcag gggccacagg gcattcaggg tccgcaaggt 
     2581 atccaggggc cgcagggccc ctacggctac ttgtcctcgg acgcaacggt tctcgacttc 
     2641 cgcaggatga cgcaagccca gtacaacgcg ctcggagcag gaaggccagc aacgacgttc 
     2701 tacgtgatcg tggggtgaca catgccagtt cgcatcggtg atgccacccc ctcggggttc 
     2761 cgcttcggtg acctgacggc caccaagatt tacctcggcg acgttctggt cttccccgcg 
     2821 ttcactgtgg tcagccagac gttctccacg gtcggcaact ggaccttcaa catcccggcc 
     2881 gaatgcggtg ccatcgacat catcctgctc ggcggtggtg gtggcgggtc gtcaggcaac 
     2941 gcgggcctcg gtaacggcgg cggcggtgac ggcggtctgt gggagacact gacgctcatt 
     3001 cgcgggatcg actttccgtc taccgcgctg cagatcaccg ggacggtcgg tgacggcggt 
     3061 accggtggtg ctggcggctg gattccgatc aacggcgcag acggtaaccc caccactgcc 
     3121 aacatccccg gcgtcggctt ggtgcaggcg ctgggcggcg gtggcggtgt gtggacatcc 
     3181 ggcagccgtc ccggcaaggg ccccggcaac agggtccaca acggcatcaa ctacacgggc 
     3241 ggggcgaata ccggcgattc ggctgccaac ggtaacccgc ctggcggcgg cgctggcggc 
     3301 ggcaactcag gcttcttcgg cttcccggcc ggtggaggcg gtaaaggagc gagaggacag 
     3361 gcatgggtga gggcatacgt ctgatgacgc agacggcacc gtatccgacc gagctcgaag 
     3421 agctggtcga cggtgtccga taccggccag gctgggcgtt tcaactggtc gaggccccac 
     3481 gcaacgacgg ggtcaacggc cttgccctgg tcatcgtcgt gcagacggtc gacgcatacg 
     3541 gcgaagagac ccaccgaccg gtgtcgatct acttcccgtt catggtgccg cccgaggtgc 
     3601 gctcccgcga cggctggaaa cgctggctgt acgaccgcat cgaggacgcc gaacgccacg 
     3661 agcgcggcga gttcttcgag gtcgacggcg agaagccgtt cgccccacgc cactaccccg 
     3721 aagcggacgg ctacctcagg ctgcctccga cttgacatcg tacacaatga aaggagggcc 
     3781 caaatgacgg ccctacaagg caaactcgcc gtcttcgcgc tgaagcaagg tgtgaagttc 
     3841 ctcaagaacc acccggacct gatccccggc gagattgacg acgccatcgt caaggttctg 
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     3901 gcgctcgcgc tgggcgtctg atggcacgcc ggctcttcag gggtcgggca ttctcggaga 
     3961 acggttggcc ctacgtcgac caaggatcgt gtacatggga cgaggtcgtt cccggtgtct 
     4021 ggctgcagat acagaacggc gctcccttca cgatcatgcg ggcgttcgct cgggacttcc 
     4081 acgcccacgt agagccgctc cgcgactacg actccgcgtg ctggacccag gacaacaccg 
     4141 tcgacaccag caaccacccc ggtggcaccg ggatggacct gaactggaac ggcgctgacc 
     4201 agaagacatt ccgctacggc atcacgaagg aacgcgccta ccccggcgac aaagcccgca 
     4261 agctcgatga gctgctggcc ttctacgagg acgtgatcta ctgcggcggc tactggagca 
     4321 tccgcgactg gatgcacttc cagatgggct acggcaccta cgactcgaag gccgaccggc 
     4381 cgaccgagaa gacgctcgac ttcatcaggc gcaagatcag gccagacggg ttctcgacgt 
     4441 tcaatcgcgg tggcggcacc acggtaccca acggcgcgtc ggtgctcgct cgagccaccg 
     4501 gtatcccgct ggacagggcc gaaaggattc tgcccgccct gcgcgagggc ttgatcctcg 
     4561 ctgagtgcaa cacgttcccc cggatcgcga tgttcctcgc acagacgtgc tgggagtccg 
     4621 atcagtaccg ggcgaccgag gagtacgcca acggtcctgc acacgaggaa cgctggattt 
     4681 acaaggggcg cacctggatt cagctcacct ggcgctcggc ctatgagggc ttcggcaagt 
     4741 ggtgccacgc ccgagggctg gtcaacgacc cgatggtgtt cgtcaacaac ccacggtcgc 
     4801 tggccgacct gaagtgggct ggcctcggcg ctgcgtacta ctggacgacg accgtccgga 
     4861 acacgcggaa gtacccgacg ctcaaccagg catcggacgc ccgcgacgtg ctggtggcga 
     4921 cacagatcgt caacggcggc acgaaccatc tggccgaacg gactgccatc tacaaccggg 
     4981 ccatcgccct tggcgatgag ctcctgcaac tcgtccaaga ggaggacggc tttttgtctg 
     5041 cactcaactc ggctgagcag cgcgaggtcc tcgacctcct gcgctggttg gccgctcccg 
     5101 aatacgggga gctccgcaag ctattcgctt ctcgcgcaat gtatcgcgac agcgacgacc 
     5161 ggttcgagac cctcgccggc ttcgtcctgg cctgcgatgc gatgcagtgg gaggaccgcg 
     5221 tcgaaggcgc ggccatgctc ggtgagcccg agtacctcga acgggtactg cgtctcgccg 
     5281 ctggccgagg tccaggagcc aagaaccccg acggcagccc gcgtcagtgg gcgatcaacc 
     5341 acgcacgagc ggttctggct gacatcgagg ccaagaaccc gcaagcacta caacgctatc 
     5401 tagcgcagaa gggggccgca tgagcccgaa agttcgacag acgatctact acctcggcac 
     5461 catcatcccc ggtgtccttg gtatcgccct gatctggggc gggatcgacg ctggcgcagc 
     5521 gcaatccatc ggtgacatca tcgcgggcgc tgtggcgctc ctcggcgcgt cggctcccgc 
     5581 cgtcgccgcc aagaaggtga acgagcagcg caaggacggc actctggtgc cgcaggctcc 
     5641 ggtggagcag gtcgtcaacg gcgtgcaggc agtcatcgcc gcgcagcagg ccgcacaggc 
     5701 tgagctcgac agggtccggg acgtggtgac cggtgccatc ggcatcgtcc ccggcatcgt 
     5761 tccgcagctc ggtccgctcg cgcagcaggc ggtcgacgct ctcaacagct tcgcaccgcc 
     5821 cacggcctac agccaggcag cgcagttcgc ggacccgtac cgggctccct gggaccgctg 
     5881 atgttgaagc tgggctccag cggcctcatg gtcagtgcct ggacggcggt gatgcggctc 
     5941 cggttcgcca gctacgcgct tggcgtcaac ggccagccga tcaaggtcga cgggtacttc 
     6001 ggctacgacg aggagaaggt ccagaaggag taccagctac ggacaggtca gttcccgagc 
     6061 gggcaggtct cacgagaaga cctgcaccgc ctcgggctgc tgcccacgct gctgtcgatc 
     6121 cacggcaccg gccaggccga cccgttcggg atcggctacc ccgccgacat cgctcggcgg 
     6181 gtgctggacc tgtactggtg gcagccggta ggcaactggc ctgcgaaggc cgtcccgatg 
     6241 aacggttcgg tcgacgctgg cgagcgtgag tgcgttcggc tgatcagcaa cccgctgatc 
     6301 gttccgggcc cgacagcgtt cgtggactac tcccaaggca gcgtgatcgg tggccgtgtc 
     6361 cggaacagga tgcggcgcaa ggagctccgt ggtgagctcg tcgctgcggc cagcttcggt 
     6421 aacccgatgc ggctgcgggg ccactacgcc ggcaacgtcg atccgggcgg tgaaggtatc 
     6481 gacccgaggc aagagctcgc ggccgagccg ttccgcatcg agctcgcggc caagggcgac 
     6541 ctgtacacga cctgccccgg tgggcagtcc ggtgagatgg agcgtgcgat ctaccacgcg 
     6601 gtcttcagcc ggttcatcgg tgaggacagc ctgatcgagc aggtctggga gctcgcccgc 
     6661 aacccgtggg tcgaggttcc ggcagccgtg aaggccatcg tgcgcggtgg gatgttcgcc 
     6721 atccgtggca ccggcccaca cgtccgctac cacattgacg agtgccctgg aacgggcatg 
     6781 acctactacg agtacgcaat caagcacctt cgagacaccg ccgaggcacg acttcggcgc 
     6841 atcgtcgcgt ctgttacttg acatcgcacg gaagggagga ggagtgagcc tcgcgaatca 
     6901 ccatccggtg ccgctcctcc cccaaccgcc ccacaagatc gggccggttt ggcaggtacg 
     6961 ggaggacggc tcctggcacc tacctgagag gactctcggc tggggcattc tgaactggct 
     7021 ggctaagtac gtgaggtcgc cagccggtgg cggtccgttc ctgccgactc tggaacaggc 
     7081 ccgcttcatt ctttggtggt acgccgtcga tgagcgcggc gtgtacgcct accgcgaagg 
     7141 cgtccttcga cgcatgaagg gctggggcaa ggacccgctc tgcgcggcca tcgcgctcgc 
     7201 ggaactctgt ggcccagttg cgttctcgca ctgggacctc gaaggcaacc cggtgggcca 
     7261 gacccgccac gcggcgtgga tcacgattgc cgccgtctcg caggaccaga cgaagaacac 
     7321 gttctcgctg ttcccggtga tgatctcgaa ggacctcaag accgactacg gccttgacgt 
     7381 gaacaagttc gtcatctact cggaggtcgg tggccggatc gaggccgcga cttcgtcgcc 
     7441 cgcgtcgatg gagggtaacc gcccgacgct ggtgatcgag aacgagaccc agtggtgggg 
     7501 cgtcggtccg gacggcaacg tcaacgacgg cgtcgacatg gacgatgtca tcgagggcaa 
     7561 cgtcgccaag attcccggcg cacgcaagct cgcgatctgc aacgcccaca tccccggcaa 
     7621 cgacaccgtg gccgagaagg catacgacca ctggcaggac gtacagaccg gtaaagcggt 
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     7681 cgatacaggc atcctgtacg acgcgctgga agcgcctgcc gacaccccgg tctcggagat 
     7741 tccctccgag aaggaggacc cggaaggcta cgccgagggc atcgccaagc tgatggacgg 
     7801 cctgcaggtc gcccgtggcg actcgtactg gctgccgctg gaggagattc tcgggtcggt 
     7861 cctgaacacc cgcaacccgg tgtcggagtc ccgacgcaag ttcctgaatc aggtgaacgc 
     7921 ccacgaggat tcgtggatcg ctcccaccga gtgggaccgg ctggctctga ccgacaaggt 
     7981 gttctgcctc aagaagaacg accggatcac gctcgggttc gacggctcga agtccaacga 
     8041 ctggagcgcc ttggtggcgt gccgggtcga ggacgggatg ctgttcgtcc tcaagacgtg 
     8101 gaaccccgag gaccatccgc acaacgaggt gccccgcgag gacgtggacg cctacgtccg 
     8161 gtcggcattc cagaggtacg acgtggtcgg cttccgggcc gacgtgaagg agttcgaggc 
     8221 atacgtcgac cagtggggcc gggacttcaa gcggaagatc aaggtcaacg ccactccggg 
     8281 caacccgatt gccttcgaca tgcgcggtca gacaaagcga ttcgctcttg actgcgagag 
     8341 attcctcgac gcggtcctcg agcgagaggt ctaccacgac ggcaatcccg ttctgcgaca 
     8401 acacgtcctg aacgcccgcc gacatccgac tacctacgac gcgatttcca tccgcaagga 
     8461 gagcaaggac agcagcaaga agatcgacgc tgccgtctgc gcggtcctgg cgtatggcgc 
     8521 gagacaggac ttcctgatga gtaagaagag ccgcacgggc cgagcggtgg tgatccgatg 
     8581 acgagcccca ccgaacagca gaacgtcaac cccgaagagc ggcttgagcc gctgctgaat 
     8641 gcgttcgagg agaagattcg gcctctcgcg gacaacaccg cctactacga gtccgagcgt 
     8701 cgtccggacg ccatcggtat cgccgtaccg cccgagatgc ggaagctgct ggcgcacgtc 
     8761 ggttaccccc ggctgtacgt caactcgatt gcggaccgac tggagctgga gggtttccgg 
     8821 atcgcaggcg agtccgacgc cgacgaacag ctctgggact ggtggtctgc caacgacctc 
     8881 gatgtcgagt cgacgctggg ccatgtggac gcactcgtcc acggccggtc gttcgtgacg 
     8941 gtctcagccc ctgaccccgc catcgacctc ggtgtggacc ccacggtccc gatgatccga 
     9001 gtcgagccgc cgaccaacct gcacgcggtc atcgacccgc gtacccgcca ggtgaaggaa 
     9061 gcgatccggg cgatctacga cgaagagggc aatgagattg tcggcgcgac gatctacctg 
     9121 cccaacgcca cggcgtactt cgacaaggtc gagggtgagt ggacgcaggg ccgtcccacc 
     9181 gtgaaccacg ggctggagat ggtcccggtc gtgccgatcc ccaaccggaa ccggctgtcg 
     9241 gacctctacg ggacatcgga gatcactccg gagctgcggt cggtcaccga cgcagcggcc 
     9301 cggacgctga tgctgatgca gtcgacggca gagctcatgg gcgtgccgct ccgactcctg 
     9361 ttcggtatca agcgatccga gatcggtctc cccgacgacc cggacgagcc ggtgtcgccg 
     9421 cgtcaggcgt tcgaggcgta ctacgcccgc atcctcggct tcgaggacga gatgggcaag 
     9481 gcgtaccagt tcgacgctgc agagctccgc aacttcgtgg atgcccttga cgcgctggac 
     9541 aagaaggcag ccgcctacac cggcctgcct ccgcagtacc tgtcgttcag ctcggacaac 
     9601 ccggcctcgg ctgaggccat ccggtcgtct gagtcccgac tggtgatgaa ctgcgagcgc 
     9661 aaggcacgca tcttcggtgg ggcctgggaa caggtcatga gggtggccta ccgggtcatg 
     9721 aaccccggtg ccgagattcc accgaacatg tatcggctgg aagcactctg ggctgacccg 
     9781 agcaccccga cgtatgccgc caaggctgac gcagccacga agctgtacgg ccagggcatg 
     9841 ggcgtcatcc cgagggagca ggcccggatc gacatgggct actccgtcga gacacgacgg 
     9901 cagatgcggg agtgggacaa ggaggagaac ccggtgggcc aactcgccgg cctctacgcc 
     9961 ccgaccgaca agaccggggg gtccgagacc ccgaatgagc ctgccgccga ggaggttcct 
    10021 gaggagtgaa cgctgaagag tacgccgcca ggcaggcggt cgtctcggca gcagtcgcga 
    10081 actacatcct ccagataggg aagctgttcc tcgggcccag attgtctgtg caggactgga 
    10141 tcggcttcct gcaggctttg tacccggagg tctaccggca ccgtctggag gccgctgagc 
    10201 tcgctcgcca gttccatgac agcgagcgtc ggcggcacgg aaaggcgttc cagccccgct 
    10261 tcttggtcga gtacgacttc aaggagttcg tgaaggacat ggagccgact cgggaccgca 
    10321 tgtcccgaga gctggcaccc cagtccgctc tgggcgatgt cgcgctgcgg gcagtacgca 
    10381 gcgtcgagaa cgccggtcgg aagcagatca tccgagcggt cgaggacgac tccgagaccg 
    10441 ggacggtcaa gggctgggcg cgagtagcga ccggtcgaga aacgtgcgcc tggtgtctga 
    10501 tgctgatctc acgaggcccc gtgtactcct cagcggagag cgcggggttg gacctcgatg 
    10561 accagtcagc ggcagatgtg ttccgcgcca gcggtggtga cctcaacaag ctcgccgcct 
    10621 atgtcgatga gaacgaactg atgaaggagt ggcatacagg ctgcgactgc aaggtggtgc 
    10681 cggtctacga cagggccaac tggcccggac gggacgcata caagcgtgcc gagcagtttt 
    10741 ggatcgaagc cacaaaggag gctcgtcgcc tcatcgactc aggaaagtcg aagagcgaca 
    10801 acctcaaccg agaggcgcag aacgcgcttc gtcgtcgtct cgaacgaggc gacctttcaa 
    10861 tgacgagatt cgccctcgcg gcgtaactca acaccacgac cccctggtgg ggtccaacac 
    10921 gcccaggagg caaacagtat ggctgacaac gacactcaga cccccgacac cacgccgggc 
    10981 aatgacggag gcaccgacac gggtcaggca cccgcaccgg aggtcttcag ccgggagtac 
    11041 gtcgaggagt tgaggcgtga gaacgccaag gcacgcacct cgaagaacca agcggtcgaa 
    11101 gacgccaagg cagaagtccg caaggagtac gaggccaagc tggccgagaa ggacacggcg 
    11161 tacaccgagc tgcagaacca gctcggagag gcgtggatcg agctggagaa ggtctacacg 
    11221 accatcgacg ccaaggtccc gtctgatcgc gtccgcgctt tcgcggccat cctgcagggg 
    11281 tctgacaagg agtcgatctc cgaatcggcc aagtcagcca agcaactgtt cggcggtatg 
    11341 acgggcaccg tcccggccgt cgatcccacc cagggctctg gtggtggcaa gcacacgccg 
    11401 ctcaacggag acccgatcct cgacgcgctt cgcaaggccg tcggggcgta atccccacta 
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    11461 cgacaagaaa gtagcatcat ggcacaagga accacgttcc aggtcgatca cgcgcagatc 
    11521 gcgcagaccg gcgactcgat gttcaagggc tacctcgagc ccgagcaggc ccaggactac 
    11581 ttcgcggaag cggagaagac ctccatcgtc cagcgtgtcg ctcgcaagat tccgatggga 
    11641 tcgaccggcg tcaagattcc gcactggacc ggcgatgtcg ccgccgcgtg gatcggtgaa 
    11701 ggcgacatga agcccatcac caagggcgac atgacggtca accaggtcga gccgcacaag 
    11761 atcgccacga tcttcatcgc ctcggctgaa accgttcgtg cgaacccggc gaactacctg 
    11821 ggcaccatgc gggtcaaggt cggcaccgcc atcgcgctgg ccttcgatga cgccgcgctg 
    11881 cacggcaccg acagcccgtt cgaccagttc gtggatcaga ccacgaagtc ggtcgacatc 
    11941 accccggccg cgccggccac cacctacgac gccatcggcg tcaacgcgct gtcgctgctc 
    12001 gtcaacgacg gcaagaagtg gcaggcgacc ctgctcgatg acatcgctga gcccgtgctc 
    12061 aacggtgcca aggacgccaa cggccgtccg ctgttcgtgg agtcgaccta cgagggtctg 
    12121 accacgccgt accgcgaggg ccgcatcctg ggtcgtacca cgatcctgag cgaccacgtc 
    12181 gccaccggca ccacggtcgg ctaccagggc gacttctccc agatcgtctg gggccaggtc 
    12241 ggcggtctgt ccttcgacgt gacggaccag gcgaccctga acctgggcac gatggaagag 
    12301 cccaagttcg tgtcgctgtg gcagcacaac ctcgtcgcag tccgtgtgga ggccgagttc 
    12361 ggtctgctca tcaacgacgt ggaagcgttc gtcaagctca ccaacgcctg agcctgactt 
    12421 gacatcgcac ggcggggggc ccttcggggc cccctgccaa gcggaaaggg ccgcatgaag 
    12481 attcgcaaca aggacaacgg cggcgtagcc gaagtcaccg aggactacgg caaggccctg 
    12541 atcgagctgg gccgctggga gccagccgac gccccgaggc gtcagcgggc caagaagtcc 
    12601 tcccccaaac cgccagagcc agcaccggcc gaggcccctg aacccgagac ccccactgag 
    12661 gtaacgacca ccgaggagta agacatggcg attgcgactg cacaagacgt tgagaatcgc 
    12721 tgggtccgtg agctctccga ggaggagacc accctcgtca acacgcggct gaacgacgcg 
    12781 gagcggatgc tcaagcgtcg gatcaagaac ctggacgcgg tcgaccccga ggacgtgaag 
    12841 caggtcgagg ccgacatggt ccttcggctg ctccgcaacc cggagggcta cacgcaggaa 
    12901 acggacggca actacacgta catgctgagc caggcgctcg catccggaaa gctggaggtg 
    12961 cttcccgaag agtgggaggc gctgggcatc cggcgtagtg gaatgttcgt cctcacaccg 
    13021 acattcgaga tgccgacatg agcgccagcg accggcagcc gcctggtccg tacccggaag 
    13081 ggttcacgga ggcggttcgt ccggaggacg ttgacgtgtc caagtgcgac cacgagttcg 
    13141 gcgtgtgctt ctgcgtgcat gactggcgca ttcactgggg caacctggat cggagcggcc 
    13201 tatgagcctc ctcgatcact gcccggacga cgtgatcgtc tacccgcagg tcgtcacgac 
    13261 cgacgacgac ggcaacacga tcaccaagcc gtccgacgag ggcatcccca cgaaggcgcg 
    13321 gctgcaggtt ctgggtcagt ccggtacgtc gtcccgtcgc caggagcagg acaacgaagg 
    13381 gttcgagtcg gagcgtgtgt acacgatccg gttcacccgg aagttcgacc gcgagcacgg 
    13441 cattctcggg atgcagtcgc aagtcgagtg ggaaggcgtg cggtgggctc tcttcggtga 
    13501 gcccgcgtac tacaactcgt ctcgtcgtac ccggcacatc acctacacgg tgaagaggta 
    13561 ctgacatggc gaagctgatt ccccgtcgca ggctgaacca catcgtcgcc catctcgcgg 
    13621 agacgaaggc ggcgatccga cgagaagcac gcgaggtcga aggcagggct cggcgcaacc 
    13681 tggccgaggc acgggcatca acgacgcact cgaagatcgt cggtcccggc cacctgacca 
    13741 agatcggttc tgccgcagac gatcccgacg tgttggtgta catggacgcg ccgaacccga 
    13801 tggcaatcga gtacggccac ggtccttccg gctacttcga cccggacaag tacgggaagg 
    13861 tcacgaaggc cccggcaggg ctctacatcc tgaaccgcgc agccggtatc gccggctcga 
    13921 tggtgacacc gtcgatgggt aggaggggcg tgaagtaatg acgttccccc gtattcagtc 
    13981 ggtggtgatc ccgctgctgc gggatgcact ggttccggac aaggccaaga aggtcggctc 
    14041 gtggatcgag aacatcgact accgcgagtt ccctctggtg aacgtccgac gcatcggcgg 
    14101 cggtcgtcat ccgaatcgac cgacgcaatt cgcaacgccg gtcatcgaat tgaccgtcta 
    14161 ccacaccaag gggctcatcg agtgtgagca gctctacgag gactgcctcg acgtgctgta 
    14221 cgacgccgtg aagacccaga agcagacgcc caagggctac ctgcactcaa tcagagaaac 
    14281 gatgggcgct acgcagttca gctcgccatt catggactcc tggagggtcc agggactgat 
    14341 cgcattgggc ctccgacccc ctcgcaacaa aggagtaacg ccaaatggca cttaacgacg 
    14401 aagcggtgtt gaccgctgca gtcgggtacg tctacaccgg ccctgtcggc acggccgcgc 
    14461 cgagcgccgc cgagctggac gacctggacc tggaatcccc cagctcctgg accgccacga 
    14521 gctgggacag catcggccac acgagccggg gcgacatgcc cgagttcggc ttcgacggcg 
    14581 gtgattccga gatcaagggc acctggcagc ggaagaagct gcgtgaggtc acgaccgaag 
    14641 acccggtcga ctacctgacg ctgttcctgc accagttcga tgaggacgcg ctctcgctgt 
    14701 actacggcaa gaacgcctcc accacggctg gtgagttcgc ggtcagcggc aagtccgatc 
    14761 ccaccgagaa ggcgttcttc gtggtcatcg aagacggcga cgttcgtatc ggcttccaca 
    14821 gcgccaaggc gtctgtgaag cgcgacgacg cgatccagct cccggtggac gacttcgcat 
    14881 cactgcccat ccgggcgacg ttcctggatc accccggttt cccgctgttc aagtgggtca 
    14941 acgaggacct gttcccgaac gtacagactc cctgagtctg acttgacatc gcccagagcg 
    15001 atgtccgagt gactaggggg gaggggttta ccttggcggg ccttcccctc cccccgctcc 
    15061 accactggcc cgcctaccca acgaaaggtc cgctatgtca aacgtattca ccctcgacag 
    15121 cctccgagag gaagccgaca agcagttcgc tccgttcaag gtgcggctca gcgacggcac 
    15181 ggaggtcgtg ctccgcaacc tgctgcggct gaacaagaac gaccgcaaga cggtactggc 
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    15241 gagcatcgag gcactcaaga ccgaagacga atcggaagag ggtcgcaccc tcgatgacat 
    15301 cgaccgcatg gtcgacaccg tctcgaagat tctggagctg gcagcgggta aggattcccg 
    15361 caagctgctc aaggagctcg acggcgacct cggtctgctg atgggcgtgc tggaaggttg 
    15421 gctggaggcc acctcaccgg gggaagcgca gaactcgccg gcctgatcga caggtacggc 
    15481 gagcatctcg tcccagacct caagcactac tacgggattg acctccggga gttgttctcg 
    15541 gaggccaacc cactcagccc ccagtacgtc ctgatccaca tcaagcatct cccgattgag 
    15601 tccgcgttcg tggctgcgat ccgtggtggg caggagttcc gtggatggaa cgccgaccgc 
    15661 tacgcactgg ccgcgatcat caacagcatc cgtgctggca actacatgtt cgtcatggcg 
    15721 aactcggacc cgaggaaggg caagccgccg cttccgagtc cgtggccggt tccccaagag 
    15781 aacaaggccg agaagaagta cgcacccaac tcgttcgccg gaatcgttgc ggcgcaggtc 
    15841 attgcggcca ggaagagaaa gcagcagaag aaggaggctg aatggcaggc gcaggaggcg 
    15901 tcgaagtcgg ccggatttct atccgggtcg tcccagacct cgacgggttc taccgagagc 
    15961 taaagaccaa gctcgaaggg atcgagaaga cccttaaggc gaagatcaag gtcgaacccg 
    16021 acatggacgg gttcgccggg gtggtcgccc agaaggcgaa gaacctcaag gccaaggtca 
    16081 agctggacgg cgacagcacc gaccttcaga aggcagtcga cgcggtaaac gcgaagggcc 
    16141 cgaagaagat caagctagag ctcgaccccg agttcgacta ccggctccga cagcggctgg 
    16201 cgaagctcaa gcccaaggtc gaagtcgatg tcgacttcaa gcgagggatg ctcgaccggc 
    16261 tctccaacag tctgagcaag attcagatgc cgtcgttcgg ctcaggcatc aacccgatgg 
    16321 gctgggcggt catccttgcc ggtgtcgcgg cggtcacgcc gctgatctcc ggtctgctgg 
    16381 gagcgatcac cacagccatc gttgcactgc cggggctgat cacgtcgatc cttgtgcccg 
    16441 tcgccgcgct ggcgctcggc atggacggcc tcaagaaggc agcggaggtc ctcaagggac 
    16501 ccttcgatga cctgaaggcg acgatgtcgt cggccgtcga ggagcagttc acgccggtct 
    16561 tcgagaagct cggaacgatc ttcccgatgc tcaaggaggc cctgcctggg gtcactgacg 
    16621 gcctggccgc gatggcgcag tccttcgcgg acgcggtcac atccccgcag ggtatggaga 
    16681 aggtccgggg tgtcattgac gacatcgcga atgcgctgaa gcaggcagct cccggcattg 
    16741 gcgacttcac caccggcttg ctggacctcg tcaaggggtt caccggcaac ctcccgagcg 
    16801 ttgccgactg gttcaacgac acgggtaagt cgttcaagga ctgggcgaaa gacttcaccg 
    16861 agaagggccc ggacggcacg tcgaagttcg accgtgcgct cgagggcctc ggctggacgc 
    16921 tgaaggaact cggcggtggc ctggtcgaca tcggcggcaa ggcgttggac ttcttctccg 
    16981 acccggagaa gatcaggtcc ttcaagaccg agctcgacgg agtcgtggcg acggtctcga 
    17041 cgctggtcga cctgtcgaac cagctcgcgt cgaacatgtc gaagattccg ggcttccggg 
    17101 acggcgaagc gaacggtccg atggacttcg ctcccatcca gattcagctc atcaaggagc 
    17161 agttcgacaa gatcgactgg tcgggcatct ggggcaacat gaagtccact gccgcaggcg 
    17221 cgttcgctga agtgacgatg ttcgcggcca acaccgcgat caccatcggc gcgaagttcc 
    17281 ggggcatctg ggatggcatt tcgaccaacg ccggaacggc atggaacggt gtcgtcacca 
    17341 tcgtcagtgg cgtcatcgcc aacatcctcc ggatagctgc ccagcttccc ggccagatcg 
    17401 cgtcggtgtg ggcgaacatc ccgtcgatga cggctggcgt ctggaacacg gtggtctcga 
    17461 ctgccgcccc gatcatcacc cagattctca cgacgttcat caacgtcggc gtgggcgtga 
    17521 tgaacgaggt cagctcgtgg ccaggcaaga tcgttggggc ccttggcagt ttggcctcca 
    17581 cactggctga gatcggctcc agagcggcgc aggcactcgt gagtgccctt gctgccggta 
    17641 tccgtgcggg catcggtccc atcggccagg cggtcggcgc tctgatgagc gcggcgcgtg 
    17701 cgctgatccc gaactccccc gccaaggagg gtccgttctc gggctctggc tggcgtgcgg 
    17761 tcgaaggatt cggtgacgcg ctgggtgacg ctctggcgag cggcattccg ggccaggagg 
    17821 acaagatcgt ctcgaagatt cgggcgatca tgcaggccat caaggatgtg ttcggtgacg 
    17881 cttccaagct gaacctgaac ttcaacttcg gctccctgga gtcggggctc aactccgtcg 
    17941 cgagtgcagc cacggatacc agtcgggccc ttggcaatac ggtcagcggc gcgatgccga 
    18001 acaagctctc cgacgaggct aagcagcaga aggacctgct ggagctcaag aaggacgagc 
    18061 tcgaagtcga gcgtcagaag ctgcagaacc agaagaacgg tctcgatccg aaggacaagg 
    18121 cgggcagggc tgctatccag cagcagatcg accagctcaa cctccagaag aagcagatcg 
    18181 acctggaaaa ggagcagctc gactacgccg gcaagtacac cgatcaggtc gctgagaccg 
    18241 actcggtgat gggcgacatg ggcaagaaga tttacgacgc cacaaagaat gtcgctcaag 
    18301 cggccagcgg acagctcatg tccgatctcg gcatcagcgg caacggtgcg ctgtctcagt 
    18361 tcctcgagca gggcctcgcc ctcggtgagc aattcatctt caacgtcggc tcgatggatg 
    18421 acgcggtcgc aggccagcag accatccaga acaagaaggc gttgcaattc gataggaggt 
    18481 aacccgttgg acaccctcgt ggagcttgag ggagtcaacg gcgaatggtt caccctcgcg 
    18541 ggccccggtg aaggggaccg tggggtgtac ctgggtaccg acgtgaaggg tctgtatgac 
    18601 ccgcccgtca aggtggtata cgaggagccg gggaactacc ccggcgctcg ttacctcaat 
    18661 caccgtattc ttcgccgtga catcaccttt ggtgtcgaga ttctcaacga cgctgcgata 
    18721 ggacccaact cctggttgag ccgggagtca gagtggcgca aggcgtgggc gttcgaccgc 
    18781 gactgcaagc tctacatcac gaccccggag tccggtaccc gctacctcaa ggtgcgactc 
    18841 ggtgagtcgc ccgaggtctc gtggttcacc gatccgcgtg gcaacaagat caaccgcaca 
    18901 gtcatggtcg tcatcgcagg cgacccgttc tggtaccagg acgatgtcgt gtactcggct 
    18961 gtgacgcaga cggatacgac gttcgacccg aacccacttc cgtggccgtg gccgcaggag 
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    19021 gcgctgccga ctgagacgct gtccatcacg gtcgacccgg ccgatggcaa gggcgggctg 
    19081 aaccccaccg accagtactc ctgggtgaag tggattctgc ctggctcgac tcaggtcccg 
    19141 gcagagccct acgttcccgg catcccgtgg ctgggggctc ccaagtcccc cgccgtcatc 
    19201 tggacggtcc cggactactc gttcgaggac gagtcactga gcaaccggcg tgtccggatg 
    19261 cccggtctga tcggcggtct ccggacggcc gaggttcaga tcgtcagcct gataggcgat 
    19321 cccaagagcg gcacattcaa gctcggtcgt gacagttcct tgacatcgtc catcgcgtac 
    19381 aacgcgacgg cagccacgat gaagacgcgc ctggaggccg tctacggggc gggcaacatc 
    19441 cgggtggacg gcggtccgac tctgttgagt ccccgccagc cgtggcgggt gtcgttcatc 
    19501 ggtgccctgg cgggctcccc gcagcccctg atgctcactg agagctctct cggcaacggc 
    19561 ggcagggttc aggtcacccg agcgacggaa ggcgctacag cgcccgctga gaacgctctg 
    19621 atcgacacgg acccaaggga agagcaagtc acttcggaga acggctcgca gttgtgggcc 
    19681 cggatgaacg gtgtccggtt ccggcacccg atcccgccgt ggactaagtc cgcgacgttc 
    19741 gagctgacgg tctccggggc ggttcccggc cagatggccg tgctccgcat cccacgagcg 
    19801 tggacaaggc cctgggggtt ggaatgagta cgagcaccat cacgtcgctg gaagacgctg 
    19861 agcgcgtctg gaataccgcg atggcccgca gggcactgcg ggagcaggaa cggctcaagc 
    19921 ccgtcctgac gcggttgtgg gacggcgaca tgcgccttcg ggggcatgtg gccggggagc 
    19981 gtggtggtga cttcgagttc atcgaaaacg acaccggcac agcctctctc cagctctcgc 
    20041 tggatcacca cctggcgaag tgggtgatga acttccgtgg acgcgagaag cggaacgtca 
    20101 tcgtcacctt cgacaagcag ggtgcccggt ggtccgggtt catggatcac taccgcgtgg 
    20161 tccgtgagga gaacggggat gtctacctcg acatcgtgtt caagcacgat tacgagcagg 
    20221 ccaagcacat cctttgctgg tgtaacccgt tcctgaggcc agaactgcag ttcccaaagc 
    20281 tgtggatcat cttcggaccg gcgaagtggt gtttgctgct gaccctgttc gtcaacatcc 
    20341 tcaggctgga aacgagtctc tggacgcttc cggacaaccc gctcgatccg accgagtgga 
    20401 tgccgctgag cttcaacatc tccaactgga ggaacatcgt caagccgttc ccgctcatcg 
    20461 gggacaactc caacctgacg atggtcttct cgcgcttcca gtcgttccac gacatcgcga 
    20521 agtcgacgtt ggaggacgcg cagctcacca tcgtgtgtcg gcgctacctc aagggcgagg 
    20581 accctcaccc gttcgaggac ctgcgtgggg agctcaacat cggtccgctc gaggacctgt 
    20641 tgtcgctcat cccgattcgg cacggctgcc tggtctggga catcgtggac aactcgggct 
    20701 ggggctcgga gacatcgttc ggtggctcct ggctgaccgg cttcatccgt gcggtcgtga 
    20761 acatcgcgag cgacggcatg accgagggtg tcgacgtgtt caccggagac ccgacgttcc 
    20821 ccggcgagta ctacacgccg tggttcctgg ggacctctcc gcaggctccg tggatcgtgt 
    20881 tcgaggaggg tccgtacacc gggatcaaga gctcggagtt caagtacttc gaggcgaccg 
    20941 acaccagctt cgtcgctggt ggagagtcga tgcccggtgt gaacgagggc atctcggctg 
    21001 gtgtgaacat gggcggggac ttcctcacct cgatgatcaa ccaggcactc ggcgggttca 
    21061 tcgacctgcc gccgctgggc ggcacgatgg acgcaatcgc gaagccgttg tacgagaacg 
    21121 tcttcctggc cttccaggaa tggccgactc tgcgggcgat gggctctccc atcccgatcc 
    21181 ccttgctgga ggcatcccag aacggtctgg gcgacttcca ctactacgag ggttgggtgg 
    21241 agaacgccac caaggcgttc accctgtcag cgttcctcgc cacgagggcg aagatttacg 
    21301 cgaccagggc gcacacggcc cacaccatca aggtgtccga cgcggctccg tactacgtcg 
    21361 gtgagccagg ctacggccac ttctggctcg gatcacgagt cggtacaagc gttctcgggt 
    21421 tcccgatccc gcacaccgtg ttcgtagaac gggtgtcgaa gatcagctac tcgtggggcg 
    21481 ctgacggccc gaagggctgg gagctcgaca tcggttaccg cgacccgaag gacccgctgc 
    21541 tgaagctctt cgagctcgtc atgaggttca acggagcgat gggccagcta ggcattctgt 
    21601 aacgaaaacg aaaggcacgc cacatgatta agccacagga agaagtcgac tggaacaagc 
    21661 ccgaggagca cttcgcttgg gccctccgca acatgccgat gctcgccggc gtcggcgcag 
    21721 tgacccatcc ggggttcctg gtgcagtggt cgaaacacct gtgggagtgt ggcttcgccc 
    21781 accgcgacta cttggagcgg cttgctgatg aggacggcaa catccatgtc agcaagctgc 
    21841 ccaagcagcg cattcgttgg caggccccct tccggggccc gagaagcaac tacaacaacg 
    21901 cggcgcgttg ggtgtcgaag aacaccccgg ctccacagcc ggtgcggctg ccggatgtct 
    21961 cgaagatgac ccagcaggaa caggagttca tgttgggcca gttccgagag ctcggtctga 
    22021 tccaggacta catcccgcag cccgacgtgg cccaagaact caacgactag gacccgcaat 
    22081 gacattccgc tatgtccccg cttggggact gagagggttg cagctcgctg tgcttttcga 
    22141 ggcagcgatg cgggggctga tgtacctgct gatgccccag atggccctgt cctcggactc 
    22201 actgaccgag cttgaacgga gtgccccgct gtacgtgtgg gggctcgtgt ttgtcgcagc 
    22261 ggctgcgttc gggctgttcg gtgagacgct gatgtcaggc accgagaact acatgggttc 
    22321 gagcagccag aacaacccgc gagcgtggcc gtcgttcgtc gcccacgccg cactcatgat 
    22381 cctgtacgtc acgctggcgc tggcctacgg cgcttcgctc tacgacgctg gtgcggcgca 
    22441 cttcgccatc atcccctacg acctgttgat gatcgcctac ctgcactggc tcttcgcacg 
    22501 gaggcgcaag tcgcatgtcc actgagattc tgcagtacct gccacagcag tgggtcggtc 
    22561 tgttcgccgt catcatgttc atcggctaca tcacgatgca ggtcatcgag aagtacccga 
    22621 cgttcgccaa gatcatgccg ttcggcacct ggtggcacga gaggcagaag accaagcgcg 
    22681 gcaagcgcaa cgcatgggtg gccgaggaca acgaggtcat tcaggctctg caggctcagg 
    22741 tttcagccat cgccgccgac ctggcggcag tcaatgagaa ggtccggacg ttcaccgcgt 
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    22801 ggtcggtcta cgacgcacgc tggcaccaca aggtgtcggt cacatgggct ggctctgaga 
    22861 cctgcctgct gccggatcac ctggactact tcgctttcga gcggctctgg cgtgacgacc 
    22921 ccgtcggggc atcgagactg tgattggagg taatgcgtga ccacaccgca ccagattccg 
    22981 gaccagggtg tccttgagaa gtggctcggc agcggtgctt tcgagctcgg tggcggtgat 
    23041 tcaagctggg gccaggacta cacggagaac gccgttcggg cgttgttcga ggtccccatc 
    23101 ggctctgtgc tcaccgcgtt cgatgttctc gaagagcagc tcctcaagct gccgctggaa 
    23161 gccctgaggt acttcaagcc gctgatcccc ggtgccacgg agaacgactt cgtggacgtg 
    23221 tacacggcgg tcgcgaagat catcgacaac ctgaccgacc tcccgatggc cctgttgaag 
    23281 ggtgagttcc tggagtggct cggtggcacc tacgcggtgc tgtcgaccga ggtcaggcag 
    23341 atactcgaga ttctgtccgg gttgatcgtg acaccgatca acgccgccgt ccaaggcgtc 
    23401 aaggactggt ggaacctgat caccggcaag acatccaagc tgggcacaga cggcaagctg 
    23461 gcggctgacc agttgaccgg cacggtgccg accgacaagg tcggcggctt cggcgggacg 
    23521 gccaacctcg cggacggtct gaccacgctg gtcgacaaca cggtgaaggc cgcaggcaac 
    23581 atcctcggat cgggcttcgg cctgcaggac ctgttcgact ccctcaaggg gatgcagtcc 
    23641 aacatcgcgg acgccaacgc ggcgctcgcg cagcttcagg ccgactgggc gggcagtgtc 
    23701 aactcgggca agaagttctt cgtcaacttc ggtgacttcg acaacgccaa cagcgtcccg 
    23761 tcgatcctca ccgaggtcgt caacaccggg cccggttcgg tagcgactgt cgatggccag 
    23821 ctccagtggc tggactcggg caacgcattc gcgcagcgga tgtacctgta caacgtcgag 
    23881 ccgttgatgg acgactactt cgaggtccag ttcgtgatgc cacggcgctc ggaggacgag 
    23941 ctcttcggct tcgccaaccc gccgtacaac tacgccatcg gccggtcgaa cgcctcgggc 
    24001 tcccgcttct gcttcgctag ggtgggctac caacgcgccc gcatcggctg catggtcgac 
    24061 ggcaccatga cgctgttcgg cacccaggac atctcgtacc aagcgcccgc tggcgctcga 
    24121 atcaagttcc gtggcggcac atctggtggt gtccgcgtgt tccagcttct ggtcaacaac 
    24181 cagatcatcg gcacggtgac ggataccggc aacgtcagct acgcaggtgc gggctaccgg 
    24241 atgatcggca tcggcttcga ggcgcagcct cgcggtaacg ggcagggcac gccaggcacg 
    24301 atctcggcgc tgtcggccaa cgacaacacc ccgcaggcgg tcgtcggcac gtccttccgg 
    24361 gcgtaccgag cggcgacagg ctcgatcagc aagggctcgg gtgcgaacgt gctcccggcg 
    24421 aactgcatcg acacgctcga ccacatcagc agcgacctga cgtggacgcc ggcgactcag 
    24481 cggctcacct acaacggtga gcggccgaag acgttcctcg tcggcatgag ggtgaagtcg 
    24541 aactcgatca tcccctcggg tggcacctgg cgtcaggtgc tctacaagaa cggcagcctg 
    24601 tacgccaggc tcgaaggcca cgaaggcatg gtggacactt cgaccaacaa cgacaacgag 
    24661 aaccgcctgt ccttcgtcgg cggcggtact ccgatggttc agatgaatcc gggcgactac 
    24721 atcagcttcg ggttcgagaa cacctcgtca gtcggcatcg tcggctccgg tgacggttcc 
    24781 cagacatggg tgaacgccat cggtctcgga taacaagaga gcccccttcc caggacccca 
    24841 cggcctggga ggggggcttt tttgcgtttc aggggctacc ggtagcggtt cgccatcagc 
    24901 gcccacaccc acgtccacat ggctgaccag aggaacccga tcatgacgaa gatcgaggtg 
    24961 ccaccggtca cgaagagcag taggaagaac gcggtcggga accccgacag gatcgagagg 
    25021 gtgaggaaca gcgggttggg cgcgggcttc cgcttcgacg gtacggggta ggggtatggc 
    25081 accggatttg acatgacaca caccctggca taggcgatgt caaatagcca ggtcaaccgc 
    25141 cacgcggtcc tggggcacga cgacctcgat gttccggggc ttgttcgagt agaggatgaa 
    25201 cttgaccttg gcgtccttca ggagctgctg gtggtcctcc gtctcccacg cttccccgta 
    25261 ggtctggccg gtggtctcct cgacccaccc ggccgaccgg cgaggcatcg cctccagctt 
    25321 ggtgcggcga gtgatgagag acctcatgcg ctccaggtag attcgctcgt cctcgtcgga 
    25381 gacgatcagg cccgcgtcgg actcacggcg caggcgggcg atggtctcgt tgatctgctc 
    25441 cagctcgtag gtgtggtcct cccccggcac gaacacgcgc cgggtgaccg gctggtctgc 
    25501 ccactcgtag aggaacgcct cttccaggag ggtgtcggcc tcgtcggcca cgatgaacac 
    25561 gccgtcgcag ttgaccggtg tccgagagca ccggtagtag cggtagacga cggacttgtc 
    25621 ggacttcttc cgcgagtgct gctgggccag tgtcgctccg cacttcccgc agatgcctat 
    25681 cccgagcata gggttcttgg tgtggacccg agagcgcggc gcttgctcgc gcagcgccac 
    25741 ggcgtcctgt atctgcttcc aggtgtccca gtcgaacgtc ggtggggcga ggacgatctg 
    25801 ctcgcccttg tcatcgagga cgggcttggc gtgcttcccc ttccccgtca tcttgatgcc 
    25861 ctgggtcttc aggttcgtga gtgcgtcctt gaccgtgctg acgttccacg gcgcttggtc 
    25921 gatgggcttg cccttcgcga gcctcgcacg gctacggctg ccgaggacgc ccctgtcgtt 
    25981 caggtccttg gcgatcccga tcagcgacca gccgtcgagc agcttgccgg ccatgtcgta 
    26041 gagcacggcc ttggtgtctt cgtctgtgtc aagtccaaac cccttaccgc tcggatgcgg 
    26101 gacggtcttg tacccgagtg gcggcagccc ggacgcccag cggtcggtct gtcgcagcac 
    26161 cctgtggctg tcctgggccc gcgacttgaa ccggttgagt tctagctgag cgaagaacga 
    26221 tccgaggtag acgaacagct cggccatcat ggcgtcgatg cccttggcag cacctggccg 
    26281 gtagtccaac cgcaggttgt cctccgcgaa catgacgacc ttctggcgct cctctgccca 
    26341 ctgtgcgaag tcaacacagt gcttggtgga tcggaatgcg cggtccatct tcgaccagac 
    26401 gatcacgtcc cacttcgagg caccctcgtc ggtaagccac ttgccgaggt ccggtcgctc 
    26461 gtccggacgc acggacgccg agaccccgag gtcctcgaac gtgccaacga tctcgtgccc 
    26521 ctgggcttct gcccacttgc gggcggtctc tagctgcgct tgttgcgaga ccttctgcgg 
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    26581 tccttggact acactgactc gggccccgac cagggctctt agcggttgtg gcatagtttc 
    26641 caatgttaca ggaactgctg gcagaatcca acacattgga agtcgatgag aaaggacccc 
    26701 tcaccagtgc agatgctatc cccagtcaga gtggcgacgg ccggaacggt cgcggtcggc 
    26761 ggcttggcct tcgcgttgtc gttcacggcg ctcagtgagc tctcagcgga caacggagtg 
    26821 tcgcaggcgt ggatggtccc cctcgttgtc gacggcggca tcatcgtcgc cacgacggcg 
    26881 actctggctc tccggacgca gtggtatgcc tggacattgc tcatcgtcgg ctcgctcgtg 
    26941 tcggtggcgg ggaacgtggc ccacgcgagc ccccacggag ccatcgcgat ggtgatcgcg 
    27001 gccatcccac cgttgtggct gctggccgca acgcatctga cggtcctcct ctaccggggg 
    27061 actcaagaaa gtcgctcagc gtcgatctca gagcctcttt tttccagggc ttttgcggaa 
    27121 aacgctgctt gactgcgccc gaccggtgaa acgacaaaaa agcccccagg cagcccagtt 
    27181 tcagggctgc ccaggggcga tttgttactc gatggttttg ccgacctcat cccggaggtt 
    27241 gatgaagccg agccgccagg gctcgtcggg gagcatcccc ggttccatcc ggacggtgta 
    27301 ctcgttccgc tcccagcggt cctgctcttg caccacgatc ttcgggagct tgctgcacgg 
    27361 atcgcaccac ccgtggtacg ggtcggtggg cccagcacac acgcagcctt ccggcttctc 
    27421 ccactcgaac gggtacacca ctcgctcgat gccggcggcg tcgatcagct tcgagcagtc 
    27481 tccgcagggg gctctggtga tgtagagagc agctccgcga aggtcctctc tatcgcagta 
    27541 gagaagcgcg ttagcctctg catgtactgc gacacaacgt gtccctcccg agctgtaact 
    27601 atcgacgcca ggtctggcgt tactcgttcg acgtggacac gtcccgcaac caggacggcc 
    27661 agcaggggct ccgttgtatc cggtagcccg aactcgtcgg tccttgacga cgactgcgcc 
    27721 aaccttgctc ctttcacagt cagaccgctc ggcagccgcc cgagcgatcc cgaggaagta 
    27781 ctcatcccac gtcggtctca tcgcggcctc cggggcaccc agggccccac gaggggctcc 
    27841 aggttcccgt tcttgtatcg gacgaacacc ccgccagtgc cgttggcacg ccccccgtag 
    27901 cggaagacga caggcgtatt cgcggatcgc ggtgtgtcga atcggtgctt cgccatcaga 
    27961 agaagatcgg gatgccgacc gggttcccct gcaccggcat gaagatcacg ccgttgggcc 
    28021 cgtcgtagtc cgagccgccc gagtcgcctt cacaggcggt caggccgagg accaaggcca 
    28081 ggagcacaag tgcggtaacg agtttcatcg gtttcctctc ggttttctga gacccatcgc 
    28141 ggacgcccat gtccgcttgg gcttcggtgg gggtgttggt tcgggctcga tcaggaccgc 
    28201 ccggatgctg acgctgatgt cggctctcgc tcggccgtag atgccgtagg gcacggagtt 
    28261 gaactcgatc cgaggctcct cgaggacgcc gaactcgcgt ccgttgaagt gcatgatcgg 
    28321 acggcccttg tcgtcctcca cgatctggag gtagacatcg cctgcgctca cagcagcgcg 
    28381 tccagggtga tcgggacacc gaagccgacg atcaaccacg ccagcaggta cagcagcacg 
    28441 atgaccccct tcatgccgct gtccagtaga tgacggtgcg gttggtgggc tcgtacttgg 
    28501 cgcggtggga ctcgaccacc aggccccgct cacggagccg gaagacggtc ggtgtcaccg 
    28561 agttgatcgg caggtcaagc agtcccgcca gttcgaggtt gcacagcggc ctcccccgct 
    28621 gcagccacgc cagggcctca acctcccgct tggggaggag aggcttgatc tggtggtacg 
    28681 actcgatgct ggttgcctgt acggtcatcg cccgagttcc tttcgtagtt cggcgttttc 
    28741 gagttcgagc tccgcgatcc ggcactcccg cgagtcgcgg tcgtagtcgg cgttgtcggc 
    28801 ttcgtccaga gccatgtgga gcttgcggac gaggtccgcg aggcagccgt ggagaccagc 
    28861 gatgaagtca gcgtcttctt ctcgctcgaa tgaagcgatg aacttacgct cgttctcctt 
    28921 gtcgacggcg agcacgagga aggtgccggg gcccccggcg tagtgctcgg tgtcctcctc 
    28981 gaccatccag taggtgtcct gtgcccctgt ggttttcgac cactgctggt acagcaggtc 
    29041 gaagaagtca cgatcctcca cgtaggattc ccttctcttc gagctcggtg atggctgcct 
    29101 ccacgacgct ctcgatgagc gtccggatcg cccagttgcg ttcgacctgg ctcatgttct 
    29161 ccacgccgag cgcgagcttc tggacggtca gtcggtggtt ctccccgaac tccgggatgg 
    29221 acgactgatc cggcagggtg atgtacagct cgaccgtcgt tgacggcggt cgcagcggtg 
    29281 cgatggccgg ggagtctccc tctcccccgt gcatccactt catgggcgct tccccacata 
    29341 cggcatgagg tctgccacga accgcaggaa cgtcagctcc ttcggtgcgc cagcaggttt 
    29401 catcgcgtcg gggatgaggt agacctcgag ggccccctcg ccgctgagcg gatgcggcat 
    29461 gatcgtcccg agcttgttca gctcgtagat ggccttgccc atcagttcct cggtcagccc 
    29521 gtccggagct ggcagtgcga ctgcagcctt cacggaagca ccccctctgc cttgagtgct 
    29581 tccttcatcg ccgcgacggc ggcgtcgtag gccaggtcca cgaagacctc gttcagccac 
    29641 aggcggtcga tgaccgcctc cgctgtggcc gtgcgcttcc cgttctcgac ggtcagcgtc 
    29701 agcttgattc catccatgtg tcctccttgt gcgatgtcta gtagttggcc ccgtaaagcg 
    29761 agccccacga gcgaccgccg acctccgggt cggtgccgat gagcaccggg cccatctgtt 
    29821 cggccatgag ctccccgatc cggttcgctc cccactccgc ttgctcggcc ggaaccgacg 
    29881 ccagaatctc gtcgtggatc ggaagccgaa ggtacggagt gaatcccgcg tcgtgcagcc 
    29941 tcagcagtgc cctacaagtc acgtcgcgag acgacgactg gatcaggtag ttgagtgctg 
    30001 agtaggcacg ctgcgggtcg accggcagtc gccggcctcc cagcccgtcg atgaacggtg 
    30061 tggtgatgta gccgttccgg atcgcctcac gctgcagccg ttggctgagc ttctggacct 
    30121 ccgggtatgc ccggtcgaac cccgcgacga ccttctgggc cgtcgccatg tccagtccgg 
    30181 tctgctcggc cacggtcttg gcaccgccgc cgtacacccg gccgaagttc accaccttgg 
    30241 cgtacttccg ctccgggtca tccttctgga tgtgctcacc gaacgccgcc ctggccgtca 
    30301 tcaggtgaag gtcagcgtcg tccaggaacg cctggatcat ccgctggtcc ttcgacagcg 
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    30361 ccgcgagcac gcggagctcc tgggcctggt agtcgaccga cgcgatccgg tgcccctcgt 
    30421 cagcgaggaa gcagcgccgg attgtcgagt ccccagcagg cagcgtttgg gcaggaatac 
    30481 ccgttataga catgcgggcc gtccgcgcac gcaaagggtt gatcgctgcg tggcaacggt 
    30541 tctgggagtc cctctgcttg aggaacccgt cgacccatgt tttcctccac ttcccggcct 
    30601 tcttggcctc gatgaccgcc gtcgcgaact ccccggcctt ctcgtgctcg gtcagctcgg 
    30661 agagcaccgc gtcgtccacc ttccgcttgc cggatggtgt gcggcccttg atccggacgc 
    30721 ccatcgactc cagaacgtcg gccacctgat cagtcgagtt gaccttctcg cacccgtagt 
    30781 tgagcgcgat ctcgttgtag tggctctcct tgacttggag gtccagcgac agctcctcgg 
    30841 tgtactcgac atcgagcagg aagcctgtcc gctccatgta cgagcagatc gccgcgagct 
    30901 tgtgctcgtt gtccaccagc tcgtcggaga ccttcaccag cggtgcgagc ttctgaatca 
    30961 gccgcgccgc gaggatcggg tccatgcccg agtagagctg gtagtgcggg tcctcgaagg 
    31021 ggaccttctt ccagacgttg accttcgtcg tcttgttcgc cttggccagg tcggccatca 
    31081 gcgtcttgac gttgtcggcc accgccgagt cgatgtagcg acgtgtcagg tcctccagcg 
    31141 agtgaccgga gccaccttcg tccttgcccc tgggatcaat caggtgagcc aggatgcggg 
    31201 tgtccttgac cttcggccac atggtctcca tcgggacgcc cagcgtccgc tcgaagacct 
    31261 ggaggtcata cgctgcgttg tgcaggacga acccctggac catctccagg gccctcttca 
    31321 cgtccccggc gtagggtcct ccgcgctcaa ccgggacaac ccaggcttcg ctcggagtac 
    31381 cgaactggac tagacggcaa cggaatccgt cgttgtagat gtccagcccg gtggtctccg 
    31441 agtcgagtcc gaggaacccc tgatgagccc ggatgaagtc catgaacccg tcgagatcac 
    31501 tctccctgtc cacgacgttg atgacgacct cgtcaccgtc cacttcatgc cggtgctcga 
    31561 tcatggtgct cctatcggtg gtactgcccc cggacgatcc gggagatggt ggatgggttc 
    31621 acgtcgaagg accgcgctac gtcgcgccgg gacacgcccg ctcggacgag gtccttgatg 
    31681 aacgcgacct cggtcttgtc caacttcgga cggttcggtc gattgggacc cttggtctcc 
    31741 aacttggctc gcagctctcg gttctggcga gcgagctcct cgcgctgttc ccacagcgtc 
    31801 gtgttcgagc ttgcgagagc gtcgatggac agattcgctt cgcgcagagc gcgtttcagt 
    31861 tccttctttc gcatcagatg ccttccagcg gtgacaccgc gtagtacatg aggttgggcc 
    31921 ggtagaagct caggtaggca cctgagtcgc cggtgatgac caacgtgttc tcgatgggat 
    31981 cgacgttgac ctctccctgt gtgcggatga tggtcccgtc gatcaacagg acagtgactt 
    32041 ccttcatgtc gcctctcagt agctgtaggg ctcgttgggg atgtcctggt aggtgttggg 
    32101 agcgatctcc cggagctgcg cgagcagttc ccctgccagt tcacggattt cggcgtcggc 
    32161 tgcctcgtgg tagcgagcct tgatgacgta ccgccacgcc cggtggttac cggtcacgac 
    32221 catcggtgag ttggtcatgt tcggcagcac cgctcgtgct gcctcgcggg ccttcttgcg 
    32281 cggcaggcca gcgttttcca gcacagcgag gagccgcttg tagtagctct ccgctgagtc 
    32341 ccacgcttcg gccaggaagt gggctgcgtc ccggtactgg ttctctggca gctcccacac 
    32401 cacgggcggc gtgtgaccgc ccaacggcgt cgggtcgaca taccgttgcg agacaacgga 
    32461 gaacgacagg tgcctgtggc gctccagctc ggtcagcacc gagcgactgg cctcgatgta 
    32521 gaacgtggcc gaggcgtgct ccagcacgct ctcgtggccg acctcgagga tgtgtgcgag 
    32581 gtagtcctcg ttctcccgag tggccgggtt cggccggtcg aacgaccggt agcagttgcg 
    32641 gcccgcgaac tccgcgagct cgtcagcgtc ccagtccccg atgccgccag cggtctcgta 
    32701 ggggctcggc ttgtacccga gcgactccag gacgtaggga tcgacctcgg ttgctgcgat 
    32761 cagcttgacc ttcaatgtgt tcctctctca ggggtggaga gggcccccgt aggggccccc 
    32821 tccgtgtgcg atgtcaagtc ggctacagcc agacaggctt ctcgtcggag ccgcgaggcg 
    32881 gcatccaagc cgaccagggc ttgccgttct tgccggtacc ggacttgtag acccagtccg 
    32941 ggccgggagc cggcggggtg cccgcaggcg gttcctgagc gccacgaggg gcgttggagc 
    33001 ggccaccgcc gccaccaccg ctgttgccac cggacgcctt ggccggtgcc atgcccgcga 
    33061 agtgctgacc cgcgttctgg acgcgctcca tgagcgcacc gagcgtggca ccctggttgg 
    33121 tcacctgatc gagggcatcg tccaggtcct cggcgtggat gacgatccac ggagcgtcga 
    33181 acccggagcc gcccttgaag gtcaggacga ccttgccctc gcctggcgca gcggcaggct 
    33241 tcggagctgc cttggctgcg gccttcttgg ccggggcctt cttgggggct tcaggcggcg 
    33301 gcgcgtcgaa cgccgactcc tgcggctcgg gagcagcctg agcctcgtcg gtggcgggag 
    33361 cggatgcgaa tgggtcctgc aatgtaacta cctttcctct tgggtgggtt atcgaatcgg 
    33421 gcacgccccg gaggcgcact cttcatcgac ggagtcggca acggcctgag cggtcgcagc 
    33481 ctcgaactgc ttcttggtga ttcgctcgta aggtgcctgt ggcatggacg attcggggaa 
    33541 gatggtcgct cccttgagca gacccccgaa ggtcctgagc tgttcaccca cgacgtgcgg 
    33601 cttgtacctg tcggggtcga cgttggcggt gaagctcacc gcgttgtcgg cccagagcat 
    33661 ctggtacatc gcctggaacg cgaggagttg gttgagcgtc aaatcctctg cggattcaac 
    33721 gatctcctca gcatcgcgtc cgaaccggtc gacaacctct tgcacgaggg tgtccttggt 
    33781 gggaatggtg accaccacgg tgttctgcgc gtagaggtca tcctcgacct cgtagccctg 
    33841 ttcccggagc tcctcgatct ggggatcgcc cttcgagaac cggatgcgcc ggtagaagta 
    33901 cttggcgaag atcgggtgga taccctcact gacgccaggc atcttcgcga tggtcccggt 
    33961 aggggccacc gtccgggtct tgaccggaac cgggattcgc agctcgtggc tgaactgctg 
    34021 tgctgactgc tcgacctcct tggcgagctc tcgcagcgtc ttccggaagt gcttgtccag 
    34081 aggcgctttc gagtacctgc ggcctgtcat ggccaggtag gacgccacac cgaggtgccc 
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    34141 gacgccgatg cgtcggttgc ggtccaggac ctcccgtgac ttcggatcac cgaccgggct 
    34201 gaacgtcgcc cggatcagga accgagccat caaccggtgc gaccggatca ggtcgatggt 
    34261 gtcgaccttc ccgttgtcct tgacgaacgc cgcgaggttg atgtggccga ggttgcacgg 
    34321 ctcccactcc tgcagcgtga tctcaccgca ggggttggtg cagacgacct cgttgggctc 
    34381 gccctggttc gacagggacg agtcccagaa cccaggctcg ccgttggcga ccatgccgtc 
    34441 cgtgatccac gtcagggcct tgtgggcctg atcgcggacc atgatggaca cctggttcgg 
    34501 catgttcaac gccgtccaga acaggtcgtc cacgacgacc gagatgttgg tcgtccagtg 
    34561 cttgccggtc tcctgcttgc agcggacgaa ctcctcgatc tgagggtcct gccagtgcat 
    34621 catcgacatg cgagccgacc ggcgaacacc gccggccacc acacactgcg cgatggcgtg 
    34681 gtcgatctcc atcgctgcga tcccgttgag agagccaccg actgtggcga tctcgctgag 
    34741 aacctcgcat acgtcgatca gcatccgagc cagcggcagc gggcccgacg cccgcccgcc 
    34801 gaaggtcttc agcttggcac cgaacggccg cactcgagac acgtcgtaga cgcgctggaa 
    34861 gtggctgacc tcgtcgcggt agtgggtgtc gatcaggtcg accagggcag ccgcccaacc 
    34921 ttcccgcgag tcctcgatga cgaaggcacc ggcccactcg gggtcgtact ccgtcgacag 
    34981 gacaccggca tccttcatcg cctggtagtc gggatgctct tcgtcgcaca cgatgtggac 
    35041 gtagagctcc tgcggcacag ggccgtagtc gatgaaccgg ttcgagtagt tcgcaccgac 
    35101 accgccgccc tccatgaggc gcatgaacgt gaactcgaag tgatccgagg gcttctcggt 
    35161 ccacccgctc acccagcagt tgaagaggtg ctgggcgttc ttcacgccgc tggcccacag 
    35221 gtgacggcct gccggaagca tcttgaactc ggtgatgagc ctgatcagct cttcccgttc 
    35281 acctggctgc tggtaccttg catccaccag cgcgaggttc ccgtcgacca cacgctcgac 
    35341 cgtctcgggc caggtctcgg acgagccgtc aggcttcacc cgtgagtagg tccggttgta 
    35401 tacgatctcg ccggtcggtc cccagttgac ttccgttgtc acttgccgcc tttcaccagt 
    35461 cgcaggtaac cgggcgtgta ctcgccgccg cagtacagct cgcgatcctc tgcaggccag 
    35521 ttgtcgatga gcatcggttt ctcgtcgggg aagagctcgg ggaagacctg agcgcggtac 
    35581 atcgccatcc ggtcgtctcc gttgaacatc ccgtcgaaga tgtcgagtcg tacttcggac 
    35641 gagtcgccgg tcgactgggt gatccagtca tcgaacacgt tcgccagctc cgtccggtat 
    35701 gtcgttgttc ctgtcacgtt gccctcctgg tcggttaatt cgagttcctc atcccccttc 
    35761 tcgatgagtg cgattgcggc gtcagcagtt ggatcactgc gtcccccaga ggatttgcgc 
    35821 gtctcggctt ggaccgccgc gctgctgaca tcaccggctg tgatgacgat gatgttgacg 
    35881 tgctcggtga tggccttgtg ggcgttcttg agcgcgtcct gggacggacc gtcctgggga 
    35941 atgaccccgt cgtcgtagcg gctccggaga gcctctgcgt agacggcgtg ctgcttctcc 
    36001 agagcagcca tagcggtggg catgatgtcc ttcaggtacc ggttgttcga ccggtccttg 
    36061 agaacgtcct tgacggcctc cgacgagtag aggttgcgac cgttgaactt gttcccggcc 
    36121 agcacctgct cggtgaggat ttggatggca gctcggcgca ccgtggcgat tgcctcgggc 
    36181 ttggagagct cctccaactt ccgttgtgtc gcaggacgtt ccagatacca cacccagagg 
    36241 tcctggacga ggtcgtccag gcccccctcg cggccccagg tgacgagagc cgacttagcg 
    36301 gcagcctcca tcaccttgac catgtgcgat gtcaagtgtc agacctccca agtgtgtccg 
    36361 tcgaccgtga agcggccgtt ggtgatcggg atgatctcgg gcttgacgtg gcgaccctcg 
    36421 atggtcagca ggccgaaccc ggactgccaa ttgccagtgc cgcctttgag gtagtcggcc 
    36481 tggcgcatgt ccatcaggtt gccgacctcg accccggtga cgatcttctt ggagatgccg 
    36541 ccgtagcccg atgtgtgcga caggatgccc tgacggtggg tgtggcccat gatcaccgac 
    36601 gtgtcgaact tccgtgccgc gttgagcgcc gtgttaccgg cgatccgcga caggctgatc 
    36661 tgaccacggt gcccgtgggt ggtgacccaa cccggtgcaa ccttgtagaa ctcgggcagc 
    36721 aggtcgatcc cgaacccgtc gaagtcgagc agcgtctcca ggtggaaagc cttgctctcg 
    36781 gccaaggccg gcgcgtactt cgagaggtac gtccgtggcc gctcatcgtg gttgccttcg 
    36841 tggacaccga ccgggccgac gtagatcgtc cgcagtggag cgaggaacct cagcttggcc 
    36901 ttctcggcgt cggtgaagac cgacccctcg aactcgcctc gagtgtcctt gttccagcgc 
    36961 gacggctgcg ggaagtccat caggtctccg atgtggatca cctgatccgg ctgatagtcc 
    37021 ccgatgaacc gcagcaccgc acggaccgct cggcggtcct catacggaat ctgggtgtcg 
    37081 gagacgatca cgatgcgctt actcaacttc gggttcctct tcgtagatgc gttcgacgca 
    37141 tccggcgtaa ccggcgatgt cggtgaacga atcgcggtgg tagccggtgc ctttgaccct 
    37201 ggcgatcttc atgaggatca tcaggttggc tacgtcgatg tcgctgatcg ggcgttcgag 
    37261 gtaaccggag aacagggccg cgatgtccga gaagttctct cgggggtgcc cgtagttctt 
    37321 gttgcgctct ccgtggatga ggcgctgtgc ctcttccagg atcgactcac tcatcgtctt 
    37381 ctccttcgtg gacgtagtcg tgaatccctt cccaccaagg ggcgtcggga tcgaggccga 
    37441 gaaactcggt ctcggtgtac tcattcggtt gggtcatgac atcctttcca gcagagcgga 
    37501 tttgcctctg ctgatgacta gcgagttgac atcctcgcca ggtggcatcg ggatcaccct 
    37561 gctgttcggc agggtcagtg ccacacggtt ggcgaactcg gctccgggct cgtcgccgtc 
    37621 cgcgaggacg tagacggttc ggtatccgat gaacagctct cgcatgtagg gcttccacat 
    37681 gttggcccca ggcaccccca cggccgggag gccgcagact tgcgctgtga tggcgtcgat 
    37741 ctcaccttcg gtgatcgcga catcggggac ctcacgcagc agcgcgagag tgttgtacag 
    37801 ccacggttga tcccccggcg cggtcatgta cttgccatgc cctcggtggt cgtggtcctg 
    37861 gatgcagcgg tagcggatcg cgacgacgat ccagccgtgt tcccgcgacc agcgcaggta 
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    37921 cgggatcgcc atgaagcccc ggaacatctc atgaccaggg agtgggtcgt ccacgtaccc 
    37981 gagcatgaac cggtcgactt cgtccctgac gctgtcgaac atcagtcccc ttgtcgccaa 
    38041 atactcttcg gctggactgc cgttcagact tcgccggtac cgttcggttg cctcccggag 
    38101 aaagctcttc tgcgattcgc tcagcctctg cataactcac ctcctcttgc ttcttgatca 
    38161 gcccgagcac gtcgcccttc accccgcagg ccaggcagtt gaacgcctgg cgcacgaacg 
    38221 agacggcagc cgagggaacc tcctcggcgt ggaacgggca cagacacttg atccagtcct 
    38281 tgccggtgtc cttcggtggc tcccagtccg ggtggtaccg gtggatcgcc tggactatca 
    38341 gcggctcatc cgttgatggc atagacgacg gtgtcctcga cgccggtctt gtacgtgtcg 
    38401 ttgatcagct catcgaactt ctcagcgaac ttcgcctcgt cctcgtccga ccggataatc 
    38461 gcctcgactc ggtatctcat gctcctcctt tctgtgcgat gtcaaggatc gggtacgact 
    38521 cgttccccga tggcttggac agccggtggg tcgtccaggt agtcgatgat ccgttgtgct 
    38581 gcctcgacgc tgtccctgag atgccccagg acgttccggt tgcacgcggt gcatagaaga 
    38641 ccccggacga tgcccgttgc gtggtcgtgg tcgacgctga gccgcttgcg cttgccgttg 
    38701 gcgcggcggc agatgtagca gcagccgccc tggtgctcgt agatcgccca gtactcgtcg 
    38761 gcggtgatgc cgtagacatc catccaccgc tgttcctgtg tcagcgttcg gcgctgcagc 
    38821 ctcttggccc ggtggtgcgt gacgcaccgt gggcccggat gcggggcctt gcgcttggtg 
    38881 acgatcccct cggccgtgca gtcgatgcac ggcttgcgct tgtgggcccg gtcctgactg 
    38941 cggactgtcg gcttacgcct tgtcgtcgtc atcgagaccc tccatgcaga ggtagaccca 
    39001 cgccccgaag ccccagacgg ccaccagtag agcgatcacg cgatcacgtc ccacatcgcc 
    39061 gtcttgatca ggtcggccgc gaactccggg tcgaccagca gccacgagtg gaagcccttg 
    39121 accgtgaaca acttgccccc ggcgagcgcc gctgcgctca ccccggccgc atacggcacg 
    39181 atctggtcac actcggcgtg cagtacagcg gtcggcaccg agttggcccg catcttctcc 
    39241 agcagcggga ccgtgtcggc cttcgtcagc gcgtaggccg cacgaacgaa ccggagaccg 
    39301 gacaccgact cctgcagaga ggaaagcagg ctcagacgct ctctgcgcgt ccgggagcgc 
    39361 atggcccggt aaccgtcccc gaggatgtcc acgagcccgc ccacggcgaa gcgagccgcc 
    39421 cgcgtcggca ggttccggcc aggtgcgatg gcgataccct cgtggtgctc cttcccggct 
    39481 gccgcgtcga tcaggatcgc ggcgtggacc cggtccggga acatcgcgga gaactcgacc 
    39541 gccatagccc cgcccatcga atgcccggcg atgaccgcct tgtcgacctt gagcgatgtc 
    39601 aaggcgcggg caatgatgtt cgccatgtct tcgaccgtgt ggccccacgg cagcgagccg 
    39661 ctgtcgccgt ggttggcggc gtccggtgcg atgacgtaga acccgaggta ggacagctcc 
    39721 tcgaagagct cctcgtaggc gatggcgctg acgctgagcc cgtgcatgaa cacgagcggg 
    39781 acgccggccg agtgacccgc cgtcgtgacg gccacgcggt acccgtcgtc taggacgagc 
    39841 gtctggtgct tcaaattcac tccttgatgt atccgtggtt gacgaccggg atgcctgctg 
    39901 cctcagccaa ttccatgcag ccgaaggtcc cgatggactc ctcgagcggg aaggcatggc 
    39961 agacatcggc tcccagcgcg accatctctg cgttgcgtcg atggcctgct gacttgccgt 
    40021 aggtgtccca gtcggccggg tgatcctcgg gctcgacctt gtagcccatc tggtgcatcc 
    40081 cccaggccca gcggtccgcg atgtcgtcgg caccgcgtgc cgcaccgtgg actacgacga 
    40141 tcccgtccgg gctcttgtcg agctcgtcct gcagggtgcg ccagacctcc ggtcggtccc 
    40201 gccagtcccg gcttccggtg acgaggactc gcctcacggc acccagcgcc tggcggcgag 
    40261 gtcgacgttg aactccgaca cgttctgtgc cagcgggaag cggagaccct cgcgggtgac 
    40321 cttcgtcttg acgacggact ccttgccgtt ctcgtccttg acgagcgact tacggtccca 
    40381 ggagaccggc ttggtcgcga tcagcgcgga gagcgcctgc tggtggatga tgttcatctt 
    40441 cggggtgggc ttcggcatag tcgattcctt tcgtttgtgc gatgtcaagc cagagggcaa 
    40501 aaagacgagc gaggatcacg gctgcgagta gtactcggag ttgttcatca gccagcgttc 
    40561 ggtgcgctcg tcgtcggccg ggacgaagtc gtggtcgtac cagccgccat cggagtagag 
    40621 gaacgagccg acgaacttgg tctcgaactt ccagtcctgg gtgatcagat ggaccgcgtc 
    40681 ccagacccgg ccgaacgtgc ggccggtggc gaccaggtca tccacgaaga cccaccgctt 
    40741 gccgatgcga ccctcggcct tcatcgacgt gtgcgatccg tcgttgggct tccgcacgac 
    40801 gaggtagttc ttgtcgagca gacgcgccag cgtcgtggcc gcgatggtcc ccgacaagcc 
    40861 cgtaccgacc aaggtgtcgt agtcgacgtt ggagaggtac tggttggcga gctccagcag 
    40921 ccgatccggc ttgtggacga cgcggaggta ggtctcgtcg gtcagatcga gcaccttctt 
    40981 ctccggacgc ggagcgaccg cctggtactg gacggtgtcc cacggggcga agattgcatc 
    41041 agcgagggtc attggcgggc cttgcctttc gttactggtt ggaggggtct ctgatctgca 
    41101 tggtgtctcc gatgaactca agctcaacga agtcgagtcc ggacgggtcc atccggccgg 
    41161 cgcggttctt gacggtcgat acgcgcagag cttcgggccc gaactcttcg gacactctgt 
    41221 gcaatgtcaa gacgagctca ggaacgcggg tgatctggcc tttgaccccg gacaacggga 
    41281 tcggcttgtc cgcgtcgttg taggagccgg tgacatggtg cagcccgacg acgcaggccc 
    41341 cggtgttgcg ggccatcgtg tgcaggtagt ccatcatcga ctccaaccct gagaacgggt 
    41401 cgtcgtcctc accaccgccc gagcggacgt tggtgatgtt gtcgaccacc accaggtccg 
    41461 ggtagtcccc gtagccctgg cagtacgcct tcatcgagtc ctcgatctgg tcaagactcg 
    41521 gtgatgcgtt gtagttgaac cggattggga tgtcctcgaa ctcctctgcg acctcggtga 
    41581 ggtcggagtt gcggaccgcc ctggccgaac gctccatgct ccacgcggtc tggatcgaaa 
    41641 ccatccggtt gagctgggtg aatgcgtcgg agtccgcgct gaagtacagc gtcggaactc 
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    41701 gagccttgag ggcataggtc agcacgaacg ctgacttgcc cgtaccgggc cccgcgcaga 
    41761 ccagcgcgag ctggccgcgt aggaaccggg tgcctttcat ctccagcgcc tggaagaccg 
    41821 ggggcagtgg gtcgcccgcc gatcccttga cgcggagact ctgcatcggt gtgtacatgt 
    41881 gcctcctaca gcttggtgaa gcagagccag ccgcccagcg caccgagcgc gatgatgaag 
    41941 ccgaagacga tcacttcggc aatcacagcc cgaactcctc gtggtacatc gggatgaact 
    42001 cgcttgcggg ccttggcagg ccagcttcac agtccttgtc gaacagtcgg atcaggtgct 
    42061 cgatgtagcc ctggtgcgac ggcggtgcct ccgcacagag ctgggtgagc ttccgtcgct 
    42121 gcttcgcgac gttcatctcc atctggacgt tcctcacacc cattcctttc cattccagcg 
    42181 acggccgtcc gggtaccgga tgacgggggc ccggtgggta tgtccttgtg cgaaccgcgt 
    42241 tgcggccgcg actgacggga acgggtactc gctgtccccg ctgcccagct ccacgaacca 
    42301 gtactcggac tcggtcgaga gcgtcagcga ttttcgatag ctctgtgtca tgtcaagtac 
    42361 tcagccagca gaaaactcac aggcgaagct cacgtcgcag aaccggcagt tgtcctcgga 
    42421 cgggttcgga tcgaacttgc cggcccggac gttggcgtcg agctccttga acttctcggt 
    42481 gatggcttcc ttcgtccagt ccgtgaggtt gtaggggtac gttgccttgc ccgactggcc 
    42541 catccagtag tcgcccagct cgggcggctc gatgccgtac tcctcggcca gggccacggc 
    42601 gtacaccgcg agctggaagt cgtcaccggg ctgcttgccc gtcttgtggt cgcggacgat 
    42661 caacccttcg tcggtctcga tcacagcgtc gataaagcca cgaacaagca caccgtcaag 
    42721 atcaatgtcg aagccaagtt caataccagg cgtgccatcg ggggcaatcc agatcacctc 
    42781 ctcggtgtgt gaagtcgccc agtcgatgta cttgccgacc tgctccaggc cgatgtcgta 
    42841 ccggcgtgcg atgtcaagtc gcccaccgta acgaccgctg gcgaaccaat actcgaagtt 
    42901 cggcgtgatt gcacacgccg cgttgatgta cttctgatag gactcccgga acaccgcctg 
    42961 agcggcctcc agagacatcg tgcgcccgct gcgctcccaa gcctctatgg cctcgtggac 
    43021 cgcgctcccc tgcgccgtcc aggccgcagg gcgctgccac gccttgtcga ggcgcgagag 
    43081 cttgtagctg taggggcact tctcgtactg cttgagctgg gacacactgc ggtgcttgcg 
    43141 ctcttcggtc atgacgcaac ctccaacgtg tgcagatgct tgcggatttg agccggtacc 
    43201 tctgtcgggt ggacggggta cttgcccttc gtgatgaagt cgaccaccgc ttgagcgcgt 
    43261 ggatcgagtg gctccgtggg atcgagggcc ccgtcgtaga cgagtgagga ttcccagtag 
    43321 ccctctccga acatgatccc ttggtccgga agtgattgga ggcagatacg tttcacggct 
    43381 ttggctctgt cgagcagagc cttgacatcc gcgaacatcg ggtcggtgtc tcggaccgct 
    43441 gaactccgat aggtcaggag cagggtgaca ccgagcaggt tgatggattc agcgaacagc 
    43501 catcccggcc tggcgacacg gattacggga gcggcgagtg cgagttggtg gcaaacgatt 
    43561 gcgagtggca cggtttcgta gctttctgcg tcttcatgtt cagtgtcatt tcgtcgtccc 
    43621 ccgtctgggt cttcaggtcg gatgtctcgg gatcacggtt cccgaggtgg gaatctccaa 
    43681 atcattgctc cttcttcggt caggtcggtg tagtcgttga cccggatcag caagtccttg 
    43741 tcctccggac ggcgcggccg gtacgcccag ccgcctgcct tgctcacgcc ttcctcaggc 
    43801 gggatgttcg ggtcgaactc gagcacatgg tcgcggagct tgttgtagaa gccgcgaagc 
    43861 ctcttgagct tgagatcgtc catgccgacg ccaccggtcg ccatgtactc gccgtgctcg 
    43921 cggagcctcc ggtacgggga gacaccctgc tgcatcggca ctggcacctg gaacgggaag 
    43981 tgctgaagca cgatctctcg cggcgtcagc cggcctccgt agtagtgctt gatccacgag 
    44041 acgtactgcc tcgtgactcc gtacatccgg gcgatctccg attgggtgta gcctttgccc 
    44101 ttcaggtctt cgaccacagc gagtgttagc tctggctggt ttttataggg cttgtccgtc 
    44161 ttcatttgtg tttctccctg tctgcgggtc ttagccgcag agtgtcacat gtaaagcatc 
    44221 attcagtcaa tccttcatgg ctttcgccgt ttatgccgac cggcgacggt gccgcctcga 
    44281 ccctgtctcg ggggatacta caggccgtaa ttgacgtgcg tttacgggcc gtaggtttta 
    44341 ggtacctcgg tgcgtctgat ctggtgtttt ggtccctacc cttctagttc ctcgatcctg 
    44401 gcccggacat cctccaggtc catgatgtct tgtggatcgt cgctccctga gagctcggcc 
    44461 tcccactcga ttgcctcgtc caagtccatg tcttcgacgt acattgtcaa gccctcacct 
    44521 tcactcggtg gccggtggtc tcgtggacgc ggaccgcgat ccccagagcc cgcgccgtgg 
    44581 tggcgcggga ctcccaggga caatcgcggc accgtgcctt gacggtcagc ccttgtccct 
    44641 gacgcgaggc ggggtctgcg actgaccgga cggagacttg tactcctgct gggtctcgga 
    44701 gatgtcgacc cagccccagc cgccgcgacc gctggcgcag gcgtgcttgt agatcaagcc 
    44761 tgggcccgtg ccgtggttgg cgcacatgcc gggggcggcc tccgcgtagg gcggggtcgc 
    44821 gacgatggct accccgatcc cagccatcgc gagggcgaag gccagcttcc tcacgacagc 
    44881 acctcgatcc ggtgccagtt gcgctcaccg atccaggcca ggagctcgtc ccatgccttc 
    44941 ggcgcgtggc cctgacgggg cgagcgggtg ccgtcctggg tgatgtacca gcggcccagc 
    45001 acgcggatgg cggcgaaggt gtagctgagg ttgtacttga cgaaccggat cacggttccg 
    45061 tcgacggacg gttcctccgg gatgtgtgct tcccggacgg cccgagccag cgccagctcg 
    45121 gcctcgagct cctcgatccg tgcgttcaag ccttgcacgg tgtcgtccac gagggttact 
    45181 gccattttct ctccttctct ctcagcggaa tctcgctgtt ttgcggggtc tcttgagccg 
    45241 attcgctcgg cgggtgacca tgcctatctc ggcgggaagg gggtcagttg tgctgagccc 
    45301 caacgcttcc cggtaggcga tgtctgactt ggtgagcttc atcagcagta ccagtgcttc 
    45361 cggcaatgcc gagacttctt gtctcggtcc tccttgggct tgccgctgtc gctcgatgcc 
    45421 ttgggcaggc cgtccttggc gtcctgctcg gtgcagggcg agggctcgcc acgctccagg 
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    45481 tggaacctgc ggtcagcagc gggcgtcgtg tggctctgct tgtccgacag atgggcgtag 
    45541 cactcggccg tgacatcggc ccgagcctcc gcgatgatcg ccggggcgtt gccgagcacg 
    45601 atggccccgc agaggccggc gagtatgtac cgtgccttca tcgagtcctc ttccgtcgct 
    45661 ggaactttcg gtccttgtag tactcgggac cgttgaccgc gttggtcagc cagcgcggtg 
    45721 tcttcggacg ggactccccg acgttgaact cgtcgtcaac gccgaggtgc cagtcctctc 
    45781 ggtggatgtt gctcatgcct ctcctacgtg cagcagccgc agcagggagc gtcctcgcag 
    45841 cggcccttgg cgttcacgga cagcaccgct ccggaattga gaacgatggt gtgggtcttg 
    45901 ggcttgtact tcgacccgta ggggcggcga cggtagttgc gtgccatgcc ttgctcctct 
    45961 ctgagcgatg taaagtgtgt gactaaggct gtagccgtcg cacgtccatc ccctgggagc 
    46021 aaacctccca gcggctgtgt ccgctgctgc cttcgggact cggcctgcca gggggaacga 
    46081 tctcgtatcg gtcccggttc ctgacggttc cttatctccg tgtcgtacct tcagttaaac 
    46141 acgcacggtg tgcgatgtca agcaagaagg tcacgaatag cggctgcggc ctgttggacg 
    46201 accaccccgt tgccgatgat cttcatcgca gcggtgcggc tgatcttgcc ttcgggggcc 
    46261 cgtcgaccag aggtctcgat gaggtcggtg acccatccct cttcccagcc catcatccat 
    46321 tcgctgaagg ctgcgttcag tcgagggttg ccgttcttgt tcggctcggt cggtaccggt 
    46381 acctcacgcc cgacgatccc ttcccatcgc cggatcgccg gctcgaactt gccccactcc 
    46441 gacgtgccgt acaggtgggt cgccgtggtc cggaggtcca tgcctccgtc gccgtggtgt 
    46501 cccccaccct gcgagtcggt ggtcagcggt gtcgggagca gagccactgc tcctggcagg 
    46561 tccatgcctc cctcacgctt gttcgggttc gggcccttgc cgtcgcgagc cgcaggcgtc 
    46621 gggaacagct tccacatcgc gtcggtcagg gtgtcgccag cgtgcgctgg tacctccttc 
    46681 ggcgtgcggt tggccgtcga gttgcgggtg cctttggcgt cagtcgcgac cggggtgggc 
    46741 aacaatgaag actcgttctc gcttgtgtgg ggctccgatg gctccagcgg caagagtctt 
    46801 ccacttcgcg tcatacccga ggtcggaaag gtcccggaga actcttccca tcgctcgcat 
    46861 ttgaaggccg gatgcgtctg ttgccttggc actgagtagt cctctcacgt tctcgatgac 
    46921 cacgactcgt ggtcgaagga tgtcgatggc ttctgcgaag tgagcccaga gcccggaccg 
    46981 ggtgccctgg ccgatgcctg ccttgagtcc agcggggctc acgtcttggc aggggaagcc 
    47041 gccgcacagg atgtcgacgg ccggaacctc gtgccagttc accttgctca cgtctccgag 
    47101 gttgggtacg ccgaacctct tcgcgagcag cgtggccgct gccttctcga cctcgacctg 
    47161 ccagatggtc tgaccgccga agacttcctc gaccgcgagg tccagacctc cggctccgct 
    47221 gaacagcgag ccgatgcggg gtccgtggct catgctgccc gccaatccgc aggcaggaag 
    47281 cctcccttgg tgatccactc atcgagagcg gtcatcagct cgaccatgcg gtcgatggct 
    47341 tcctgtccga cagccagacc gtggcggtcg tagtcggaca tcaggagccg cagctcttcg 
    47401 agcgtggcgt cgggtgccat gcctaacctc tcttcttcca gacgacgggg ctgctgctcg 
    47461 gacggcagcg gcagcgccaa ccctcgagcc tcttgggctg gcggtagcgg gcgaattgct 
    47521 ttccgtggct gcaggttccg atccacggcg cggtcgggtc gatgtcttcc atctcgaagc 
    47581 accgctgtcc gttgccaccg agctcgcgat gcttcgcagc ccacacagcg tcgtgaccat 
    47641 gactcccgcc gacgagcgcg tgagcgatct cgtgggtgat cgtctgcatg gtgtcttcgg 
    47701 ccgaccgaag cctcatcagg tgcagcgaga ggctgatggt gcgggtgcgg tagttgcact 
    47761 ggcccgcacg gcgtttggcg ttgtcgaacc tcaggtgcca atcgtccaga ccgtgctcgt 
    47821 ccatcaggct ccgagcctgg aaccgtgcct gcggcggggt catcgtggtc gggcggtcca 
    47881 acatcgcggt cattgctcgt ctcgcttcca tgccttgcgg tggcccttgc cggggcgctt 
    47941 catctctcgc ttgcgattgc ggtgcggctg tgccgcgttc gactgcctga gcccgagccg 
    48001 tgcctctagc tgctcgggtg tggctcgggt gctcatggct tgctccttgt gcgatgtcaa 
    48061 gcggcgtaca cgcgcttgtg cgtcatgacg gccaggtcag ccccggcgaa cggtgtctcg 
    48121 tcatcggcgt agacgaacgt cgagtacttg cgggggttgt aggtcacaag cctcgcgttc 
    48181 acgtcgaggt cgacagcttc gccctggacc agctctccga caaggccggc gtgtacgttc 
    48241 ttgcgtccct cacgcaggac acgctggcgt cccgcctccg ataccttgcc ttcgacgttg 
    48301 cggaggatga cgtagtggct gcgggtgatg actcgaccct tgtccgggcc ttcgagcgcc 
    48361 ttgacgctcc acatgtgctt gtgcaggttg aagtagacga agactctcac agcgcgtcga 
    48421 tcccttcgct catgatctcg gacacgacct cgaacggacg cagtccgtcg tcgtgcatgt 
    48481 ctcggtagca gcggtcagcg atgtctcggg tggtcacacc catgcgcttg agcagttggg 
    48541 cgtccacgag tcgcatccat tgcttgaagg cggcgtcgga catgtcatcc ctcctcgacg 
    48601 gtgtcgtcca cgacgagcac cgagctctcg ccgaggctca ggtaccagtt gcccgtgtct 
    48661 tcatcgagcc acatgcccac ctggcccggt tgatccgagc aatcctcttc gacgcactcg 
    48721 gggagcatgt cgatgtcgat gtcggacagg tcgactgtgg gcccgatgcc tagtgcgatg 
    48781 agcgcagcga tgatcacttc gatcccttcg gtttggtctg acgtgggggg taccagccgg 
    48841 atcgctggtg tcgccgtgcc ttacgcatgg cgagcatgat gtcggcgttc acgactcggt 
    48901 caggtggtcg atgatggaga ccagcgcggc cgaaacctca cccacgggca ggatgactgc 
    48961 ggcgtgacgc ttcttgccgt cgtgaccggt gaccgtgaag cgcaagcctc cggtcggttc 
    49021 ggcctccacg aggagcccgt gcgggctccc ggtcgaagac ttgcccgtga tctggacgat 
    49081 ggtgtcgcgc ttcatgcctg tcctctcgtg tgcgatgtca agccgtggcc cgaatgaagc 
    49141 cagcggtgtt gtctttcttc cactcgtggc ccttggcccg caggccgacg accacgcctc 
    49201 gtgggtcgtt ccgacgctcg tcggactcgt cgccgtcgat gactcggtac ccgttccatt 
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    49261 cctcgggcag agcctcgcca cgcctcgtgg tgaagggcat cgcgacgttg cctccgctgg 
    49321 cgaggatgcc ttgcaggtac tcgtcgctcg tgtgcgacgg ttccttggcc gagtacgtca 
    49381 ggctgtagtc cgaagactcg gcacgatccc tcggagacca cgcggtgtag tcgtacatca 
    49441 gcacgccagc ctcagccaac gcttgcacca tgtgcggtgc gacgatctcc cagcggatgt 
    49501 cgctggtcgt gttcagccgc aggttgatcc ggccatgcct acgaagggcc gaccgaatct 
    49561 cggcaccgat gagcaagcct gccaagactg gatgcgagag caggaacgcg gtcctcacag 
    49621 cttgagcacg ctgctgggca ggcatacctg actgtcccga ccgagacagg cacgctgcgg 
    49681 cgcatccctt ggatgccatc gggcacaggt tgatcgcacc ggacaggccg aaggcttccc 
    49741 gcacgtcccg aaggcttgct gccatcatgc ctcgctcggg tgtgagcatg agaccgaagc 
    49801 tgggcaggct gttcttcgac agcttctgct gcgatgctcc gctggtcagc agtgcggccg 
    49861 atgccttgcg atagccaacg ctctcgcgaa gctcagccca cacctggcgg gcccaccgca 
    49921 cgtccgtcga tccctcgagg ccggcgatca cagcagcccc gaagtctgcc ttgctgagga 
    49981 tggtttctac acgggtggtc atgtcttgcc tctctgtgcg atgtcaagtc tcagggcaga 
    50041 ggaatgacgc ggtaggaccg ctcacccgtc tcgatgtctt cgaccagcac tcgcaggacg 
    50101 ttgccttgtg cgttctggct gatcactcgg tgcttgccgt acacgtccat gtccactcct 
    50161 gactctgtgc gatgtcaagt ctgctggtaa aaaaggggca tgggtagcgg ccaggacgat 
    50221 tgccttcttg aatcgtgcct actccgatga gcaggtcagt cgtcgtttcc aaccatgcct 
    50281 agtggacagc cagcatcgaa gctggggacc agtgatgtcg gtcctgcgaa cctgcctgtc 
    50341 ctgcctcttc gagctatcgc tccgggttga ggcccaaccc tgtgattgtg tgcgttgttc 
    50401 ccggacagtg cttccggcgg gccaacgctt gcccattagc cttatgtcgt ccgcaacact 
    50461 tccaatcaag tctcacgtcc gatgcgtggc ggtccggttt actgctaccg gcatagacca 
    50521 cggttacgga ccatgactgg tcacacgcgg attcaacacg ttgtgacatg gtgtggctca 
    50581 acaaccatgc cttgcgcccg ccttgcttgg ctatcgcttc gagaagggta cgtccctgcc 
    50641 gtaagtcatt tctgacggcg agctttatcc ccccgccagc cgagacgggg ggatgatgcc 
    50701 cctctgacgg gcgacgctga ccgaagctat cggctgactc ctacccggac aagtcgacgg 
    50761 gggagaactt ggtggtgctg gtaaaaccaa cgctagcgga tcgtgtgtgc gatgtcaagt 
    50821 gactcgtact cggtaccgct tgtgctgttg tgtcttcgac tctagctgat ggactgtgcg 
    50881 atgtcaagtg ccgggttgat ccggctggtt cgtagtgttc ctgtgcgctg tgctgtctca 
    50941 aacccgctgg catgtgggtt cccgaaccga ttcgcgatgt ccgctgtgct gttgtcgagt 
    51001 acgacgctac acgatgcggt gagcgatgtc aagtgacctg ctctgcgatc ccctgtgctg 
    51061 ttgtgctttc caagctacac cacggtgctg tgcgatgtca aaccccaatc tgtttgccct 
    51121 ggtcacaggg cgtgtcgccc ggcgtgtcgc cccctgctct gggtaccccc cgggggtacc 
    51181 ccccctcctg ccacaggggg gtcgggtccc ggtcccccct tcggggggac cgggcccggt 
    51241 gggccctggg ccaccccccg gtccaggacc ccccttcggg gggtcctggc cggcccccct 
    51301 cggggtaccc ctccggggta ccccaggggg gtataccctc cacccccgga ccccgaccgg 
    51361 ccggtaa 
